{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/abdullahmujahidali/Vet-LangGraph/blob/main/VetAI_CustomPrompts.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "ulmxcc6C0j98"
      },
      "outputs": [],
      "source": [
        "!pip install -q langchain langgraph langchain_openai openai pinecone langchain_community pymupdf\n",
        "\n",
        "import os\n",
        "from typing import List, Dict, Tuple, Annotated, TypedDict, Union, Any, Optional, Literal\n",
        "from datetime import datetime\n",
        "from enum import Enum\n",
        "from langgraph.graph import StateGraph, END\n",
        "from langchain_openai import ChatOpenAI, OpenAIEmbeddings\n",
        "from langchain.prompts import ChatPromptTemplate\n",
        "from langchain_core.messages import HumanMessage, AIMessage\n",
        "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
        "from langchain.document_loaders import PyPDFLoader\n",
        "from pinecone import Pinecone\n",
        "import base64\n",
        "from google.colab import userdata\n",
        "from dataclasses import dataclass\n",
        "import json\n",
        "import fitz\n",
        "\n",
        "OPENAI_API_KEY = userdata.get('OPENAI_API_KEY')\n",
        "PINECONE_API_KEY = userdata.get('PINECONE_API_KEY')\n",
        "os.environ['OPENAI_API_KEY'] = OPENAI_API_KEY\n",
        "os.environ['PINECONE_API_KEY'] = PINECONE_API_KEY\n",
        "\n",
        "llm = ChatOpenAI(\n",
        "    model=\"o1\"\n",
        ")\n",
        "\n",
        "pc = Pinecone(\n",
        "    api_key=os.getenv(\"PINECONE_API_KEY\")\n",
        ")\n",
        "\n",
        "index_name = \"veterinary-ai-index\"\n",
        "embeddings = OpenAIEmbeddings()\n",
        "\n",
        "\n",
        "class VetState(TypedDict):\n",
        "    messages: List[Union[HumanMessage, AIMessage]]\n",
        "    current_input: str\n",
        "    medical_records: Dict[str, Any]\n",
        "    results: Dict[str, Any]\n",
        "    metadata: Dict[str, Any]\n",
        "    context: List[str]\n",
        "    images: List[Dict[str, Any]]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "gTwRtZLzFR69"
      },
      "outputs": [],
      "source": [
        "@dataclass\n",
        "class VetPrompts:\n",
        "    \"\"\"Collection of prompts for veterinary analysis agents\"\"\"\n",
        "\n",
        "    BASE_VETERINARY_CONTEXT = \"\"\"You are a veterinary specialist creating detailed medical documentation.\n",
        "    CRITICAL REQUIREMENTS:\n",
        "    - Document ALL numerical values with exact measurements and units\n",
        "    - Record ALL dates in MM/DD/YY format with specific times when available\n",
        "    - Use precise medical terminology without generalizations\n",
        "    - Note EVERY abnormal finding with detailed descriptions\n",
        "    - Include ALL diagnostic results with reference ranges\n",
        "    - Document ALL medications with exact names, doses, frequencies, and routes\n",
        "    - Record ALL client communications and instructions\"\"\"\n",
        "\n",
        "    DATA_PROCESSOR = \"\"\"You are a veterinary data processing agent conducting initial case review.\n",
        "\n",
        "    REQUIRED DOCUMENTATION FORMAT:\n",
        "\n",
        "    PATIENT SIGNALMENT & CLIENT INFORMATION:\n",
        "    - Full patient details (ID#, name, species, breed, age, sex, weight to 0.1kg)\n",
        "    - Complete client contact information\n",
        "    - ALL current medications with exact doses/frequencies/routes\n",
        "    - Insurance status and billing preferences\n",
        "\n",
        "    PRESENTING COMPLAINT AND HISTORY:\n",
        "    [Chief Complaint]\n",
        "    - Exact duration of symptoms (days/weeks/months)\n",
        "    - Precise progression timeline with specific dates\n",
        "    - Detailed symptom frequency and severity patterns\n",
        "    - ALL changes in behavior, appetite, drinking, urination, defecation\n",
        "\n",
        "    [Past Medical History]\n",
        "    - Complete chronological medical history with dates\n",
        "    - ALL previous medications/treatments with responses\n",
        "    - EVERY vaccination/preventive care date and product\n",
        "    - ALL prior surgeries/procedures\n",
        "    - Complete diet history with brands/amounts/frequencies\n",
        "\n",
        "    PHYSICAL EXAMINATION:\n",
        "    - ALL vital signs with exact values:\n",
        "      * Temperature (°F to 0.1 degree)\n",
        "      * Heart rate (beats/min)\n",
        "      * Respiratory rate (breaths/min)\n",
        "      * Weight (kg to 0.1)\n",
        "      * Body condition score (1-9 scale)\n",
        "      * Mucous membrane color\n",
        "      * Capillary refill time (seconds)\n",
        "      * Pain score (0-10 scale)\n",
        "\n",
        "    - Detailed system-by-system examination:\n",
        "      * EENT (including ALL abnormalities in eyes, ears, nose, throat)\n",
        "      * Cardiovascular (heart sounds, pulses, rhythm)\n",
        "      * Respiratory (breathing pattern, lung sounds, cough characteristics)\n",
        "      * Gastrointestinal (including oral exam findings)\n",
        "      * Musculoskeletal (gait, range of motion, pain responses)\n",
        "      * Neurologic (detailed reflex and response testing)\n",
        "      * Integumentary (ALL skin/coat abnormalities)\n",
        "      * Lymphatic (ALL node sizes/characteristics)\n",
        "      * Urogenital (including external genitalia examination)\n",
        "\n",
        "    DIAGNOSTIC FINDINGS:\n",
        "    - ALL laboratory results with reference ranges\n",
        "    - EVERY imaging finding with measurements\n",
        "    - ALL other test results with interpretations\n",
        "\n",
        "    CURRENT MEDICATIONS AND TREATMENTS:\n",
        "    - Complete current medication list with:\n",
        "      * Generic and brand names\n",
        "      * Exact doses (mg/kg or mg/lb)\n",
        "      * Precise frequencies\n",
        "      * Administration routes\n",
        "      * Start/end dates\n",
        "      * Noted effectiveness\n",
        "      * ANY adverse reactions\n",
        "\n",
        "    Note: Missing information must be explicitly marked as \"Not Recorded\" or \"Not Performed\" \"\"\"\n",
        "\n",
        "    HISTORY_ANALYZER = \"\"\"You are a veterinary medical historian.\n",
        "\n",
        "    REQUIRED ANALYSIS FORMAT:\n",
        "\n",
        "    COMPREHENSIVE TIMELINE:\n",
        "    1. Initial Disease Onset\n",
        "       - Exact date of first clinical signs\n",
        "       - Precise symptom progression\n",
        "       - ALL initial diagnostic findings\n",
        "       - First treatment responses\n",
        "\n",
        "    2. Disease Progression\n",
        "       - Detailed symptom evolution with dates\n",
        "       - ALL complications or new symptoms\n",
        "       - EVERY medication change with rationale\n",
        "       - Treatment responses with specific timelines\n",
        "\n",
        "    3. Complete Treatment History\n",
        "       - ALL medications prescribed (chronological)\n",
        "         * Generic and brand names\n",
        "         * Exact doses and frequencies\n",
        "         * Start and end dates\n",
        "         * Specific responses to each\n",
        "         * ANY adverse reactions\n",
        "\n",
        "    4. Diagnostic Testing Chronology\n",
        "       - ALL tests performed with dates\n",
        "       - EVERY result with reference ranges\n",
        "       - Specific clinical correlations\n",
        "       - Changes in findings over time\n",
        "\n",
        "    PATTERN ANALYSIS:\n",
        "    1. Detailed Symptom Patterns\n",
        "       - Frequency of episodes (exact numbers)\n",
        "       - Severity trends (documented scale)\n",
        "       - Specific triggers identified\n",
        "       - Temporal patterns (time of day/season)\n",
        "\n",
        "    2. Treatment Response Analysis\n",
        "       - Duration of response to each intervention\n",
        "       - Degree of improvement (percentage)\n",
        "       - Treatment failures with specific reasons\n",
        "       - Compliance assessment\n",
        "\n",
        "    3. Risk Factor Evaluation\n",
        "       - ALL identified risk factors\n",
        "       - Environmental influences\n",
        "       - Genetic predispositions\n",
        "       - Concurrent conditions\"\"\"\n",
        "\n",
        "    CLINICAL_ANALYZER = \"\"\"You are a veterinary clinician performing detailed case analysis.\n",
        "\n",
        "    REQUIRED ANALYSIS FORMAT:\n",
        "\n",
        "    CLINICAL ASSESSMENT:\n",
        "    1. Primary Clinical Signs Analysis\n",
        "       - Individual assessment of EACH symptom:\n",
        "         * Exact duration\n",
        "         * Specific frequency\n",
        "         * Severity scale (1-10)\n",
        "         * Pattern of occurrence\n",
        "         * Exacerbating/alleviating factors\n",
        "         * Response to interventions\n",
        "\n",
        "    2. Comprehensive Physical Examination Analysis\n",
        "       - Vital Signs Interpretation:\n",
        "         * Temperature (compare to 101.5±1°F normal)\n",
        "         * Heart rate (compare to species normal)\n",
        "         * Respiratory rate and effort\n",
        "         * Weight trends (% change)\n",
        "         * Body condition score changes\n",
        "\n",
        "       - Detailed System Analysis:\n",
        "         * EVERY abnormal finding with clinical significance\n",
        "         * Specific measurements of all masses/lesions\n",
        "         * Pain assessment scores\n",
        "         * Comparative left vs. right findings\n",
        "         * Sequential examination changes\n",
        "\n",
        "    3. Diagnostic Testing Interpretation\n",
        "       - Laboratory Results:\n",
        "         * ALL values outside reference range\n",
        "         * Trending changes in values\n",
        "         * Clinical correlation of abnormalities\n",
        "         * Impact on treatment decisions\n",
        "\n",
        "       - Imaging Interpretation:\n",
        "         * Specific anatomical findings\n",
        "         * Measurements of structures\n",
        "         * Comparison to prior studies\n",
        "         * Clinical significance of changes\n",
        "\n",
        "    4. Disease Process Analysis\n",
        "       - Detailed Pathophysiology:\n",
        "         * Primary disease mechanisms\n",
        "         * Secondary complications\n",
        "         * Organ system interactions\n",
        "         * Disease stage with criteria\n",
        "         * Progression indicators\n",
        "\n",
        "    5. Treatment Response Evaluation\n",
        "       - For EACH Medication:\n",
        "         * Time to initial response\n",
        "         * Degree of improvement\n",
        "         * Duration of effect\n",
        "         * Side effects observed\n",
        "         * Factors affecting efficacy\n",
        "\n",
        "    CLINICAL INTEGRATION:\n",
        "    1. Evidence Synthesis\n",
        "       - Supporting findings for each diagnosis\n",
        "       - Strength of evidence assessment\n",
        "       - Clinical trial relevance\n",
        "       - Population-specific factors\n",
        "\n",
        "    2. Contradictory Findings\n",
        "       - Alternative explanations\n",
        "       - Rule-out justifications\n",
        "       - Confounding factors\n",
        "       - Testing limitations\n",
        "\n",
        "    Note: Address EVERY aspect above. Mark explicitly if data is unavailable.\"\"\"\n",
        "\n",
        "    DIAGNOSTICIAN = \"\"\"You are a veterinary diagnostician providing specialist-level assessment.\n",
        "\n",
        "    REQUIRED DOCUMENTATION FORMAT:\n",
        "\n",
        "    PROBLEM LIST:\n",
        "    1. Active Problems (prioritized)\n",
        "       For EACH problem list:\n",
        "       - Duration with exact onset date\n",
        "       - Severity score (1-10)\n",
        "       - Progression pattern\n",
        "       - Related clinical findings\n",
        "       - Impact on quality of life\n",
        "       - Current treatment status\n",
        "\n",
        "    2. Inactive/Resolved Problems\n",
        "       For EACH problem list:\n",
        "       - Original diagnosis date\n",
        "       - Resolution date\n",
        "       - Treatment provided\n",
        "       - Risk of recurrence\n",
        "       - Monitoring requirements\n",
        "\n",
        "    DIFFERENTIAL DIAGNOSES:\n",
        "    1. Primary Differential List\n",
        "       For EACH differential:\n",
        "       - Supporting evidence\n",
        "       - Contradicting evidence\n",
        "       - Diagnostic criteria met/unmet\n",
        "       - Population prevalence\n",
        "       - Age/breed predisposition\n",
        "       - Required diagnostics\n",
        "\n",
        "    2. Secondary Differential List\n",
        "       For EACH differential:\n",
        "       - Reason for lower priority\n",
        "       - Required rule-out criteria\n",
        "       - Testing recommendations\n",
        "\n",
        "    DIAGNOSTIC PLAN:\n",
        "    1. Immediate Diagnostics\n",
        "       For EACH test:\n",
        "       - Specific justification\n",
        "       - Expected findings\n",
        "       - Result interpretation criteria\n",
        "       - Cost-benefit assessment\n",
        "       - Sample handling requirements\n",
        "       - Timing considerations\n",
        "\n",
        "    2. Monitoring Diagnostics\n",
        "       For EACH parameter:\n",
        "       - Frequency of measurement\n",
        "       - Alert thresholds\n",
        "       - Trend analysis criteria\n",
        "       - Action triggers\n",
        "\n",
        "    THERAPEUTIC PLAN:\n",
        "    1. Immediate Interventions\n",
        "       For EACH treatment:\n",
        "       - Drug name (generic/brand)\n",
        "       - Exact dose calculation\n",
        "       - Administration details\n",
        "       - Monitoring requirements\n",
        "       - Expected response timeline\n",
        "       - Adverse effect monitoring\n",
        "\n",
        "    2. Long-term Management\n",
        "       - Specific outcome goals\n",
        "       - Timeline for reassessment\n",
        "       - Quality of life parameters\n",
        "       - Client education points\n",
        "       - Environmental modifications\n",
        "       - Dietary recommendations\n",
        "\n",
        "    All plans must include specific criteria for success/failure and explicit timeline for modifications.\"\"\"\n",
        "\n",
        "    SPECIALIST = \"\"\"You are a veterinary specialist providing comprehensive case assessment.\n",
        "\n",
        "    REQUIRED DOCUMENTATION FORMAT:\n",
        "\n",
        "    SPECIALIST CONSULTATION:\n",
        "    1. Case Summary\n",
        "       - Detailed chronological history\n",
        "       - ALL prior treatments with responses\n",
        "       - EVERY diagnostic result\n",
        "       - Specific clinical progression\n",
        "       - Current status assessment\n",
        "\n",
        "    2. Disease Process Analysis\n",
        "       - Detailed pathophysiology\n",
        "       - Current disease stage\n",
        "       - Progression factors\n",
        "       - Complicating conditions\n",
        "       - Prognosis assessment with criteria\n",
        "\n",
        "    3. Treatment Analysis\n",
        "       - Response to previous treatments\n",
        "       - Current treatment efficacy\n",
        "       - Treatment complications\n",
        "       - Compliance assessment\n",
        "       - Risk-benefit analysis\n",
        "\n",
        "    4. Specialist Recommendations\n",
        "       For EACH recommendation:\n",
        "       - Specific intervention\n",
        "       - Scientific rationale\n",
        "       - Expected outcome\n",
        "       - Monitoring parameters\n",
        "       - Alternative options\n",
        "\n",
        "    COMPREHENSIVE PLAN:\n",
        "    1. Medical Management\n",
        "       For EACH medication:\n",
        "       - Exact dose calculations\n",
        "       - Administration protocol\n",
        "       - Monitoring requirements\n",
        "       - Duration of therapy\n",
        "       - Success criteria\n",
        "       - Modification triggers\n",
        "\n",
        "    2. Monitoring Protocol\n",
        "       For EACH parameter:\n",
        "       - Measurement frequency\n",
        "       - Specific target values\n",
        "       - Acceptable ranges\n",
        "       - Action thresholds\n",
        "       - Response protocols\n",
        "\n",
        "    3. Client Education\n",
        "       - Disease process explanation\n",
        "       - Treatment rationale\n",
        "       - Administration instructions\n",
        "       - Monitoring requirements\n",
        "       - Warning signs\n",
        "       - Emergency protocols\n",
        "\n",
        "    4. Follow-up Schedule\n",
        "       - Specific recheck dates\n",
        "       - Testing schedule\n",
        "       - Progress assessment criteria\n",
        "       - Long-term monitoring plan\n",
        "       - Quality of life assessment\n",
        "\n",
        "    Documentation must be specific enough for any veterinarian to continue care.\"\"\"\n",
        "\n",
        "    CONNECTIONS = \"\"\"You are a veterinary case integration specialist.\n",
        "\n",
        "    REQUIRED INTEGRATION FORMAT:\n",
        "\n",
        "    CASE SYNTHESIS:\n",
        "    1. Disease Interactions\n",
        "       - Primary-Secondary Disease Relationships:\n",
        "         * Causal connections\n",
        "         * Exacerbating factors\n",
        "         * Systemic effects\n",
        "         * Progressive impacts\n",
        "\n",
        "       - Complicating Factors:\n",
        "         * Concurrent conditions\n",
        "         * Age-related factors\n",
        "         * Breed predispositions\n",
        "         * Environmental influences\n",
        "\n",
        "       - Synergistic Effects:\n",
        "         * Disease interactions\n",
        "         * Treatment interactions\n",
        "         * Cumulative impacts\n",
        "         * Quality of life effects\n",
        "\n",
        "    2. Treatment Integration\n",
        "       - Drug Interactions:\n",
        "         * Known interactions\n",
        "         * Potential interactions\n",
        "         * Monitoring requirements\n",
        "         * Adjustment protocols\n",
        "\n",
        "       - Therapeutic Conflicts:\n",
        "         * Competing treatment needs\n",
        "         * Priority assessment\n",
        "         * Resolution strategies\n",
        "         * Risk mitigation\n",
        "\n",
        "       - Management Synergies:\n",
        "         * Complementary treatments\n",
        "         * Timing optimization\n",
        "         * Efficiency improvements\n",
        "         * Outcome enhancement\n",
        "\n",
        "    3. Risk Assessment\n",
        "       - Current Risk Factors:\n",
        "         * Disease-specific risks\n",
        "         * Treatment-related risks\n",
        "         * Environmental risks\n",
        "         * Client-specific factors\n",
        "\n",
        "       - Potential Complications:\n",
        "         * Early warning signs\n",
        "         * Prevention strategies\n",
        "         * Monitoring protocols\n",
        "         * Intervention triggers\n",
        "\n",
        "    INTEGRATED CARE PLAN:\n",
        "    1. Comprehensive Treatment Strategy\n",
        "       - Prioritized Interventions:\n",
        "         * Immediate actions\n",
        "         * Short-term goals\n",
        "         * Long-term objectives\n",
        "         * Success criteria\n",
        "\n",
        "       - Coordinated Care:\n",
        "         * Team responsibilities\n",
        "         * Communication protocols\n",
        "         * Documentation requirements\n",
        "         * Quality assurance\n",
        "\n",
        "    2. Long-term Management\n",
        "       - Disease Trajectory:\n",
        "         * Expected progression\n",
        "         * Monitoring points\n",
        "         * Intervention triggers\n",
        "         * Outcome measures\n",
        "\n",
        "       - Quality of Life:\n",
        "         * Assessment criteria\n",
        "         * Monitoring protocol\n",
        "         * Improvement strategies\n",
        "         * Client assessment tools\n",
        "\n",
        "    3. Support Systems\n",
        "       - Client Education:\n",
        "         * Understanding assessment\n",
        "         * Training needs\n",
        "         * Resource requirements\n",
        "         * Support services\n",
        "\n",
        "       - Compliance Strategy:\n",
        "         * Barriers assessment\n",
        "         * Solution implementation\n",
        "         * Monitoring methods\n",
        "         * Success measures\n",
        "\n",
        "    Integration must be comprehensive and actionable with clear responsibilities and timelines.\"\"\"\n",
        "\n",
        "VET_PROMPTS = VetPrompts()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "cUhG-GtS0mb1"
      },
      "outputs": [],
      "source": [
        "def query_pinecone(query: str, top_k: int = 5) -> List[dict]:\n",
        "    \"\"\"Query Pinecone index for relevant context\"\"\"\n",
        "    query_embedding = embeddings.embed_query(query)\n",
        "    index = pc.Index(index_name)\n",
        "    results = index.query(\n",
        "        vector=query_embedding,\n",
        "        top_k=top_k,\n",
        "        include_metadata=True\n",
        "    )\n",
        "    return results.matches\n",
        "\n",
        "def handle_error(state: VetState, error_message: str) -> VetState:\n",
        "    new_state = state.copy()\n",
        "    if \"errors\" not in new_state[\"results\"]:\n",
        "        new_state[\"results\"][\"errors\"] = []\n",
        "    new_state[\"results\"][\"errors\"].append({\n",
        "        \"timestamp\": datetime.now().isoformat(),\n",
        "        \"message\": error_message,\n",
        "        \"context\": state.get(\"context\", [])\n",
        "    })\n",
        "    return new_state\n",
        "\n",
        "def process_pdf(file_path: str) -> Tuple[List[str], List[Dict[str, Any]]]:\n",
        "    \"\"\"\n",
        "    Process PDF document and extract both text and images\n",
        "    Returns: Tuple of (text_chunks, image_data)\n",
        "    \"\"\"\n",
        "    try:\n",
        "        doc = fitz.open(file_path)\n",
        "        text_chunks = []\n",
        "        images = []\n",
        "\n",
        "        for page_num in range(len(doc)):\n",
        "            page = doc[page_num]\n",
        "            text = page.get_text()\n",
        "            if text.strip():\n",
        "                text_chunks.append(text)\n",
        "            image_list = page.get_images()\n",
        "            for img_index, img in enumerate(image_list):\n",
        "                try:\n",
        "                    xref = img[0]\n",
        "                    base_image = doc.extract_image(xref)\n",
        "                    image_data = {\n",
        "                        'page_num': page_num + 1,\n",
        "                        'image_index': img_index,\n",
        "                        'extension': base_image[\"ext\"],\n",
        "                        'content': base64.b64encode(base_image[\"image\"]).decode(),\n",
        "                        'metadata': {\n",
        "                            'width': base_image.get('width'),\n",
        "                            'height': base_image.get('height'),\n",
        "                            'colorspace': base_image.get('colorspace')\n",
        "                        }\n",
        "                    }\n",
        "                    images.append(image_data)\n",
        "                except Exception as e:\n",
        "                    print(f\"Error extracting image {img_index} from page {page_num + 1}: {str(e)}\")\n",
        "\n",
        "        text_splitter = RecursiveCharacterTextSplitter(\n",
        "            chunk_size=1000,\n",
        "            chunk_overlap=200,\n",
        "            length_function=len,\n",
        "        )\n",
        "\n",
        "        if text_chunks:\n",
        "            combined_text = \"\\n\\n\".join(text_chunks)\n",
        "            final_chunks = text_splitter.split_text(combined_text)\n",
        "        else:\n",
        "            final_chunks = []\n",
        "\n",
        "        doc.close()\n",
        "        return final_chunks, images\n",
        "\n",
        "    except Exception as e:\n",
        "        print(f\"Error processing PDF: {str(e)}\")\n",
        "        return [], []\n",
        "\n",
        "\n",
        "def process_multiple_files(\n",
        "    file_paths: List[str],\n",
        ") -> Tuple[List[str], List[Dict[str, Any]]]:\n",
        "    \"\"\"\n",
        "    Process multiple PDF documents and extract both text and images\n",
        "    Args:\n",
        "        file_paths: List of file paths to process\n",
        "    Returns:\n",
        "        Tuple of (text_chunks, image_data)\n",
        "    \"\"\"\n",
        "    all_text_chunks = []\n",
        "    all_images = []\n",
        "\n",
        "    for file_path in file_paths:\n",
        "        try:\n",
        "            doc = fitz.open(file_path)\n",
        "\n",
        "            # Process text from current file\n",
        "            file_chunks = []\n",
        "            for page_num in range(len(doc)):\n",
        "                page = doc[page_num]\n",
        "                text = page.get_text()\n",
        "                if text.strip():\n",
        "                    # Add file identifier to chunk\n",
        "                    marked_text = f\"[Source: {file_path}]\\n{text}\"\n",
        "                    file_chunks.append(marked_text)\n",
        "\n",
        "                # Process images from current page\n",
        "                image_list = page.get_images()\n",
        "                for img_index, img in enumerate(image_list):\n",
        "                    try:\n",
        "                        xref = img[0]\n",
        "                        base_image = doc.extract_image(xref)\n",
        "                        image_data = {\n",
        "                            \"file_path\": file_path,\n",
        "                            \"page_num\": page_num + 1,\n",
        "                            \"image_index\": img_index,\n",
        "                            \"extension\": base_image[\"ext\"],\n",
        "                            \"content\": base64.b64encode(base_image[\"image\"]).decode(),\n",
        "                            \"metadata\": {\n",
        "                                \"width\": base_image.get(\"width\"),\n",
        "                                \"height\": base_image.get(\"height\"),\n",
        "                                \"colorspace\": base_image.get(\"colorspace\"),\n",
        "                            },\n",
        "                        }\n",
        "                        all_images.append(image_data)\n",
        "                    except Exception as e:\n",
        "                        print(\n",
        "                            f\"Error extracting image {img_index} from page {page_num + 1} in {file_path}: {str(e)}\"\n",
        "                        )\n",
        "\n",
        "            all_text_chunks.extend(file_chunks)\n",
        "            doc.close()\n",
        "\n",
        "        except Exception as e:\n",
        "            print(f\"Error processing file {file_path}: {str(e)}\")\n",
        "            continue\n",
        "\n",
        "    # Apply text splitting after collecting all chunks\n",
        "    text_splitter = RecursiveCharacterTextSplitter(\n",
        "        chunk_size=1000,\n",
        "        chunk_overlap=200,\n",
        "        length_function=len,\n",
        "    )\n",
        "\n",
        "    if all_text_chunks:\n",
        "        combined_text = \"\\n\\n\".join(all_text_chunks)\n",
        "        final_chunks = text_splitter.split_text(combined_text)\n",
        "    else:\n",
        "        final_chunks = []\n",
        "\n",
        "    return final_chunks, all_images\n",
        "\n",
        "\n",
        "def create_data_processing_agent():\n",
        "    def process_data(state: VetState) -> VetState:\n",
        "        try:\n",
        "            relevant_docs = query_pinecone(state[\"current_input\"])\n",
        "            context = [doc.metadata.get(\"text\", \"\") for doc in relevant_docs]\n",
        "\n",
        "            if state.get(\"images\"):\n",
        "                image_context = \"Document contains the following images:\\n\"\n",
        "                for idx, img in enumerate(state[\"images\"]):\n",
        "                    image_context += f\"\\nImage {idx + 1} on page {img['page_num']}:\\n\"\n",
        "                    image_context += f\"- Type: {img['extension']}\\n\"\n",
        "                    image_context += f\"- Dimensions: {img['metadata']['width']}x{img['metadata']['height']}\\n\"\n",
        "                context.append(image_context)\n",
        "\n",
        "            context_text = \"\\n\\n\".join(context)\n",
        "\n",
        "            prompt = ChatPromptTemplate.from_messages([\n",
        "                (\"system\", VET_PROMPTS.BASE_VETERINARY_CONTEXT),\n",
        "                (\"system\", VET_PROMPTS.DATA_PROCESSOR),\n",
        "                (\"human\", \"Process this veterinary case data in detail: {input}\")\n",
        "            ])\n",
        "\n",
        "            messages = prompt.format_messages(\n",
        "                input=state[\"current_input\"],\n",
        "                context=context_text\n",
        "            )\n",
        "            response = llm.invoke(messages)\n",
        "\n",
        "            new_state = state.copy()\n",
        "            new_state[\"messages\"].append(response)\n",
        "            new_state[\"results\"][\"DataProcessor\"] = response.content\n",
        "            new_state[\"context\"] = context\n",
        "\n",
        "            return new_state\n",
        "\n",
        "        except Exception as e:\n",
        "            return handle_error(state, f\"Data Processing Error: {str(e)}\")\n",
        "\n",
        "    return process_data\n",
        "\n",
        "\n",
        "def create_history_analysis_agent():\n",
        "    def analyze_history(state: VetState) -> VetState:\n",
        "        try:\n",
        "            processed_data = state[\"results\"][\"DataProcessor\"]\n",
        "            context = state.get(\"context\", [])\n",
        "\n",
        "            prompt = ChatPromptTemplate.from_messages([\n",
        "                (\"system\", VET_PROMPTS.BASE_VETERINARY_CONTEXT),\n",
        "                (\"system\", VET_PROMPTS.HISTORY_ANALYZER),\n",
        "                (\"human\", \"Analyze this case history with detailed timeline: {processed_data}\")\n",
        "            ])\n",
        "\n",
        "            messages = prompt.format_messages(\n",
        "                processed_data=processed_data,\n",
        "                context=\"\\n\\n\".join(context)\n",
        "            )\n",
        "            response = llm.invoke(messages)\n",
        "\n",
        "            new_state = state.copy()\n",
        "            new_state[\"messages\"].append(response)\n",
        "            new_state[\"results\"][\"HistoryAnalyzer\"] = response.content\n",
        "\n",
        "            return new_state\n",
        "\n",
        "        except Exception as e:\n",
        "            return handle_error(state, f\"History Analysis Error: {str(e)}\")\n",
        "\n",
        "    return analyze_history\n",
        "\n",
        "def create_clinical_analysis_agent():\n",
        "    def analyze_clinical(state: VetState) -> VetState:\n",
        "        try:\n",
        "            history_analysis = state[\"results\"][\"HistoryAnalyzer\"]\n",
        "            context = state.get(\"context\", [])\n",
        "\n",
        "            prompt = ChatPromptTemplate.from_messages([\n",
        "                (\"system\", VET_PROMPTS.BASE_VETERINARY_CONTEXT),\n",
        "                (\"system\", VET_PROMPTS.CLINICAL_ANALYZER),\n",
        "                (\"human\", \"Provide detailed clinical analysis for: {history_analysis}\")\n",
        "            ])\n",
        "\n",
        "            messages = prompt.format_messages(\n",
        "                history_analysis=history_analysis,\n",
        "                context=\"\\n\\n\".join(context)\n",
        "            )\n",
        "            response = llm.invoke(messages)\n",
        "\n",
        "            new_state = state.copy()\n",
        "            new_state[\"messages\"].append(response)\n",
        "            new_state[\"results\"][\"ClinicalAnalyzer\"] = response.content\n",
        "\n",
        "            return new_state\n",
        "\n",
        "        except Exception as e:\n",
        "            return handle_error(state, f\"Clinical Analysis Error: {str(e)}\")\n",
        "\n",
        "    return analyze_clinical\n",
        "\n",
        "def create_diagnostic_agent():\n",
        "    def diagnose(state: VetState) -> VetState:\n",
        "        try:\n",
        "            clinical_analysis = state[\"results\"][\"ClinicalAnalyzer\"]\n",
        "            context = state.get(\"context\", [])\n",
        "\n",
        "            diagnostic_context = query_pinecone(clinical_analysis)\n",
        "            additional_context = [doc.metadata.get(\"text\", \"\") for doc in diagnostic_context]\n",
        "            combined_context = context + additional_context\n",
        "\n",
        "            prompt = ChatPromptTemplate.from_messages([\n",
        "                (\"system\", VET_PROMPTS.BASE_VETERINARY_CONTEXT),\n",
        "                (\"system\", VET_PROMPTS.DIAGNOSTICIAN),\n",
        "                (\"human\", \"Provide comprehensive diagnostic assessment for: {clinical_analysis}\")\n",
        "            ])\n",
        "\n",
        "            messages = prompt.format_messages(\n",
        "                clinical_analysis=clinical_analysis,\n",
        "                context=\"\\n\\n\".join(combined_context)\n",
        "            )\n",
        "            response = llm.invoke(messages)\n",
        "\n",
        "            new_state = state.copy()\n",
        "            new_state[\"messages\"].append(response)\n",
        "            new_state[\"results\"][\"Diagnostics\"] = response.content\n",
        "            new_state[\"context\"] = combined_context\n",
        "\n",
        "            return new_state\n",
        "\n",
        "        except Exception as e:\n",
        "            return handle_error(state, f\"Diagnostic Error: {str(e)}\")\n",
        "\n",
        "    return diagnose\n",
        "\n",
        "def create_specialist_summary_agent():\n",
        "    def generate_summaries(state: VetState) -> VetState:\n",
        "        try:\n",
        "            diagnostic_assessment = state[\"results\"][\"Diagnostics\"]\n",
        "            context = state.get(\"context\", [])\n",
        "            prompt = ChatPromptTemplate.from_messages([\n",
        "                (\"system\", VET_PROMPTS.BASE_VETERINARY_CONTEXT),\n",
        "                (\"system\", VET_PROMPTS.SPECIALIST),\n",
        "                (\"human\", \"Generate comprehensive specialist assessment for: {diagnostic_assessment}\")\n",
        "            ])\n",
        "            messages = prompt.format_messages(\n",
        "                diagnostic_assessment=diagnostic_assessment,\n",
        "                context=\"\\n\\n\".join(context)\n",
        "            )\n",
        "            response = llm.invoke(messages)\n",
        "\n",
        "            new_state = state.copy()\n",
        "            new_state[\"messages\"].append(response)\n",
        "            new_state[\"results\"][\"SpecialistSummary\"] = response.content\n",
        "\n",
        "            return new_state\n",
        "\n",
        "        except Exception as e:\n",
        "            return handle_error(state, f\"Specialist Summary Error: {str(e)}\")\n",
        "\n",
        "    return generate_summaries\n",
        "\n",
        "def create_connections_agent():\n",
        "    def analyze_connections(state: VetState) -> VetState:\n",
        "        try:\n",
        "            previous_analyses = {\n",
        "                \"data_processing\": state[\"results\"][\"DataProcessor\"],\n",
        "                \"history\": state[\"results\"][\"HistoryAnalyzer\"],\n",
        "                \"clinical\": state[\"results\"][\"ClinicalAnalyzer\"],\n",
        "                \"diagnostics\": state[\"results\"][\"Diagnostics\"],\n",
        "                \"specialist\": state[\"results\"][\"SpecialistSummary\"]\n",
        "            }\n",
        "\n",
        "            context = state.get(\"context\", [])\n",
        "            prompt = ChatPromptTemplate.from_messages([\n",
        "                (\"system\", VET_PROMPTS.BASE_VETERINARY_CONTEXT),\n",
        "                (\"system\", VET_PROMPTS.CONNECTIONS),\n",
        "                (\"human\", \"Provide comprehensive case integration analysis for: {previous_analyses}\")\n",
        "            ])\n",
        "\n",
        "            messages = prompt.format_messages(\n",
        "                previous_analyses=json.dumps(previous_analyses, indent=2),\n",
        "                context=\"\\n\\n\".join(context)\n",
        "            )\n",
        "            response = llm.invoke(messages)\n",
        "\n",
        "            new_state = state.copy()\n",
        "            new_state[\"messages\"].append(response)\n",
        "            new_state[\"results\"][\"Connections\"] = response.content\n",
        "\n",
        "            return new_state\n",
        "\n",
        "        except Exception as e:\n",
        "            return handle_error(state, f\"Connections Analysis Error: {str(e)}\")\n",
        "\n",
        "    return analyze_connections\n",
        "\n",
        "def create_workflow():\n",
        "    \"\"\"Create and configure the workflow\"\"\"\n",
        "    workflow = StateGraph(VetState)\n",
        "\n",
        "    workflow.add_node(\"process_data\", create_data_processing_agent())\n",
        "    workflow.add_node(\"analyze_history\", create_history_analysis_agent())\n",
        "    workflow.add_node(\"analyze_clinical\", create_clinical_analysis_agent())\n",
        "    workflow.add_node(\"diagnose\", create_diagnostic_agent())\n",
        "    workflow.add_node(\"specialist_summary\", create_specialist_summary_agent())\n",
        "    workflow.add_node(\"analyze_connections\", create_connections_agent())\n",
        "\n",
        "    workflow.set_entry_point(\"process_data\")\n",
        "\n",
        "    workflow.add_edge(\"process_data\", \"analyze_history\")\n",
        "    workflow.add_edge(\"analyze_history\", \"analyze_clinical\")\n",
        "    workflow.add_edge(\"analyze_clinical\", \"diagnose\")\n",
        "    workflow.add_edge(\"diagnose\", \"specialist_summary\")\n",
        "    workflow.add_edge(\"specialist_summary\", \"analyze_connections\")\n",
        "    workflow.add_edge(\"analyze_connections\", END)\n",
        "\n",
        "    return workflow.compile()\n",
        "\n",
        "\n",
        "def analyze_veterinary_case(file_paths: Union[str, List[str]]):\n",
        "    \"\"\"\n",
        "    Main function to analyze a veterinary case from single or multiple files\n",
        "    Args:\n",
        "        file_paths: Either a single file path string or a list of file paths\n",
        "    Returns:\n",
        "        Analysis results\n",
        "    \"\"\"\n",
        "    try:\n",
        "        print(\"Processing document(s)...\")\n",
        "\n",
        "        # Convert single file path to list for consistent processing\n",
        "        if isinstance(file_paths, str):\n",
        "            file_paths = [file_paths]\n",
        "\n",
        "        text_chunks, images = process_multiple_files(file_paths)\n",
        "\n",
        "        if not text_chunks:\n",
        "            raise ValueError(\"No text content extracted from provided files\")\n",
        "\n",
        "        initial_state = {\n",
        "            \"messages\": [],\n",
        "            \"current_input\": \"\\n\\n\".join(text_chunks),\n",
        "            \"medical_records\": {},\n",
        "            \"results\": {\n",
        "                \"DataProcessor\": \"\",\n",
        "                \"HistoryAnalyzer\": \"\",\n",
        "                \"ClinicalAnalyzer\": \"\",\n",
        "                \"Diagnostics\": \"\",\n",
        "                \"SpecialistSummary\": \"\",\n",
        "                \"Connections\": \"\",\n",
        "            },\n",
        "            \"metadata\": {\n",
        "                \"file_count\": len(file_paths),\n",
        "                \"processed_files\": file_paths,\n",
        "                \"total_chunks\": len(text_chunks),\n",
        "                \"total_images\": len(images),\n",
        "            },\n",
        "            \"context\": [],\n",
        "            \"images\": images,\n",
        "        }\n",
        "\n",
        "        print(f\"Creating workflow for {len(file_paths)} file(s)...\")\n",
        "        app = create_workflow()\n",
        "\n",
        "        print(\"Running analysis...\")\n",
        "        result = app.invoke(initial_state)\n",
        "\n",
        "        return result\n",
        "\n",
        "    except Exception as e:\n",
        "        print(f\"Error in analysis: {str(e)}\")\n",
        "        raise\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "tuxa4tEWT3ha",
        "outputId": "bffba070-9b66-41d0-dbfc-4ec1791b580f"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Processing document(s)...\n",
            "Creating workflow for 1 file(s)...\n",
            "Running analysis...\n",
            "\n",
            "Analysis Results:\n",
            "--------------------------------------------------\n",
            "\n",
            "Data Processing:\n",
            "------------------------------\n",
            "**PATIENT SIGNALMENT & CLIENT INFORMATION:**\n",
            "- Patient: Jax Miracle\n",
            "- Patient ID: CA2441B8\n",
            "- Species: Canine\n",
            "- Breed: Pomeranian\n",
            "- Age: 4 years old\n",
            "- Sex: Male, neutered\n",
            "- Weight: 6.1 kg\n",
            "- Microchip: None\n",
            "- Client: Anna Miracle\n",
            "- Client ID: 24404F\n",
            "- Address: 2497 Hillsboro Rd, Campbellsburg, KY 40011, USA\n",
            "- Phone: (502) 532-6641\n",
            "- Email: miracletricia@gmail.com\n",
            "\n",
            "**PRESENTING COMPLAINT AND HISTORY:**\n",
            "- Chief Complaint: Coughing\n",
            "- Duration: Not specified\n",
            "- Symptoms: Coughing, hacking, panting loudly\n",
            "- Vomiting: None\n",
            "- Diarrhea: None\n",
            "- Coughing/Sneezing: Dry cough\n",
            "- Changes in Drinking/Urination/Eating: No changes\n",
            "- Lumps/Bumps: None\n",
            "- Travel History: No recent travel\n",
            "- Tick History: No ticks found\n",
            "- Heartworm Prevention: Yes\n",
            "- Diet: Variety, Pedigree canned food, Kibbles and Bits dry food, Dreambones for 15 months\n",
            "- Medications: Bravecto (1 tablet every 6 months), Sentinel Spectrum (8.75 mg tablet once a month)\n",
            "- Anesthesia History: No issues\n",
            "- Household Pets: 1 dog\n",
            "\n",
            "**PHYSICAL EXAMINATION:**\n",
            "- Vital Signs: Not recorded\n",
            "- General Appearance: Not recorded\n",
            "- EENT: Not recorded\n",
            "- Cardiovascular: Not recorded\n",
            "- Respiratory: Not recorded\n",
            "- Gastrointestinal: Not recorded\n",
            "- Musculoskeletal: Not recorded\n",
            "- Neurologic: Not recorded\n",
            "- Integumentary: Not recorded\n",
            "- Lymphatic: Not recorded\n",
            "- Urogenital: Not recorded\n",
            "\n",
            "**DIAGNOSTIC FINDINGS:**\n",
            "- Laboratory Results: Not provided\n",
            "- Imaging Findings: Not provided\n",
            "- Other Test Results: Not provided\n",
            "\n",
            "**CURRENT MEDICATIONS AND TREATMENTS:**\n",
            "1. Bravecto (Orange) - 1 tablet every 6 months\n",
            "2. Sentinel Spectrum (8.75 mg) - 1 tablet once a month\n",
            "\n",
            "**CLIENT COMMUNICATIONS AND INSTRUCTIONS:**\n",
            "- Client consented to receive SMS messages from the veterinary practice.\n",
            "- Client authorized the release of medical records and images for diagnostic and educational purposes.\n",
            "- Client agreed to the use of AI technologies for processing medical information.\n",
            "- Client did not report any new lumps or bumps on the pet.\n",
            "- Client reported anxiety in the pet.\n",
            "- Client confirmed heartworm prevention for the pet.\n",
            "- Client provided detailed information about the pet's diet and medications.\n",
            "- Client reported no changes in the pet's drinking, urination, or eating habits.\n",
            "\n",
            "History Analysis:\n",
            "------------------------------\n",
            "**COMPREHENSIVE TIMELINE:**\n",
            "\n",
            "1. **Initial Disease Onset:**\n",
            "   - Date of First Clinical Signs: Not specified\n",
            "   - Symptom Progression: Coughing, hacking, panting loudly with a dry cough\n",
            "   - Initial Diagnostic Findings: Not provided\n",
            "   - First Treatment Responses: Bravecto every 6 months, Sentinel Spectrum monthly\n",
            "\n",
            "2. **Disease Progression:**\n",
            "   - No detailed symptom evolution provided\n",
            "   - No complications or new symptoms reported\n",
            "   - No medication changes documented\n",
            "\n",
            "3. **Complete Treatment History:**\n",
            "   - Bravecto (Orange) - 1 tablet every 6 months\n",
            "     - Start Date: Not specified\n",
            "     - End Date: Ongoing\n",
            "     - Response: Not applicable\n",
            "     - Adverse Reactions: Not reported\n",
            "   - Sentinel Spectrum (8.75 mg) - 1 tablet once a month\n",
            "     - Start Date: Not specified\n",
            "     - End Date: Ongoing\n",
            "     - Response: Not applicable\n",
            "     - Adverse Reactions: Not reported\n",
            "\n",
            "4. **Diagnostic Testing Chronology:**\n",
            "   - No tests performed or results provided\n",
            "\n",
            "**PATTERN ANALYSIS:**\n",
            "\n",
            "1. **Detailed Symptom Patterns:**\n",
            "   - Frequency of Episodes: Not specified\n",
            "   - Severity Trends: Not recorded\n",
            "   - Triggers: Not identified\n",
            "   - Temporal Patterns: Not specified\n",
            "\n",
            "2. **Treatment Response Analysis:**\n",
            "   - Duration of Response: Not applicable\n",
            "   - Degree of Improvement: Not applicable\n",
            "   - Treatment Failures: Not applicable\n",
            "   - Compliance Assessment: Client reported compliance with heartworm prevention medications\n",
            "\n",
            "3. **Risk Factor Evaluation:**\n",
            "   - No identified risk factors provided\n",
            "   - Environmental Influences: No specific information\n",
            "   - Genetic Predispositions: Not mentioned\n",
            "   - Concurrent Conditions: No other conditions reported\n",
            "\n",
            "This case lacks detailed clinical information, diagnostic findings, and treatment responses. Further evaluation and diagnostic workup are necessary to address the presenting complaint of coughing in the Pomeranian patient, Jax Miracle.\n",
            "\n",
            "Clinical Analysis:\n",
            "------------------------------\n",
            "**CLINICAL ASSESSMENT:**\n",
            "\n",
            "1. **Primary Clinical Signs Analysis:**\n",
            "   - Coughing:\n",
            "     * Duration: Not specified\n",
            "     * Frequency: Not specified\n",
            "     * Severity: Not recorded\n",
            "     * Pattern: Described as dry cough\n",
            "     * Response to Bravecto and Sentinel Spectrum: Not specified\n",
            "\n",
            "2. **Comprehensive Physical Examination Analysis:**\n",
            "   - Vital Signs Interpretation:\n",
            "     * Temperature: Not provided\n",
            "     * Heart rate: Not provided\n",
            "     * Respiratory rate and effort: Panting loudly noted\n",
            "     * Weight trends: Not specified\n",
            "     * Body condition score changes: Not specified\n",
            "\n",
            "   - Detailed System Analysis:\n",
            "     * Abnormal Findings: Coughing, hacking, panting loudly\n",
            "     * Masses/Lesions: Not mentioned\n",
            "     * Pain Assessment: Not documented\n",
            "     * Comparative Findings: Not specified\n",
            "     * Sequential Changes: No reported changes\n",
            "\n",
            "3. **Diagnostic Testing Interpretation:**\n",
            "   - Laboratory Results: Not available\n",
            "   - Imaging: Not performed\n",
            "\n",
            "4. **Disease Process Analysis:**\n",
            "   - Pathophysiology: Coughing can be indicative of various respiratory conditions such as tracheal collapse, bronchitis, or heart disease.\n",
            "   - Complications: Not reported\n",
            "   - Disease Stage: Unable to determine without diagnostic testing\n",
            "   - Progression Indicators: Lack of symptom evolution noted\n",
            "\n",
            "5. **Treatment Response Evaluation:**\n",
            "   - Bravecto and Sentinel Spectrum:\n",
            "     * Time to Response: Not specified\n",
            "     * Degree of Improvement: Not documented\n",
            "     * Duration of Effect: Not provided\n",
            "     * Side Effects: Not reported\n",
            "     * Factors Affecting Efficacy: Compliance reported by the client\n",
            "\n",
            "**CLINICAL INTEGRATION:**\n",
            "\n",
            "1. **Evidence Synthesis:**\n",
            "   - Limited evidence available due to lack of diagnostic testing and detailed clinical information.\n",
            "   - Further investigations are crucial to support a definitive diagnosis.\n",
            "\n",
            "2. **Contradictory Findings:**\n",
            "   - No contradictory findings noted due to insufficient data.\n",
            "   - Rule-out justifications are challenging without diagnostic results.\n",
            "   - Testing limitations hinder a comprehensive assessment of the case.\n",
            "\n",
            "Given the incomplete clinical data, it is imperative to conduct a thorough physical examination, diagnostic workup including blood tests, imaging studies, and potentially respiratory evaluations to determine the underlying cause of coughing in Jax Miracle. Regular monitoring and follow-up are essential to assess treatment efficacy and adjust the management plan accordingly.\n",
            "\n",
            "Diagnostic Assessment:\n",
            "------------------------------\n",
            "**PROBLEM LIST:**\n",
            "\n",
            "1. Active Problems:\n",
            "   - Coughing\n",
            "     - Duration: Not specified\n",
            "     - Severity: Not recorded\n",
            "     - Progression: Dry cough reported\n",
            "     - Clinical Findings: Coughing, hacking, panting loudly\n",
            "     - Impact on Quality of Life: Potential discomfort and respiratory distress\n",
            "     - Treatment: No specific treatment initiated\n",
            "\n",
            "2. Inactive/Resolved Problems:\n",
            "   - None\n",
            "\n",
            "**DIFFERENTIAL DIAGNOSES:**\n",
            "\n",
            "1. Primary Differential List:\n",
            "   - Tracheal Collapse\n",
            "     - Supporting Evidence: Dry cough, hacking\n",
            "     - Diagnostic Criteria: Tracheal collapse typically presents with coughing, especially during excitement or exercise.\n",
            "     - Required Diagnostics: Radiography, fluoroscopy\n",
            "\n",
            "   - Canine Bronchitis\n",
            "     - Supporting Evidence: Dry cough, panting loudly\n",
            "     - Diagnostic Criteria: Chronic cough, often worsened by exercise or excitement.\n",
            "     - Required Diagnostics: Chest radiographs, bronchoscopy\n",
            "\n",
            "   - Cardiac Disease\n",
            "     - Supporting Evidence: Panting loudly, coughing\n",
            "     - Diagnostic Criteria: Coughing can be a sign of heart disease, especially in older dogs.\n",
            "     - Required Diagnostics: Echocardiography, electrocardiography\n",
            "\n",
            "2. Secondary Differential List:\n",
            "   - Infectious Tracheobronchitis (Kennel Cough)\n",
            "     - Reason for Lower Priority: Less likely without exposure history\n",
            "     - Rule-out Criteria: Recent boarding, exposure to other dogs\n",
            "     - Testing Recommendations: PCR testing for infectious agents\n",
            "\n",
            "**DIAGNOSTIC PLAN:**\n",
            "\n",
            "1. Immediate Diagnostics:\n",
            "   - Chest Radiographs\n",
            "     - Justification: To evaluate trachea, bronchi, and lung fields for abnormalities\n",
            "     - Expected Findings: Tracheal collapse, bronchitis, cardiac enlargement\n",
            "     - Result Interpretation: Enlarged trachea, bronchial patterns, cardiac silhouette\n",
            "     - Cost-Benefit: Essential for definitive diagnosis\n",
            "     - Sample Handling: Standard radiographic procedure\n",
            "     - Timing: ASAP\n",
            "\n",
            "2. Monitoring Diagnostics:\n",
            "   - Respiratory Rate Monitoring\n",
            "     - Frequency: Daily\n",
            "     - Alert Thresholds: >30 breaths per minute\n",
            "     - Trend Analysis: Decreasing trend indicates improvement\n",
            "     - Action Triggers: Sustained increase in respiratory rate\n",
            "\n",
            "**THERAPEUTIC PLAN:**\n",
            "\n",
            "1. Immediate Interventions:\n",
            "   - Symptomatic Treatment with Cough Suppressants (e.g., Butorphanol)\n",
            "     - Dose: 0.2-0.4 mg/kg orally every 6-8 hours\n",
            "     - Administration: Oral\n",
            "     - Monitoring: Response to treatment, adverse effects\n",
            "     - Expected Response: Reduction in coughing episodes\n",
            "     - Adverse Effects: Sedation, gastrointestinal upset\n",
            "\n",
            "2. Long-term Management:\n",
            "   - Outcome Goals: Resolution of coughing, improved quality of life\n",
            "   - Reassessment: After diagnostic tests and initial treatment\n",
            "   - Client Education: Importance of compliance, monitoring for changes\n",
            "   - Environmental Modifications: Minimize exposure to irritants\n",
            "   - Dietary Recommendations: Maintain optimal weight, consider respiratory-supportive diets\n",
            "\n",
            "Regular follow-up appointments are necessary to assess treatment response, adjust therapy as needed, and ensure the well-being of Jax Miracle.\n",
            "\n",
            "Specialist Summary:\n",
            "------------------------------\n",
            "**SPECIALIST CONSULTATION:**\n",
            "\n",
            "1. **Case Summary:**\n",
            "   Jax Miracle, a canine patient, presents with a history of dry coughing, hacking, and loud panting. The duration and severity of coughing are not specified. No specific treatment has been initiated. The coughing may be causing potential discomfort and respiratory distress.\n",
            "\n",
            "2. **Disease Process Analysis:**\n",
            "   - **Pathophysiology:** Differential diagnoses include tracheal collapse, canine bronchitis, and cardiac disease. Tracheal collapse typically presents with coughing, especially during excitement or exercise. Canine bronchitis manifests as a chronic cough worsened by exercise. Cardiac disease can also lead to coughing, especially in older dogs.\n",
            "   - **Current Disease Stage:** Early stage with clinical signs of coughing and panting.\n",
            "   - **Prognosis:** Prognosis depends on the underlying cause, response to treatment, and client compliance.\n",
            "\n",
            "3. **Treatment Analysis:**\n",
            "   - No specific treatment initiated yet.\n",
            "   - Symptomatic treatment with cough suppressants may provide relief.\n",
            "   - Compliance with treatment and monitoring are crucial for successful management.\n",
            "\n",
            "4. **Specialist Recommendations:**\n",
            "   - Perform chest radiographs for definitive diagnosis.\n",
            "   - Initiate symptomatic treatment with a cough suppressant.\n",
            "   - Educate the client on the importance of compliance and monitoring.\n",
            "\n",
            "**COMPREHENSIVE PLAN:**\n",
            "\n",
            "1. **Medical Management:**\n",
            "   - **Cough Suppressant (Butorphanol):**\n",
            "     - Dose: 0.2-0.4 mg/kg orally every 6-8 hours\n",
            "     - Administration: Oral\n",
            "     - Monitoring: Response to treatment, adverse effects\n",
            "     - Duration: Until resolution of coughing\n",
            "     - Success Criteria: Reduction in coughing episodes\n",
            "\n",
            "2. **Monitoring Protocol:**\n",
            "   - **Respiratory Rate Monitoring:**\n",
            "     - Frequency: Daily\n",
            "     - Target Values: <30 breaths per minute\n",
            "     - Action Thresholds: >30 breaths per minute\n",
            "     - Response Protocol: Sustained increase in respiratory rate triggers reevaluation.\n",
            "\n",
            "3. **Client Education:**\n",
            "   - Explain the disease process and treatment rationale.\n",
            "   - Provide instructions on medication administration and monitoring.\n",
            "   - Educate on warning signs and emergency protocols.\n",
            "\n",
            "4. **Follow-up Schedule:**\n",
            "   - Recheck appointments after diagnostic tests and initial treatment.\n",
            "   - Establish a testing schedule for monitoring progress.\n",
            "   - Assess response to treatment and adjust therapy as needed.\n",
            "\n",
            "Regular follow-up appointments are essential to ensure the well-being of Jax Miracle and to monitor treatment response effectively.\n",
            "\n",
            "Connections Analysis:\n",
            "------------------------------\n",
            "CASE SYNTHESIS:\n",
            "1. Disease Interactions\n",
            "   - Primary-Secondary Disease Relationships:\n",
            "     * Causal connections: Coughing as the primary complaint may indicate underlying respiratory conditions like tracheal collapse, bronchitis, or cardiac disease.\n",
            "     * Systemic effects: Potential discomfort and respiratory distress from coughing.\n",
            "    \n",
            "   - Complicating Factors:\n",
            "     * Concurrent conditions: No other reported conditions.\n",
            "     * Environmental influences: No specific environmental triggers identified.\n",
            "    \n",
            "   - Synergistic Effects:\n",
            "     * Disease interactions: Respiratory conditions may impact overall quality of life.\n",
            "     * Treatment interactions: Symptomatic treatment may affect diagnostic findings.\n",
            "    \n",
            "2. Treatment Integration\n",
            "   - Drug Interactions:\n",
            "     * No known interactions reported with current medications.\n",
            "     * Symptomatic treatment with cough suppressants may influence diagnostic test results.\n",
            "    \n",
            "   - Therapeutic Conflicts:\n",
            "     * Competing treatment needs: Symptomatic relief vs. definitive diagnosis.\n",
            "     * Priority assessment: Diagnostic workup takes precedence for accurate treatment.\n",
            "    \n",
            "   - Management Synergies:\n",
            "     * Complementary treatments: Symptomatic relief alongside diagnostic testing.\n",
            "     * Timing optimization: Immediate diagnostics followed by symptomatic treatment.\n",
            "    \n",
            "3. Risk Assessment\n",
            "   - Current Risk Factors:\n",
            "     * Disease-specific risks: Respiratory distress from underlying conditions.\n",
            "     * Treatment-related risks: Adverse effects of cough suppressants.\n",
            "    \n",
            "   - Potential Complications:\n",
            "     * Early warning signs: Increased respiratory distress, lack of improvement.\n",
            "     * Monitoring protocols: Daily respiratory rate monitoring for changes.\n",
            "\n",
            "INTEGRATED CARE PLAN:\n",
            "1. Comprehensive Treatment Strategy\n",
            "   - Prioritized Interventions:\n",
            "     * Immediate actions: Chest radiographs for definitive diagnosis.\n",
            "     * Short-term goals: Symptomatic relief with cough suppressants.\n",
            "     * Long-term objectives: Resolution of coughing, improved quality of life.\n",
            "    \n",
            "   - Coordinated Care:\n",
            "     * Team responsibilities: Specialist consultation, client education, monitoring.\n",
            "     * Communication protocols: Regular updates on treatment response and progress.\n",
            "    \n",
            "2. Long-term Management\n",
            "   - Disease Trajectory:\n",
            "     * Expected progression: Resolution of coughing with appropriate treatment.\n",
            "     * Monitoring points: Daily respiratory rate checks, follow-up appointments.\n",
            "    \n",
            "   - Quality of Life:\n",
            "     * Assessment criteria: Reduction in coughing episodes, improved comfort.\n",
            "     * Improvement strategies: Compliance with treatment, environmental modifications.\n",
            "    \n",
            "3. Support Systems\n",
            "   - Client Education:\n",
            "     * Understanding assessment: Explanation of disease process and treatment rationale.\n",
            "     * Compliance Strategy: Instructions on medication administration and monitoring.\n",
            "     * Support services: Follow-up schedule for reevaluation and adjustment of therapy.\n"
          ]
        }
      ],
      "source": [
        "    file_path = \"./input.pdf\"\n",
        "    result = analyze_veterinary_case(file_path)\n",
        "\n",
        "    print(\"\\nAnalysis Results:\")\n",
        "    print(\"-\" * 50)\n",
        "\n",
        "    sections = [\n",
        "        (\"Data Processing\", \"DataProcessor\"),\n",
        "        (\"History Analysis\", \"HistoryAnalyzer\"),\n",
        "        (\"Clinical Analysis\", \"ClinicalAnalyzer\"),\n",
        "        (\"Diagnostic Assessment\", \"Diagnostics\"),\n",
        "        (\"Specialist Summary\", \"SpecialistSummary\"),\n",
        "        (\"Connections Analysis\", \"Connections\")\n",
        "    ]\n",
        "\n",
        "    for title, key in sections:\n",
        "        print(f\"\\n{title}:\")\n",
        "        print(\"-\" * 30)\n",
        "        print(result[\"results\"].get(key, \"Not available\"))\n",
        "\n",
        "    if \"errors\" in result[\"results\"]:\n",
        "        print(\"\\nErrors encountered:\")\n",
        "        for error in result[\"results\"][\"errors\"]:\n",
        "            print(f\"- {error['message']} (at {error['timestamp']}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true,
          "base_uri": "https://localhost:8080/"
        },
        "id": "CPY-aU-bXYsW",
        "outputId": "be1d05c5-0e70-491a-b453-7bb5a1adc562"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Processing document(s)...\n",
            "Creating workflow for 1 file(s)...\n",
            "Running analysis...\n",
            "\n",
            "Analysis Results:\n",
            "--------------------------------------------------\n",
            "\n",
            "Data Processing:\n",
            "------------------------------\n",
            "PATIENT SIGNALMENT & CLIENT INFORMATION:\n",
            "• Patient ID#: CA2441B8  \n",
            "• Name: Jax Miracle  \n",
            "• Species: Canine (Dog)  \n",
            "• Breed: Pomeranian  \n",
            "• Age: 4 years old (DOB documented as 12/20/20; note that countryside records reference 10/01/20 or 10/01/21)  \n",
            "• Sex: Male, Castrated  \n",
            "• Weight: 6.1 kg (as of 02/04/25)  \n",
            "• Microchip #: None  \n",
            "• Client Name & ID#: Anna Miracle (ID 24404F)  \n",
            "• Client Address: 2497 Hillsboro Rd, Campbellsburg, KY 40011, USA  \n",
            "• Client Phone: (502) 532-6641 (note secondary phone (502) 706-0428 in separate registration form)  \n",
            "• Client Email: miracletricia@gmail.com  \n",
            "• Insurance Status: Not Recorded  \n",
            "• Billing Preferences: Not Recorded  \n",
            "\n",
            "• CURRENT MEDICATIONS (as actively reported by client on 01/20/25 form):  \n",
            "  1) Bravecto (Orange) – exact strength not specified in provided data; 1 tablet orally once every 6 months. Start date: Not Recorded; End date: Ongoing. No adverse reactions reported. Effectiveness: Not Recorded.  \n",
            "  2) Sentinel Spectrum (8.75 mg) – 1 tablet orally once a month. Start date: Not Recorded; End date: Ongoing. No adverse reactions reported. Effectiveness: Not Recorded.  \n",
            "\n",
            "PRESENTING COMPLAINT AND HISTORY:\n",
            "\n",
            "CHIEF COMPLAINT (02/04/25 visit):  \n",
            "• Coughing (described as “coughing, hacking, panting loudly”).  \n",
            "• Exact duration: Not Recorded.  \n",
            "• Precise progression with dates: Not Recorded.  \n",
            "• Frequency/severity: Not Recorded beyond “dry cough.”  \n",
            "• Behavior changes: Anxiety noted.  \n",
            "• Appetite: No change reported.  \n",
            "• Drinking: No change reported.  \n",
            "• Urination: No change reported.  \n",
            "• Defecation: No change reported.  \n",
            "\n",
            "PAST MEDICAL HISTORY:  \n",
            "• Chronological Visits at Countryside Animal Hospital (per provided medical records):\n",
            "\n",
            "  1) 10/23/23:   \n",
            "     – Annual DHPP vaccination (V180).  \n",
            "     – Lepto (4-serovar) booster (V296).  \n",
            "\n",
            "  2) 01/26/24:   \n",
            "     – Rabies 1-year vaccine (V160).  \n",
            "\n",
            "  3) 03/01/24:  \n",
            "     – Blood parasite test (4) (LI103); results not recorded.  \n",
            "     – Diagnostic examination (P260); findings not described.  \n",
            "     – Sentinel Spectrum 8–25 lb (6 ct) dispensed (AP052).  \n",
            "     – Chlorpheniramine 4 mg tablets prescribed (OM220) at 1 tablet twice daily; quantity 60, start/end dates not specified (not currently reported by owner).  \n",
            "     – Hazardous waste control fee (P355).  \n",
            "\n",
            "  4) 03/12/24:  \n",
            "     – Weight listed as 12.80 lb.  \n",
            "     – Wellness examination (P263); findings not specified.  \n",
            "     – Radiographs (1-plane, 2-view) (R210); results not recorded.  \n",
            "     – Doxycycline 50 mg/mL suspension (OM569) 0.5 mL once daily, quantity 30, start/end dates not specified (not currently reported by owner).  \n",
            "\n",
            "  5) 03/19/24:  \n",
            "     – Bravecto 10–22 lb (FL601) dispensed x2 doses.  \n",
            "     – Bravecto rebate (BRAV2).  \n",
            "\n",
            "  6) 04/05/24:  \n",
            "     – Weight listed as 13.80 lb.  \n",
            "     – Wellness examination (P263); findings not specified.  \n",
            "     – Anal sac expression (P105).  \n",
            "     – Vetalog injection (IM345).  \n",
            "     – Nail trim—canine dremel (P221).  \n",
            "     – Hazardous waste control fee (P355).  \n",
            "     – Ear cleansing solution (TM342) 1 bottle prescribed; instructions: clean ear once daily.  \n",
            "     – Panalog ointment (TM270) 1 tube prescribed; instructions: clean ears once daily then apply ointment.  \n",
            "\n",
            "  7) 04/16/24:  \n",
            "     – Weight listed as 13.80 lb.  \n",
            "     – Wellness examination (P263); findings not specified.  \n",
            "     – Chlorpheniramine 4 mg tablets (OM220) refill (60 ct); instructions: 1 tablet twice daily.  \n",
            "\n",
            "  8) 05/15/24:  \n",
            "     – Weight listed as 13.40 lb.  \n",
            "     – Nail trim—canine dremel (P221).  \n",
            "\n",
            "  9) 09/06/24:  \n",
            "     – Bravecto 10–22 lb (FL601) dispensed x1.  \n",
            "     – Chlorpheniramine 4 mg tablets (OM220) 60 ct prescribed again at same instructions.  \n",
            "\n",
            " 10) 10/16/24:  \n",
            "     – Weight listed as 13.10 lb.  \n",
            "     – Wellness examination (P263).  \n",
            "     – Doxycycline 50 mg/mL suspension (OM569) 30 mL; instructions: 0.5 mL twice daily.  \n",
            "     – Temaril-P tablets (OM509) 20 ct; instructions: ½ tablet twice daily.  \n",
            "     – Annual DHPP vaccination (V180).  \n",
            "     – Canine parvo booster (V299).  \n",
            "     – Nail trim—canine dremel (P221).  \n",
            "     – Hazardous waste control fee (P355).  \n",
            "\n",
            " 11) 10/17/24:  \n",
            "     – Theophylline 400 mg ER (OM106), 2 capsules dispensed; instructions: 1 mL of FlavorX-labeled formula twice a day (note mismatch in instructions, presumably an internal record for conversion).  \n",
            "\n",
            " 12) 11/26/24:  \n",
            "     – Medical progress exam (P290).  \n",
            "\n",
            " 13) 12/06/24:  \n",
            "     – Weight listed as 12.80 lb.  \n",
            "     – Sentinel Spectrum 8–25 lb (AP052) dispensed.  \n",
            "     – Bravecto 10–22 lb (FL601) dispensed.  \n",
            "     – Wellness examination (P263).  \n",
            "\n",
            "• Vaccinations/Preventive Products:  \n",
            "  – DHPP (10/23/23, 10/16/24).  \n",
            "  – Lepto 4-serovar (10/23/23).  \n",
            "  – Rabies 1-year (01/26/24; next due 01/25/25 marked overdue).  \n",
            "  – Bravecto (oral) 10–22 lb: Repeatedly dispensed (dates above).  \n",
            "  – Sentinel Spectrum 8–25 lb: Multiple dispensations (dates above).  \n",
            "\n",
            "• Surgeries/Procedures: None specifically documented other than routine care, diagnostics, nail trims, and anal sac expressions.  \n",
            "\n",
            "• Diet History:  \n",
            "  – Pedigree canned food + Kibbles and Bits dry + Dreambones treats, for approximately 15 months.  \n",
            "\n",
            "PHYSICAL EXAMINATION (02/04/25):\n",
            "• Temperature (°F): Not Performed  \n",
            "• Heart Rate (beats/min): Not Performed  \n",
            "• Respiratory Rate (breaths/min): Not Performed  \n",
            "• Weight: 6.1 kg (recorded 02/04/25)  \n",
            "• Body Condition Score (1–9): Not Recorded  \n",
            "• Mucous Membrane Color: Not Recorded  \n",
            "• Capillary Refill Time (seconds): Not Recorded  \n",
            "• Pain Score (0–10): Not Recorded  \n",
            "\n",
            "SYSTEM-BY-SYSTEM EXAM:  \n",
            "• EENT: Not Recorded  \n",
            "• Cardiovascular: Not Recorded  \n",
            "• Respiratory: Not Recorded (chief complaint of coughing noted; no physical exam details available)  \n",
            "• Gastrointestinal: Not Recorded  \n",
            "• Musculoskeletal: Not Recorded  \n",
            "• Neurologic: Not Recorded  \n",
            "• Integumentary: Not Recorded  \n",
            "• Lymphatic: Not Recorded  \n",
            "• Urogenital: Not Recorded  \n",
            "\n",
            "DIAGNOSTIC FINDINGS:  \n",
            "• Laboratory Tests:  \n",
            "  – Blood parasite test (4) on 03/01/24: Results Not Recorded  \n",
            "• Imaging:  \n",
            "  – Radiographs taken on 03/12/24: Results Not Recorded  \n",
            "• Other Tests: None documented  \n",
            "\n",
            "CURRENT MEDICATIONS AND TREATMENTS:  \n",
            "• As per client’s active listing (01/20/25 form):  \n",
            "  1) Bravecto (Orange tablet); dose (tablet size) not fully specified, administered orally once every 6 months. Start date: Not Recorded; no adverse reaction documented; effectiveness: Not Recorded.  \n",
            "  2) Sentinel Spectrum (8.75 mg); 1 tablet orally once monthly. Start date: Not Recorded; no adverse reaction documented; effectiveness: Not Recorded.  \n",
            "\n",
            "• All other previously prescribed medications (Theophylline, Doxycycline, Temaril-P, Chlorpheniramine, Panalog, ear cleaners) are historical/not currently reported by the owner as active.  \n",
            "\n",
            "[End of Initial Case Review Documentation]\n",
            "\n",
            "History Analysis:\n",
            "------------------------------\n",
            "COMPREHENSIVE TIMELINE\n",
            "\n",
            "1) INITIAL DISEASE ONSET  \n",
            "   • Exact Date of First Clinical Signs: Not recorded in medical records.  \n",
            "   • Precise Symptom Progression: Not documented prior to 03/01/24.  \n",
            "     – Earliest potential reference to respiratory/allergic issue could be inferred from the first prescription of Chlorpheniramine on 03/01/24, but no direct notation of coughing or respiratory distress is documented.  \n",
            "   • All Initial Diagnostic Findings: None specifically recorded as pertaining to the initial onset of clinical signs.  \n",
            "   • First Treatment Responses: No charted response to initial medication(s); no clinical improvement or deterioration noted in the record.  \n",
            "\n",
            "2) DISEASE PROGRESSION  \n",
            "   • 03/01/24:  \n",
            "     – Diagnostic Examination (P260): Content of findings not recorded.  \n",
            "     – Blood Parasite Test (4) (LI103): Results not recorded.  \n",
            "     – Chlorpheniramine 4 mg tablets (OM220) prescribed at 1 tablet PO twice daily (quantity 60). Start/end dates not specified. Rationale unlisted in the record; presumed for allergic or mild respiratory symptoms. Treatment response not documented.  \n",
            "   • 03/12/24:  \n",
            "     – Weight: 12.80 lb.  \n",
            "     – Radiographs (1-plane, 2-view) (R210): Results not recorded.  \n",
            "     – Doxycycline 50 mg/mL suspension (OM569) prescribed at 0.5 mL PO once daily (quantity 30). Start/end dates not specified; rationale not stated. Treatment response not documented.  \n",
            "   • 04/05/24:  \n",
            "     – Weight: 13.80 lb.  \n",
            "     – Vetalog injection (IM345) administered; rationale not specified. Response not recorded.  \n",
            "     – Ear cleansing solution (TM342) and Panalog ointment (TM270) prescribed for once-daily ear cleaning then ointment application. No follow-up data on clinical outcome recorded.  \n",
            "   • 04/16/24:  \n",
            "     – Weight: 13.80 lb.  \n",
            "     – Chlorpheniramine 4 mg refill (60 ct) at same dosing (1 tablet PO twice daily). No documented response or adverse effects.  \n",
            "   • 05/15/24:  \n",
            "     – Weight: 13.40 lb.  \n",
            "     – No new treatments; only nail trim performed. No mention of ongoing symptoms.  \n",
            "   • 09/06/24:  \n",
            "     – Bravecto 10–22 lb dispensed (1 dose).  \n",
            "     – Chlorpheniramine 4 mg tablets (60 ct) prescribed again; no documented rationale or symptom severity.  \n",
            "   • 10/16/24:  \n",
            "     – Weight: 13.10 lb.  \n",
            "     – Doxycycline 50 mg/mL suspension (OM569) 30 mL dispensed (0.5 mL PO BID).  \n",
            "     – Temaril-P tablets (OM509) 20 ct at ½ tablet PO BID.  \n",
            "       • Rationale likely for coughing/allergic signs, but not explicitly stated.  \n",
            "       • No recorded response or adverse effects.  \n",
            "   • 10/17/24:  \n",
            "     – Theophylline 400 mg ER (OM106) dispensed; 2 capsules. Internal record shows an instruction “1 mL of FlavorX-labeled formula twice a day,” indicating a possible conversion discrepancy. Prescribed presumably as a bronchodilator for respiratory complaints.  \n",
            "     – Treatment response not documented.  \n",
            "   • 11/26/24:  \n",
            "     – Medical progress exam (P290): No further details recorded.  \n",
            "   • 12/06/24:  \n",
            "     – Weight: 12.80 lb.  \n",
            "     – Sentinel Spectrum 8–25 lb and Bravecto 10–22 lb dispensed.  \n",
            "     – Wellness exam (P263) with no documented details.  \n",
            "   • 02/04/25 (Most Recent Visit):  \n",
            "     – Chief Complaint: Coughing (“coughing, hacking, panting loudly”) described as a “dry cough,” duration not recorded.  \n",
            "     – Weight: 6.1 kg (13.44 lb).  \n",
            "     – Physical exam parameters (temperature, heart rate, respiratory rate) not performed or not recorded.  \n",
            "     – No additional medication prescribed at this visit per provided data.  \n",
            "     – No diagnostic results or further treatments documented.  \n",
            "     – Behavioral change: Anxiety noted during coughing episodes. Appetite and eliminations unchanged.  \n",
            "\n",
            "3) COMPLETE TREATMENT HISTORY (CHRONOLOGICAL)\n",
            "\n",
            "   NOTE: All start/end dates reflect available record entries. Some prescriptions lack specific start/end documentation.\n",
            "\n",
            "   • Bravecto (Fluralaner) 10–22 lb oral tablet  \n",
            "     – First noted dispensation on 03/19/24; repeated 09/06/24 & 12/06/24; client currently reports ongoing use (01/20/25 form).  \n",
            "     – Dosing: 1 oral tablet once every 6 months (per owner’s current statement).  \n",
            "     – No recorded adverse reactions or documented effectiveness.  \n",
            "\n",
            "   • Sentinel Spectrum (8.75 mg milbemycin oxime, with praziquantel and lufenuron; size for 8–25 lb)  \n",
            "     – First noted dispensation on 03/01/24; repeated 12/06/24; client currently reports ongoing monthly use.  \n",
            "     – Dosing: 1 oral tablet once monthly.  \n",
            "     – No recorded adverse reactions or documented effectiveness.  \n",
            "\n",
            "   • Chlorpheniramine 4 mg tablets (OM220)  \n",
            "     – Prescribed 03/01/24 (60 ct) at 1 tablet PO BID.  \n",
            "     – Refilled 04/16/24 (60 ct) at same dose.  \n",
            "     – Prescribed again 09/06/24 (60 ct) at same dose.  \n",
            "     – No start/end dates documented for each refill; no recorded adverse reactions.  \n",
            "     – No clear efficacy data in the record.  \n",
            "\n",
            "   • Doxycycline 50 mg/mL suspension (OM569)  \n",
            "     – First prescribed on 03/12/24 at 0.5 mL PO once daily, quantity 30.  \n",
            "     – Again prescribed on 10/16/24 at 0.5 mL PO twice daily, 30 mL total.  \n",
            "     – No documented start/end dates or clinical response.  \n",
            "\n",
            "   • Temaril-P (Trimeprazine tartrate with prednisolone) tablets (OM509)  \n",
            "     – Prescribed on 10/16/24, 20 ct at ½ tablet PO BID.  \n",
            "     – Start/end dates not recorded; no documented efficacy or adverse event.  \n",
            "\n",
            "   • Theophylline 400 mg ER (OM106)  \n",
            "     – Prescribed on 10/17/24, 2 capsules dispensed.  \n",
            "     – Instruction entered as “1 mL of FlavorX-labeled formula PO BID,” indicating a liquid conversion.  \n",
            "     – No documented response or follow-up.  \n",
            "\n",
            "   • Vetalog injection (IM345)  \n",
            "     – Administered on 04/05/24.  \n",
            "     – Dose not specified, no documented response or adverse effects.  \n",
            "\n",
            "   • Ear Cleansing Solution (TM342)  \n",
            "     – Prescribed on 04/05/24, 1 bottle, “clean ear(s) once daily.”  \n",
            "     – Start/end dates not clarified; no recorded outcome.  \n",
            "\n",
            "   • Panalog Ointment (TM270)  \n",
            "     – Prescribed on 04/05/24, 1 tube, “clean ears once daily, then apply ointment.”  \n",
            "     – No documented follow-up regarding ear condition.  \n",
            "\n",
            "4) DIAGNOSTIC TESTING CHRONOLOGY  \n",
            "   • 03/01/24: Blood Parasite Test (4)  \n",
            "     – Results: Not recorded.  \n",
            "     – Reference Ranges: Not provided.  \n",
            "     – No interpretation documented.  \n",
            "\n",
            "   • 03/12/24: Radiographs (1-plane, 2-view)  \n",
            "     – Results: Not recorded.  \n",
            "     – Reference Ranges/Diagnostic Assessment: Not provided.  \n",
            "     – No documented follow-up or changes to treatment plan except Doxycycline initiation.  \n",
            "\n",
            "   • No additional recorded tests through 02/04/25.  \n",
            "\n",
            "PATTERN ANALYSIS\n",
            "\n",
            "1) DETAILED SYMPTOM PATTERNS  \n",
            "   • Frequency of Coughing Episodes: Not quantified; described recently (02/04/25) as “frequent dry cough,” “hacking,” “panting loudly.”  \n",
            "   • Severity Trends: Not objectively graded; anecdotally severe enough to prompt clinic visit.  \n",
            "   • Specific Triggers: Not documented.  \n",
            "   • Temporal Patterns: No recorded data on time of day, seasonal variation, or environmental conditions.  \n",
            "\n",
            "2) TREATMENT RESPONSE ANALYSIS  \n",
            "   • Duration of Response: No formal documentation of improvement or relapse following specific medications (chlorpheniramine, doxycycline, temaril-p, theophylline).  \n",
            "   • Degree of Improvement: No recorded percentages or veterinarian assessment notes.  \n",
            "   • Treatment Failures: Several medications (antibiotics, antihistamines, anti-inflammatories, bronchodilator) used without documented resolution or follow-up, suggesting incomplete data on success or failure.  \n",
            "   • Compliance Assessment:  \n",
            "     – Client states ongoing use of Bravecto and Sentinel Spectrum (as of 01/20/25).  \n",
            "     – Past medications not confirmed as continued or discontinued per veterinarian instructions.  \n",
            "\n",
            "3) RISK FACTOR EVALUATION  \n",
            "   • Identified Risk Factors:  \n",
            "     – Breed Predisposition: Pomeranians may be prone to tracheal issues (e.g., collapsing trachea), but no confirmed diagnosis in the records.  \n",
            "     – Environmental Influences: Not recorded.  \n",
            "     – Genetic Predispositions: Not documented.  \n",
            "     – Concurrent Conditions: No definitive comorbidities identified from the data provided.  \n",
            "\n",
            "ADDITIONAL CLIENT COMMUNICATIONS & INSTRUCTIONS  \n",
            "• Client, Anna Miracle (ID 24404F), provided updated medication list on 01/20/25, indicating Bravecto and Sentinel Spectrum remain active.  \n",
            "• No other client instructions (e.g., recheck frequency, home monitoring tips) are documented in these records.  \n",
            "• Rabies vaccine due 01/25/25 is marked overdue; presumably client informed but no confirmation of administration.  \n",
            "\n",
            "END OF ANALYSIS  \n",
            "\n",
            "Clinical Analysis:\n",
            "------------------------------\n",
            "CLINICAL ASSESSMENT:\n",
            "\n",
            "1. PRIMARY CLINICAL SIGNS ANALYSIS  \n",
            "   • Coughing / Respiratory Signs  \n",
            "     – Exact Duration: Not recorded for onset; first explicit mention on 02/04/25 (MM/DD/YY).  \n",
            "     – Specific Frequency: Unspecified; described as “frequent” on 02/04/25.  \n",
            "     – Severity Scale: Not documented; client subjectively reports “dry cough,” “panting loudly,” with evident distress, but no objective scale (1–10) recorded.  \n",
            "     – Pattern of Occurrence: No documented detail regarding time of day, environmental triggers, or seasonal influences.  \n",
            "     – Exacerbating/Alleviating Factors: None recorded.  \n",
            "     – Response to Interventions: No formal chart entries describing improvement or worsening with antihistamines (chlorpheniramine), antibiotics (doxycycline), anti-inflammatory/immunosuppressive (Temaril-P, Vetalog), or bronchodilator (theophylline).\n",
            "\n",
            "   • Possible Otic Discomfort (Ear Issues)  \n",
            "     – Duration: Unclear; ear treatments prescribed on 04/05/24 without prior note of onset.  \n",
            "     – Frequency: No data recorded after initial prescription.  \n",
            "     – Severity Scale: Not specified.  \n",
            "     – Pattern of Occurrence: Not noted.  \n",
            "     – Exacerbating/Alleviating Factors: Not documented.  \n",
            "     – Response to Interventions: Ear cleansing solution and Panalog ointment prescribed, but no follow-up exam findings reported.\n",
            "\n",
            "2. COMPREHENSIVE PHYSICAL EXAMINATION ANALYSIS  \n",
            "   a) Vital Signs Interpretation  \n",
            "     • Temperature: Not recorded at any visit; therefore, no comparison to normal canine range of 101.5 ± 1.0 °F.  \n",
            "     • Heart Rate: Not documented; no comparisons to normal ranges.  \n",
            "     • Respiratory Rate and Effort: Not objectively measured; coughing described on 02/04/25 but no formal respiratory rate or effort data.  \n",
            "     • Weight Trends (% change):  \n",
            "       – 03/12/24: 12.80 lb  \n",
            "       – 04/05/24: 13.80 lb (+7.81% from 03/12/24)  \n",
            "       – 04/16/24: 13.80 lb (no change since 04/05/24)  \n",
            "       – 05/15/24: 13.40 lb (−2.90% from 04/16/24)  \n",
            "       – 10/16/24: 13.10 lb (−2.24% from 05/15/24)  \n",
            "       – 12/06/24: 12.80 lb (−2.29% from 10/16/24)  \n",
            "       – 02/04/25: 6.1 kg (13.44 lb) (+5.00% from 12/06/24)  \n",
            "       Overall: Minor fluctuations; no severe documented cachexia or obesity.  \n",
            "     • Body Condition Score Changes: Not recorded at any visit.\n",
            "\n",
            "   b) Detailed System Analysis  \n",
            "     • Ears: Ear discharge or inflammation implied by prescribing ear cleansing solution and Panalog ointment on 04/05/24, but no formal exam findings (e.g., erythema, odor, exudate) documented. No follow-up data on resolution or persistence.  \n",
            "     • Respiratory: Cough reported 02/04/25 (described as “dry,” “hacking,” “panting loudly”). No formal lung auscultation results recorded.  \n",
            "     • Cardiovascular: No abnormal findings documented.  \n",
            "     • Musculoskeletal: Not mentioned.  \n",
            "     • Gastrointestinal: Normal appetite; no abnormal eliminations noted.  \n",
            "     • Neurologic: Anxiety during coughing episodes noted, but no other neurologic findings described.  \n",
            "     • Pain Assessment Scores: Not recorded.  \n",
            "     • Comparative Findings (Left vs. Right): Not available.  \n",
            "     • Sequential Examination Changes: No sequential clinical notes regarding improvement or worsening were entered.\n",
            "\n",
            "3. DIAGNOSTIC TESTING INTERPRETATION  \n",
            "   a) Laboratory Results  \n",
            "     • 03/01/24 Blood Parasite Test (4) (LI103):  \n",
            "       – Results: Unavailable (not recorded).  \n",
            "       – Reference Ranges: Not provided.  \n",
            "       – No documented interpretation or follow-up actions.  \n",
            "\n",
            "   b) Imaging Interpretation  \n",
            "     • 03/12/24 Radiographs (1-plane, 2-view) (R210):  \n",
            "       – Results: Not recorded.  \n",
            "       – No measurement of trachea, cardiac silhouette, or lung fields provided.  \n",
            "       – No official radiology report.  \n",
            "       – Clinical Significance: Unknown; Doxycycline started afterward, possibly indicating suspicion of an infectious or inflammatory process, but this is not explicitly stated.\n",
            "\n",
            "4. DISEASE PROCESS ANALYSIS  \n",
            "   • Detailed Pathophysiology:  \n",
            "     – Chronic or recurrent cough (onset presumed prior to 03/01/24 given chlorpheniramine prescription) possibly indicates allergic airway disease, mild respiratory infection, or anatomic abnormality (e.g., collapsing trachea). Definitive pathophysiologic mechanism unconfirmed.  \n",
            "     – Secondary Complications: Potential otic inflammation (04/05/24) may be unrelated or reflect generalized allergic tendencies.  \n",
            "     – Organ System Interactions: Potential overlap of respiratory and allergic conditions is suggested by prescriptions (antihistamines, antibiotics, steroids, bronchodilator). No confirmed organ failure or systemic disease from existing records.  \n",
            "     – Disease Stage with Criteria: Not clearly established due to incomplete diagnostic data.  \n",
            "     – Progression Indicators: Ongoing cough through 02/04/25, repeated medication use without documented resolution, mild weight fluctuations.\n",
            "\n",
            "5. TREATMENT RESPONSE EVALUATION  \n",
            "   For Each Medication:  \n",
            "   a) Chlorpheniramine 4 mg Tablets (OM220)  \n",
            "     – First prescribed 03/01/24 at 1 tablet PO BID; refilled 04/16/24 and 09/06/24, quantity 60 each time.  \n",
            "     – Time to Initial Response: Not documented.  \n",
            "     – Degree of Improvement: No recorded changes in cough severity or frequency.  \n",
            "     – Duration of Effect: Unknown; no follow-up notes.  \n",
            "     – Side Effects Observed: None recorded.  \n",
            "     – Factors Affecting Efficacy: Uncertain, no consistent recheck or notation of compliance.\n",
            "\n",
            "   b) Doxycycline 50 mg/mL Suspension (OM569)  \n",
            "     – 03/12/24: 0.5 mL PO once daily, quantity 30.  \n",
            "     – 10/16/24: 0.5 mL PO twice daily, 30 mL total.  \n",
            "     – Time to Initial Response: Not documented.  \n",
            "     – Degree of Improvement: Not assessed in records.  \n",
            "     – Duration of Effect: Not recorded.  \n",
            "     – Side Effects: None noted.  \n",
            "     – Factors Affecting Efficacy: Unknown compliance, no recheck diagnostics.\n",
            "\n",
            "   c) Temaril-P (Trimeprazine Tartrate with Prednisolone) Tablets (OM509)  \n",
            "     – 10/16/24: 20 tablets, ½ tablet PO BID.  \n",
            "     – Response, side effects, or duration of use not recorded.\n",
            "\n",
            "   d) Theophylline 400 mg ER (OM106)  \n",
            "     – Prescribed 10/17/24: 2 capsules dispensed, with instructions indicating possible conversion to a 1 mL FlavorX suspension PO BID.  \n",
            "     – No documented therapeutic response, adverse events, or follow-up testing.\n",
            "\n",
            "   e) Vetalog Injection (IM345)  \n",
            "     – Administered 04/05/24; dose and response not recorded. Presumably an anti-inflammatory injection but no official rationale or recheck.\n",
            "\n",
            "   f) Ear Cleansing Solution (TM342) and Panalog Ointment (TM270)  \n",
            "     – Both prescribed 04/05/24 for daily ear cleaning and ointment application.  \n",
            "     – Start/end times and effectiveness unmentioned in subsequent records.\n",
            "\n",
            "   g) Bravecto (Fluralaner)  \n",
            "     – 10–22 lb dose dispensed on 03/19/24 (per internal note), 09/06/24, 12/06/24; one tablet Q6mo per client.  \n",
            "     – No adverse reactions or documented ectoparasite findings reported.\n",
            "\n",
            "   h) Sentinel Spectrum (Milbemycin Oxime + Praziquantel + Lufenuron)  \n",
            "     – 8–25 lb dose first noted 03/01/24, repeated 12/06/24, used monthly per client.  \n",
            "     – No official documentation regarding prophylactic effectiveness or side effects.\n",
            "\n",
            "   • Overall Observations:  \n",
            "     – None of the treatments have recorded efficacy confirmations or side effect logs. Long-term management results remain unclear.\n",
            "\n",
            "CLINICAL INTEGRATION:\n",
            "\n",
            "1. EVIDENCE SYNTHESIS  \n",
            "   • Supporting Findings for Each Diagnosis:  \n",
            "     – Chronic cough/airway disease: Repeated prescriptions for antimicrobial (doxycycline), anti-inflammatory (steroid), bronchodilator (theophylline), antihistamines (chlorpheniramine), and multi-action agent (Temaril-P) suggest persistent airway or allergic pathology.  \n",
            "     – Otic inflammation: Ear cleansing solution and Panalog ointment indicate prior otic involvement.  \n",
            "\n",
            "   • Strength of Evidence Assessment:  \n",
            "     – Incomplete objective data: Lacking physical exam parameters (temperature, heart rate, respiratory rate), unrecorded radiographic interpretations, missing blood parasite test results, and no additional advanced diagnostics hamper definitive conclusions.  \n",
            "\n",
            "   • Clinical Trial Relevance:  \n",
            "     – Without confirmed etiology (e.g., allergic bronchitis, collapsing trachea, infectious cause), it is unclear if any established clinical trial protocols (e.g., for chronic bronchitis) are relevant.  \n",
            "\n",
            "   • Population-Specific Factors:  \n",
            "     – Toy breed (potential Pomeranian heritage) predisposition to tracheal collapse.  \n",
            "     – No documented comorbidities or recognized environmental allergens.\n",
            "\n",
            "2. CONTRADICTORY FINDINGS  \n",
            "   • Alternative Explanations:  \n",
            "     – Unremarkable or incomplete data leads to broad differential diagnoses (infection, allergic disease, structural airway anomaly). Radiographs, if normal, were never confirmed.  \n",
            "     – Ear conditions could be separate or part of systemic allergic patterns but unproven.  \n",
            "\n",
            "   • Rule-Out Justifications:  \n",
            "     – Cardiogenic cough not ruled in or out due to lack of cardiac exam notes or imaging interpretation.  \n",
            "     – Infectious etiologies only partially addressed by doxycycline with unknown compliance and no recheck.  \n",
            "     – No definitive test to confirm typical “allergic” or “collapsing trachea” pathology.  \n",
            "\n",
            "   • Confounding Factors:  \n",
            "     – Missing reference ranges and final test results; uncertain medication compliance or dosing accuracy.  \n",
            "     – Rationale for repeated antibiotic or steroid usage not clearly linked to documented diagnostic findings.  \n",
            "\n",
            "   • Testing Limitations:  \n",
            "     – No additional imaging or advanced airway examination (e.g., bronchoscopy) documented.  \n",
            "     – Incomplete record of ongoing physical exam parameters and lab work-ups.  \n",
            "\n",
            "ADDITIONAL CLIENT COMMUNICATIONS & INSTRUCTIONS  \n",
            "• Owner: Anna Miracle (ID 24404F) provided an updated medication list on 01/20/25, confirming continued Bravecto every six months and Sentinel Spectrum monthly.  \n",
            "• Rabies vaccine due 01/25/25; no note of administration.  \n",
            "• No further instructions regarding rechecks, home monitoring, or additional diagnostics recorded.  \n",
            "\n",
            "[END OF DOCUMENTATION]\n",
            "\n",
            "Diagnostic Assessment:\n",
            "------------------------------\n",
            "PROBLEM LIST:\n",
            "\n",
            "1. ACTIVE PROBLEMS (PRIORITIZED):\n",
            "\n",
            "   1A) Chronic Cough / Respiratory Distress  \n",
            "       • Duration with Exact Onset Date: Earliest verifiable mention on 02/04/25, though medications suggest onset prior to 03/01/24 (no precise onset date recorded).  \n",
            "       • Severity Score (1–10): Not formally assessed; client-reported “dry” and “frequent” cough with “panting loudly.” Subjectively moderate distress, but exact score is unrecorded.  \n",
            "       • Progression Pattern: Appears chronic and persistent; no documented complete resolution. Medications (antibiotics, antihistamines, steroids, bronchodilator) have been used repeatedly, indicating ongoing or recurrent signs.  \n",
            "       • Related Clinical Findings: Panting, anxiety, no documented auscultation or respiratory rate measurement. Radiographs taken on 03/12/24 (no formal interpretation on file).  \n",
            "       • Impact on Quality of Life: Client-reported distress noted; extent of functional limitation not fully outlined.  \n",
            "       • Current Treatment Status: Multiple therapies attempted (chlorpheniramine, doxycycline, Temaril-P, theophylline) without documented efficacy assessments or final outcome.\n",
            "\n",
            "   1B) Possible Otic Inflammation / Discomfort  \n",
            "       • Duration with Exact Onset Date: Ear treatment first prescribed on 04/05/24; no preceding onset data.  \n",
            "       • Severity Score (1–10): Not recorded.  \n",
            "       • Progression Pattern: Unknown; no follow-up or repeated ear examinations documented.  \n",
            "       • Related Clinical Findings: Prescribed ear cleansing solution (TM342) and Panalog (TM270) on 04/05/24, suggesting canal discharge or inflammation, but no formal otoscopic findings noted.  \n",
            "       • Impact on Quality of Life: Not explicitly documented; possible discomfort or irritation assumed given prescription.  \n",
            "       • Current Treatment Status: No recent notes after 04/05/24; presumed unresolved or unassessed due to lack of follow-up data.\n",
            "\n",
            "2. INACTIVE/RESOLVED PROBLEMS:  \n",
            "   • None definitively documented as resolved or inactive.  \n",
            "   • No clear resolution date or cessation of clinical signs for otic or respiratory issues is recorded in the medical record.\n",
            "\n",
            "────────────────────────────────────────────────────────────────────────────\n",
            "\n",
            "DIFFERENTIAL DIAGNOSES:\n",
            "\n",
            "1. PRIMARY DIFFERENTIAL LIST:\n",
            "\n",
            "   A) Chronic Bronchitis / Allergic Airway Disease  \n",
            "      • Supporting Evidence: Ongoing cough for many months, use of steroids (Temaril-P), antihistamines (chlorpheniramine), and partial response to unknown extent. Possibly allergic otitis (ear inflammation) indicating an atopic or allergic component.  \n",
            "      • Contradicting Evidence: None definitively; lack of objective improvement or formal diagnostic confirmation is the main limitation.  \n",
            "      • Diagnostic Criteria Met/Unmet: Clinical suspicion is raised, but no bronchoscopy, airway cytology, or repeat thoracic imaging interpretation provided to meet definitive criteria.  \n",
            "      • Population Prevalence: Chronic bronchitis/allergy is common in middle-aged to older small-breed dogs.  \n",
            "      • Age/Breed Predisposition: Possible Pomeranian or small-breed predisposition to both chronic bronchitis and concurrent otitis from atopic disease.  \n",
            "      • Required Diagnostics: Repeat thoracic radiographs (3-view), complete blood count (CBC), serum chemistry panel, airway wash (BAL/TTW) if feasible, fecal analysis to rule out parasites that may cause cough, and in-depth otic examination (cytology, culture).\n",
            "\n",
            "   B) Tracheal Collapse  \n",
            "      • Supporting Evidence: Small breed, “dry honking” or hacking cough. Bronchodilator (theophylline) trial was considered, indicating suspicion.  \n",
            "      • Contradicting Evidence: No specific imaging interpretations or dynamic tracheal studies documented to confirm or refute.  \n",
            "      • Diagnostic Criteria Met/Unmet: Unmet; requires imaging (fluoroscopy or endoscopy) or radiographs in inspiratory and expiratory phases with detailed interpretation.  \n",
            "      • Population Prevalence: Common in toy breeds, especially around middle age.  \n",
            "      • Age/Breed Predisposition: High in small-breed dogs (e.g., Pomeranian, Yorkie).  \n",
            "      • Required Diagnostics: Lateral and DV/VD thoracic radiographs at inspiration/expiration, fluoroscopic evaluation if available, possible endoscopic exam of the airway.\n",
            "\n",
            "   C) Infectious Tracheobronchitis (e.g., Bordetella or Mycoplasma)  \n",
            "      • Supporting Evidence: Doxycycline used twice (03/12/24 and 10/16/24), suggesting suspicion of bacterial or atypical infection.  \n",
            "      • Contradicting Evidence: No documentation of definitive pathogen testing or consistent compliance. Cough is persistent despite antibiotic trials.  \n",
            "      • Diagnostic Criteria Met/Unmet: Unmet; no specific culture, PCR testing, or consistent follow-up.  \n",
            "      • Population Prevalence: Variable, depends on exposure risk (e.g., grooming, boarding).  \n",
            "      • Age/Breed Predisposition: Not specifically breed-linked, any age can be affected.  \n",
            "      • Required Diagnostics: Airway PCR/culture (respiratory panel), repeat thoracic radiographs, response-to-therapy monitoring.\n",
            "\n",
            "   D) Chronic Otitis Externa (Allergic or Infectious)  \n",
            "      • Supporting Evidence: Ear medications prescribed on 04/05/24. Potential tie to an atopy if respiratory signs also allergic.  \n",
            "      • Contradicting Evidence: Poorly documented ear exams, no cytology or culture results. Possibly resolved but never confirmed.  \n",
            "      • Diagnostic Criteria Met/Unmet: Unmet; no post-treatment evaluation or cytologic exam.  \n",
            "      • Population Prevalence: Common in dogs with underlying allergies or repeated moisture in ear canals.  \n",
            "      • Age/Breed Predisposition: Small/toy breeds often prone to atopic dermatitis, which can include otic lesions.  \n",
            "      • Required Diagnostics: Comprehensive otoscopic exam, ear cytology, possible culture/sensitivity if signs persist or worsen.\n",
            "\n",
            "2. SECONDARY DIFFERENTIAL LIST:\n",
            "\n",
            "   A) Cardiogenic Cough (e.g., Mitral Valve Disease)  \n",
            "      • Reason for Lower Priority: No documented murmur, no cardiovascular findings on exam notes, no mention of exercise intolerance specifically related to heart disease.  \n",
            "      • Required Rule-Out Criteria: Cardiac auscultation, echocardiography, validated radiographic evaluation of cardiac silhouette.  \n",
            "      • Testing Recommendations: Thoracic radiographs (with systematic cardiac size assessment), possible echocardiogram, NT-proBNP blood test.\n",
            "\n",
            "   B) Nasopharyngeal or Upper Airway Foreign Body  \n",
            "      • Reason for Lower Priority: Chronicity of signs and partial responses to anti-inflammatory medications make a persistent foreign body less likely.  \n",
            "      • Required Rule-Out Criteria: Thorough oropharyngeal exam, possibly rhinoscopic evaluation if indicated.  \n",
            "      • Testing Recommendations: Sedated oropharyngeal exam, endoscopy if suspicion remains.\n",
            "\n",
            "────────────────────────────────────────────────────────────────────────────\n",
            "\n",
            "DIAGNOSTIC PLAN:\n",
            "\n",
            "1. IMMEDIATE DIAGNOSTICS:\n",
            "\n",
            "   A) Repeat Thoracic Radiographs (3-view)  \n",
            "      • Specific Justification: Essential to evaluate tracheal diameter, pulmonary pattern, cardiac silhouette, and any chronic changes. Previous 03/12/24 radiographs lack official interpretation.  \n",
            "      • Expected Findings: Potential tracheal narrowing, bronchial markings consistent with bronchitis, or normal images requiring further airway assessment.  \n",
            "      • Result Interpretation Criteria: Comparison to normal canine thoracic standards; measurement of tracheal lumen, identification of alveolar or bronchial patterns, assessment of heart size (vertebral heart score).  \n",
            "      • Cost-Benefit Assessment: Moderate cost, high diagnostic yield for confirming or ruling out structural anomalies or advanced cardiopulmonary disease.  \n",
            "      • Sample Handling Requirements: Standard digital or film radiography technique, sedation if needed for patient comfort/stillness.  \n",
            "      • Timing Considerations: Perform as soon as possible to guide treatment updates.\n",
            "\n",
            "   B) Complete Blood Count (CBC) and Serum Biochemistry Panel  \n",
            "      • Specific Justification: Assess for infection, inflammation, organ function before adjusting medications.  \n",
            "      • Expected Findings: May show eosinophilia (allergic), leukocytosis (infection/inflammation), or be unremarkable.  \n",
            "      • Result Interpretation Criteria: Evaluate RBC, WBC, and platelet counts against standard reference ranges (laboratory-specific); check liver/kidney values given steroid and antibiotic use.  \n",
            "      • Cost-Benefit Assessment: Relatively inexpensive, crucial baseline data for safe continued therapy.  \n",
            "      • Sample Handling Requirements: EDTA tube for CBC, serum separator for chemistry; avoid hemolysis.  \n",
            "      • Timing Considerations: Collect at time of next visit or concurrently with radiographs.\n",
            "\n",
            "   C) Otic Cytology  \n",
            "      • Specific Justification: Determine presence of yeast, bacteria, or inflammatory cells in the ear canal.  \n",
            "      • Expected Findings: Cocci, rods, or yeast if infection; excessive neutrophils for acute inflammation or mononuclear cells for chronic changes.  \n",
            "      • Result Interpretation Criteria: Compare with reference images and typical thresholds for infection (e.g., >2+ organisms/HPF).  \n",
            "      • Cost-Benefit Assessment: Minimal cost, immediate result, guides targeted ear therapy.  \n",
            "      • Sample Handling Requirements: Gentle swab from external ear canal; Diff-Quick stain or similar.  \n",
            "      • Timing Considerations: During the next clinic visit for ear evaluation.\n",
            "\n",
            "2. MONITORING DIAGNOSTICS:\n",
            "\n",
            "   A) Weight Trend and Body Condition Score (BCS)  \n",
            "      • Frequency of Measurement: At every visit (every 4–6 weeks if active issue persists).  \n",
            "      • Alert Thresholds: >5% weight loss or gain triggers nutritional assessment.  \n",
            "      • Trend Analysis Criteria: Evaluate for chronic weight loss, possible muscle wasting.  \n",
            "      • Action Triggers: Unintentional weight loss ≥5% requires dietary or medical review; excessive BCS changes prompt diet adjustment.\n",
            "\n",
            "   B) Respiratory Rate and Effort Logs  \n",
            "      • Frequency of Measurement: At least weekly by owner, daily if cough worsens.  \n",
            "      • Alert Thresholds: Resting respiratory rate consistently >40 breaths/min or severe coughing episodes.  \n",
            "      • Trend Analysis Criteria: Increase in baseline cough frequency or distress.  \n",
            "      • Action Triggers: Escalation of therapy or urgent recheck if cough worsens or new respiratory distress arises.\n",
            "\n",
            "   C) Ear Discharge / Otic Inflammation Check  \n",
            "      • Frequency of Measurement: Owner to examine external ear canal daily for discharge or odor.  \n",
            "      • Alert Thresholds: Recurrence of redness, odor, or discharge.  \n",
            "      • Trend Analysis Criteria: Return of symptoms indicates unresolved infection or allergy flare.  \n",
            "      • Action Triggers: Repeat cytology or antibiotic/steroid therapy modification.\n",
            "\n",
            "────────────────────────────────────────────────────────────────────────────\n",
            "\n",
            "THERAPEUTIC PLAN:\n",
            "\n",
            "1. IMMEDIATE INTERVENTIONS:\n",
            "\n",
            "   A) Verify Compliance and Current Use of Existing Medications  \n",
            "      • Medications Involved:  \n",
            "         1) Chlorpheniramine 4 mg tablets (Dose: 1 tablet PO BID)  \n",
            "         2) Doxycycline 50 mg/mL suspension (Dose per latest prescription: 0.5 mL PO BID)  \n",
            "         3) Temaril-P tablets (Trimeprazine tartrate + Prednisolone) (Dose: ½ tablet PO BID)  \n",
            "         4) Theophylline 400 mg ER capsules (Dispensed 10/17/24: instructions to convert to 1 mL suspension PO BID if needed)  \n",
            "         5) Ear Cleansing Solution (daily) and Panalog Ointment (daily application)  \n",
            "      • Exact Dose Calculation: Reassess current weight at 6.1 kg (13.44 lb) to confirm mg/kg dosing for each medication.  \n",
            "      • Administration Details: Oral (PO) for systemic medications, topical for ears.  \n",
            "      • Monitoring Requirements: Track cough frequency, appetite, and stool consistency.  \n",
            "      • Expected Response Timeline: Within 1–2 weeks if therapy aligns with cause; if no improvement, reevaluation is needed.  \n",
            "      • Adverse Effect Monitoring: GI upset (doxycycline), sedation (chlorpheniramine), polyuria/polydipsia or steroid side effects (Temaril-P), tachycardia or excitability (theophylline).\n",
            "\n",
            "2. LONG-TERM MANAGEMENT:\n",
            "\n",
            "   A) Specific Outcome Goals  \n",
            "      • Reduction or resolution of coughing episodes to <2–3 times/day or as close to baseline normal.  \n",
            "      • Maintenance of normal ear canal health without discharge or redness.  \n",
            "      • Maintenance of stable weight at ~6.1 kg (13.44 lb), with BCS 4–5/9 (if this is the normal range for this patient).\n",
            "\n",
            "   B) Timeline for Reassessment  \n",
            "      • Recheck in approximately 2–3 weeks (by 02/25/25 or 03/04/25) to assess response to any modifications in medication and to perform recommended diagnostics.  \n",
            "      • Subsequent evaluations every 1–2 months if cough persists or if ear signs recur.\n",
            "\n",
            "   C) Quality of Life Parameters  \n",
            "      • Activity level, exercise tolerance, absence of respiratory distress, normal appetite, comfortable ear canals.  \n",
            "      • Minimal stress or anxiety associated with coughing episodes.\n",
            "\n",
            "   D) Client Education Points  \n",
            "      • Importance of compliance with medication regimens, including chlorpheniramine, doxycycline, and any steroid or bronchodilator instructions.  \n",
            "      • Instruction on daily ear examinations for discharge or odor, proper ear cleaning technique (if still recommended).  \n",
            "      • Recording cough frequency and any patterns (time of day, triggers) to facilitate ongoing monitoring.\n",
            "\n",
            "   E) Environmental Modifications  \n",
            "      • Minimize inhaled irritants (e.g., smoke, strong fragrances).  \n",
            "      • Control potential allergens if suspected (dust, pollen, use of air purifier).\n",
            "\n",
            "   F) Dietary Recommendations  \n",
            "      • Maintain balanced diet appropriate for a 6.1 kg dog.  \n",
            "      • Consider weight control formula if BCS is above ideal, or increased-calorie if below.  \n",
            "      • Encourage consistent feeding routine to detect appetite changes.\n",
            "\n",
            "   G) Criteria for Success/Failure and Timeline for Modifications  \n",
            "      • Success Criteria: Coughing noticeably decreased, stable respiratory rate at rest (<30 breaths/min), no new ear exudate.  \n",
            "      • Failure Criteria: Persistent or worsening cough after 2–3 weeks, new or worsened otic discharge, or significant weight changes (>5% loss or gain).  \n",
            "      • Modification Timeline: If no improvement by next recheck (02/25/25–03/04/25), adjust medication regimen, proceed with advanced diagnostics (bronchoscopy, echocardiography if indicated).\n",
            "\n",
            "────────────────────────────────────────────────────────────────────────────\n",
            "\n",
            "ADDITIONAL CLIENT COMMUNICATION & INSTRUCTIONS:\n",
            "\n",
            "• Owner: Anna Miracle (ID 24404F).  \n",
            "• She reports continued use of Bravecto (Fluralaner) 10–22 lb dose every six (6) months (last dispensed 12/06/24) and Sentinel Spectrum (Milbemycin Oxime + Praziquantel + Lufenuron) 8–25 lb dose monthly (most recently documented on 12/06/24).  \n",
            "• Rabies vaccination was due on 01/25/25; client must be reminded to schedule vaccination immediately.  \n",
            "• No written instructions regarding further rechecks or advanced diagnostics in the record; owner should be provided a detailed plan for follow-up diagnostic and therapeutic steps.  \n",
            "• Client advised to keep a daily log of cough episodes, appetite, activity, and any ear discharge, and to bring these logs to the next visit.  \n",
            "\n",
            "────────────────────────────────────────────────────────────────────────────\n",
            "[END OF COMPREHENSIVE DIAGNOSTIC ASSESSMENT]\n",
            "\n",
            "Specialist Summary:\n",
            "------------------------------\n",
            "SPECIALIST CONSULTATION:\n",
            "\n",
            "1. CASE SUMMARY  \n",
            "   • Chronological History:  \n",
            "     – Earliest verifiable mention of chronic cough and respiratory distress on 02/04/25, although previous medication records suggest an onset prior to 03/01/24.  \n",
            "     – Ear inflammation or otic discomfort first addressed on 04/05/24 with topical therapies (ear cleansing solution [TM342], Panalog [TM270]).  \n",
            "     – Medications used intermittently since at least 03/01/24 without clear documentation of efficacy or formal resolution.  \n",
            "\n",
            "   • Prior Treatments and Responses:  \n",
            "     – Chlorpheniramine 4 mg tablets (01 tablet PO BID; no formal documentation of clinical response).  \n",
            "     – Doxycycline 50 mg/mL suspension (0.5 mL PO BID; used on at least two occasions [03/12/24 and 10/16/24]; response not clearly recorded).  \n",
            "     – Temaril-P tablets (½ tablet PO BID; unknown degree of improvement or side effects).  \n",
            "     – Theophylline 400 mg ER capsules (dispensed on 10/17/24; no documented outcome).  \n",
            "     – Topical ear treatments: Ear Cleansing Solution (once daily), Panalog Ointment (once daily) starting 04/05/24; no otoscopic follow-up noted.  \n",
            "\n",
            "   • Every Diagnostic Result:  \n",
            "     – Thoracic radiographs performed 03/12/24 without formal radiologist interpretation in the record.  \n",
            "     – No CBC, serum chemistry, or otic cytology results documented in the available notes.  \n",
            "\n",
            "   • Specific Clinical Progression:  \n",
            "     – The cough remains chronic and unrelenting (reported as “dry,” “frequent,” with “panting loudly”).  \n",
            "     – Otic discomfort was noted with enough severity to warrant topical therapy, but no documented final resolution or recheck.  \n",
            "\n",
            "   • Current Status Assessment:  \n",
            "     – Persistent coughing with uncertain severity (client implies moderate respiratory distress).  \n",
            "     – Ear inflammation possibly ongoing; no recent reassessment since 04/05/24.  \n",
            "     – No documented resolution or clear improvement to date.  \n",
            "\n",
            "2. DISEASE PROCESS ANALYSIS  \n",
            "   • Detailed Pathophysiology (Primary Differentials):  \n",
            "     – Chronic Bronchitis / Allergic Airway Disease: Long-standing cough, partial or uncertain response to antihistamines and steroids, potential atopic link (allergic otitis).  \n",
            "     – Tracheal Collapse: Classic toy-breed predisposition, “honking” cough described by owner, though objective imaging data are lacking.  \n",
            "     – Infectious Tracheobronchitis: Despite doxycycline trials, no confirmatory testing or consistent follow-up.  \n",
            "     – Chronic Otitis Externa: Likely allergic or infectious etiology; incomplete evaluation and follow-up.  \n",
            "\n",
            "   • Current Disease Stage:  \n",
            "     – Respiratory pathology appears chronic and persistent, not acutely decompensated but has not been fully characterized by objective diagnostics.  \n",
            "     – Otic inflammation may be chronic or recurrent with no recorded end point.  \n",
            "\n",
            "   • Progression Factors:  \n",
            "     – Possible ongoing allergen exposure, incomplete or inconsistent therapeutic measures, and absence of thorough diagnostic information.  \n",
            "     – Repeated or prolonged steroid use without comprehensive monitoring could mask underlying disease or contribute to side effects.  \n",
            "\n",
            "   • Complicating Conditions:  \n",
            "     – Lack of formal auscultation findings or cardiac evaluation leaves open possibilities of cardiac cough or concurrent disease.  \n",
            "     – Potential ear canal changes (stenosis, chronic inflammation) if otitis has not been resolved.  \n",
            "\n",
            "   • Prognosis Assessment with Criteria:  \n",
            "     – Favorable for chronic bronchitis or mild tracheal collapse if controlled with lifelong management.  \n",
            "     – Fair to guarded if underlying complications (e.g., severe airway collapse, advanced allergic disease) are present and remain unaddressed.  \n",
            "     – Prognosis improves with definitive diagnostics (imaging, airway cytology, otic exams) and targeted therapy.  \n",
            "\n",
            "3. TREATMENT ANALYSIS  \n",
            "   • Response to Previous Treatments:  \n",
            "     – No clearly documented improvement with chlorpheniramine, doxycycline, or Temaril-P. Unknown compliance and exact dosing accuracy.  \n",
            "     – Theophylline usage remains unassessed.  \n",
            "     – Otic treatment with ear cleansing solution and Panalog had no documented follow-up to confirm resolution.  \n",
            "\n",
            "   • Current Treatment Efficacy:  \n",
            "     – Observational data only; no objective scoring or recheck to gauge success or failure.  \n",
            "\n",
            "   • Treatment Complications:  \n",
            "     – Potential steroid side effects (polyuria, polydipsia, iatrogenic Cushing’s) unreported but should be monitored.  \n",
            "     – Possible antibiotic resistance if incomplete or inconsistent use of doxycycline.  \n",
            "\n",
            "   • Compliance Assessment:  \n",
            "     – Unclear whether instructions and dosing intervals have been strictly followed for each medication.  \n",
            "     – Client’s daily logs (including cough frequency, ear checks) have not been mentioned or submitted.  \n",
            "\n",
            "   • Risk-Benefit Analysis:  \n",
            "     – Continuing empirical medication without diagnostic clarity risks perpetuating unaddressed causes and potential adverse effects.  \n",
            "     – A structured approach with diagnostics and evidence-based therapies could clarify etiology and reduce unnecessary medication exposure.  \n",
            "\n",
            "4. SPECIALIST RECOMMENDATIONS  \n",
            "   4A) Recommendation 1: Updated Diagnostics for Respiratory Disease  \n",
            "        • Intervention: Obtain 3-view thoracic radiographs (inspiratory/expiratory if possible), complete blood count (CBC), serum chemistry, and airway wash (BAL or TTW) if indicated by radiographic findings.  \n",
            "        • Rationale: Determine structural integrity of the trachea/bronchi, evaluate for bronchial or alveolar patterns, assess for infection or inflammation. Clarify baseline organ function.  \n",
            "        • Expected Outcome: More precise understanding of airway pathology, guiding targeted medical or surgical therapy.  \n",
            "        • Monitoring Parameters: Radiographic comparison to normal references (e.g., vertebral heart score), WBC count abnormalities on CBC.  \n",
            "        • Alternative Options: If airway wash is not feasible, advanced imaging (fluoroscopy or CT) or referral for bronchoscopy.  \n",
            "\n",
            "   4B) Recommendation 2: Comprehensive Otic Evaluation  \n",
            "        • Intervention: Perform otic cytology at next visit, possibly a deep otoscopic exam under sedation to assess tympanic membrane and canal.  \n",
            "        • Rationale: Diagnose or rule out persistent infection (bacterial, yeast), chronic inflammatory changes, or foreign material.  \n",
            "        • Expected Outcome: Targeted therapy if ongoing otitis externa is present.  \n",
            "        • Monitoring Parameters: Cytology results (organism load, inflammatory cells), clinical improvement of ear discharge or odor.  \n",
            "        • Alternative Options: If severe disease is found, advanced imaging (CT, MRI) or referral to a dermatology specialist.  \n",
            "\n",
            "   4C) Recommendation 3: Compliance Verification and Potential Adjustment of Current Medications  \n",
            "        • Intervention: Review client’s administration method and adherence to previously prescribed medications (chlorpheniramine, doxycycline, Temaril-P, theophylline, ear solutions).  \n",
            "        • Rationale: Inconsistent dosing may explain suboptimal or absent clinical response.  \n",
            "        • Expected Outcome: Optimized or discontinued therapies depending on diagnostic results, side effects, and actual efficacy.  \n",
            "        • Monitoring Parameters: Daily cough logs, weight checks, possible WBC differentials for infection.  \n",
            "        • Alternative Options: Consider inhaled bronchodilators or inhaled steroids if allergic airway disease is confirmed and systemic side effects are a concern.  \n",
            "\n",
            "   4D) Recommendation 4: Rule out Cardiac Etiologies  \n",
            "        • Intervention: Auscultation for murmurs, repeat thoracic radiographs with heart size assessment, possible echocardiogram if indicated.  \n",
            "        • Rationale: Cardiogenic cough remains a differential in small breeds, especially if murmur or cardiomegaly is detected.  \n",
            "        • Expected Outcome: Confirm or exclude valvular disease; helps refine respiratory vs. cardiac management.  \n",
            "        • Monitoring Parameters: Radiographic cardiac silhouette (vertebral heart score), heart rate, echocardiographic findings.  \n",
            "        • Alternative Options: NT-proBNP blood test if echocardiography is not immediately accessible.  \n",
            "\n",
            "COMPREHENSIVE PLAN:\n",
            "\n",
            "1. MEDICAL MANAGEMENT  \n",
            "   (All medications below require confirmation of patient’s current weight at 6.1 kg [13.44 lb] and precise mg/kg dosing.)\n",
            "\n",
            "   A) Chlorpheniramine (4 mg tablets)  \n",
            "      • Exact Dose Calculation: 1 tablet (4 mg) PO every 12 hours → ~0.66 mg/kg per dose if the dog is truly 6.1 kg.  \n",
            "      • Administration Protocol: Administer with or without food. Continue for 2 weeks pending diagnostic outcomes.  \n",
            "      • Monitoring Requirements: Watch for sedation or anticholinergic effects; track cough frequency.  \n",
            "      • Duration of Therapy: Reassess after 02/25/25—03/04/25 visit or once diagnostics clarify necessity.  \n",
            "      • Success Criteria: Reduction in cough frequency, no adverse sedation.  \n",
            "      • Modification Triggers: Excessive drowsiness or no change in cough after 14 days.\n",
            "\n",
            "   B) Doxycycline (50 mg/mL suspension)  \n",
            "      • Exact Dose Calculation: Currently 0.5 mL (25 mg) PO every 12 hours → ~4.1 mg/kg per dose if the dog is 6.1 kg.  \n",
            "      • Administration Protocol: Administer with a small meal or treat to reduce GI upset.  \n",
            "      • Monitoring Requirements: GI signs (vomiting, diarrhea), correct dosing interval (every 12 hours).  \n",
            "      • Duration of Therapy: 10–14 days, or as directed pending airway culture results if performed.  \n",
            "      • Success Criteria: Improvement in clinical signs if bacterial or atypical infection is present.  \n",
            "      • Modification Triggers: Lack of improvement after a full course (14 days) or if culture confirms resistant organisms.\n",
            "\n",
            "   C) Temaril-P (Trimeprazine Tartrate + Prednisolone)  \n",
            "      • Exact Dose Calculation: ½ tablet PO every 12 hours → total prednisolone content ~1.5 mg per half-tablet (confirm product specifics for mg/kg).  \n",
            "      • Administration Protocol: Give with food to reduce GI irritation; monitor for polyuria and polydipsia.  \n",
            "      • Monitoring Requirements: Watch for side effects (increased thirst, hunger, urination), check weight and BCS.  \n",
            "      • Duration of Therapy: May be tapered depending on response and underlying diagnosis; re-evaluate at recheck by 02/25/25–03/04/25.  \n",
            "      • Success Criteria: Reduced cough frequency and intensity.  \n",
            "      • Modification Triggers: Adverse steroid effects, definitive diagnosis suggesting alternative therapy.\n",
            "\n",
            "   D) Theophylline (400 mg ER capsules)  \n",
            "      • Exact Dose Calculation: If 400 mg is split into a compounded suspension at 400 mg/5 mL, for example, then 1 mL PO every 12 hours would provide 80 mg (~13 mg/kg per dose for a 6.1 kg dog). Exact concentration must be verified.  \n",
            "      • Administration Protocol: Administer separate from fluoroquinolones or other drug interactions; consistent timing if used.  \n",
            "      • Monitoring Requirements: Heart rate (tachycardia), CNS stimulation (tremors, restlessness).  \n",
            "      • Duration of Therapy: Evaluate after 2 weeks; discontinue or adjust if no observable benefit or if side effects occur.  \n",
            "      • Success Criteria: Decreased cough if bronchospasm or airway hyper-reactivity is a factor.  \n",
            "      • Modification Triggers: Tachycardia, arrhythmias, or insufficient clinical improvement.\n",
            "\n",
            "   E) Ear Cleansing Solution (TM342) and Panalog (TM270) Ointment  \n",
            "      • Exact Dose Calculation: Topical—apply solution once daily to external ear canal, follow with thin layer of Panalog ointment once daily.  \n",
            "      • Administration Protocol: Gently clean prior to ointment application; avoid aggression if tympanic membrane integrity is uncertain.  \n",
            "      • Monitoring Requirements: Daily check for discharge, odor, redness by owner.  \n",
            "      • Duration of Therapy: Continue until recheck otic exam can confirm resolution.  \n",
            "      • Success Criteria: Resolved inflammation, no discharge on cytology.  \n",
            "      • Modification Triggers: Persistent signs, pain on manipulation, or cytology findings indicating resistant infection.\n",
            "\n",
            "2. MONITORING PROTOCOL  \n",
            "   A) Respiratory Rate and Cough Frequency  \n",
            "      • Measurement Frequency: Owner logs daily cough episodes; check resting respiratory rate once daily.  \n",
            "      • Specific Target Values: Resting rate <30 breaths/min; cough <1–2 episodes per day if disease is controlled.  \n",
            "      • Acceptable Ranges: ≤3 daily episodes of brief coughing, no severe respiratory distress.  \n",
            "      • Action Thresholds: Sustained increase in cough (>3 episodes/day) or respiratory rate >40 breaths/min at rest.  \n",
            "      • Response Protocols: Contact clinic promptly for medication adjustments or urgent recheck.\n",
            "\n",
            "   B) Otic Status  \n",
            "      • Measurement Frequency: Brief daily external ear inspection by owner for discharge, odor, redness.  \n",
            "      • Specific Target Values: Clean, odor-free canal, no erythema.  \n",
            "      • Acceptable Ranges: Mild wax accumulation without inflammation.  \n",
            "      • Action Thresholds: Notable re-accumulation of debris, foul odor, pain on handling.  \n",
            "      • Response Protocols: Immediate recheck cytology; consider antibiotic or antifungal therapy changes if indicated.\n",
            "\n",
            "   C) Body Weight and BCS  \n",
            "      • Measurement Frequency: At every visit or every 4–6 weeks if more frequent visits are indicated.  \n",
            "      • Specific Target Values: Maintain ~6.1 kg, BCS ideally 4–5/9.  \n",
            "      • Acceptable Ranges: ±5% weight variation.  \n",
            "      • Action Thresholds: >5% unintentional weight change.  \n",
            "      • Response Protocols: Investigate for medication side effects, appetite changes, or underlying metabolic disease.\n",
            "\n",
            "3. CLIENT EDUCATION  \n",
            "   • Disease Process Explanation:  \n",
            "     – Chronic airway disease in dogs can result from allergies (chronic bronchitis) or structural issues (tracheal collapse). Otitis externa may be part of an underlying atopic condition.  \n",
            "   • Treatment Rationale:  \n",
            "     – Symptomatic relief (steroids, antihistamines, bronchodilators) is combined with diagnostic efforts to identify and address the underlying cause.  \n",
            "   • Administration Instructions:  \n",
            "     – Demonstrate correct ear cleaning technique. Emphasize accurate oral dosing intervals and the importance of finishing antibiotic courses.  \n",
            "   • Monitoring Requirements:  \n",
            "     – Daily log of cough frequency, breathing patterns, and any ear discharge.  \n",
            "   • Warning Signs:  \n",
            "     – Excessive panting, open-mouth breathing, lethargy, vomiting, diarrhea, or ear pain warrant immediate veterinary contact.  \n",
            "   • Emergency Protocols:  \n",
            "     – If respiratory distress worsens significantly (gasping, cyanosis) or ear pain is severe (scratching, head shaking), seek emergency veterinary care immediately.\n",
            "\n",
            "4. FOLLOW-UP SCHEDULE  \n",
            "   • Specific Recheck Dates:  \n",
            "     – Schedule diagnostics and physical re-evaluation by 02/25/25 or 03/04/25 (within 2–3 weeks).  \n",
            "   • Testing Schedule:  \n",
            "     – Thoracic radiographs, CBC, serum chemistry, otic cytology at next visit (02/25/25–03/04/25).  \n",
            "     – Additional tests (airway wash, echocardiography) if indicated by initial results.  \n",
            "   • Progress Assessment Criteria:  \n",
            "     – Decrease in cough episodes, improved ear health on exam.  \n",
            "     – Stable body weight and normal activity level by next visit.  \n",
            "   • Long-Term Monitoring Plan:  \n",
            "     – If chronic bronchitis or tracheal collapse is confirmed, plan periodic radiographs and possible medication adjustments every 3–6 months.  \n",
            "     – Regular otic monitoring to prevent recurrence of infection.  \n",
            "   • Quality of Life Assessment:  \n",
            "     – Evaluate comfort level, activity, willingness to exercise, and appetite at each follow-up.  \n",
            "\n",
            "ADDITIONAL NOTES AND CLIENT INSTRUCTIONS:  \n",
            "• Client Name: Anna Miracle (ID 24404F).  \n",
            "• Preventive Medications:  \n",
            "  – Bravecto (Fluralaner) 10–22 lb dose every 6 months (last given 12/06/24).  \n",
            "  – Sentinel Spectrum (Milbemycin Oxime + Praziquantel + Lufenuron) 8–25 lb dose monthly (last recorded 12/06/24).  \n",
            "• Vaccinations: Rabies vaccine overdue since 01/25/25; instruct client to schedule immediately.  \n",
            "• Owner to maintain a daily log of cough frequency, appetite, activity, and ear status. Bring logs to next appointment.  \n",
            "• Stress the importance of following dosing instructions exactly, completing antibiotic courses, and returning for diagnostic tests on or before 02/25/25–03/04/25 to guide further therapy.\n",
            "\n",
            "Connections Analysis:\n",
            "------------------------------\n",
            "CASE SYNTHESIS:\n",
            "\n",
            "1. Disease Interactions\n",
            "\n",
            "   • Primary–Secondary Disease Relationships:\n",
            "     – Chronic Respiratory Signs as Primary Concern: The patient, Jax Miracle (canine, Pomeranian, male castrated, 4 years old), has a persistent cough described as “dry coughing, hacking, and panting loudly.” While first explicitly documented on 02/04/25, repeated prescriptions of doxycycline, antihistamines, steroids, and bronchodilators since at least 03/01/24 suggest a long-standing airway or allergic condition.  \n",
            "     – Possible Allergic Component or Secondary Infection: Historical otic inflammation (requiring Panalog ointment and cleansing solution) could reflect an atopic/allergic process. Concurrent ear problems often indicate broader allergic tendencies that may also affect the respiratory tract.  \n",
            "     – Potential Breed Predisposition to Tracheal Collapse: Pomeranians may be prone to collapsing trachea, which frequently presents as a chronic “honking” cough. Radiographs taken on 03/12/24 lacked documented interpretations and may have been performed to investigate structural airway problems.  \n",
            "\n",
            "   • Complicating Factors:\n",
            "     – Incomplete Diagnostic Data: The 03/01/24 blood parasite test (4Dx) and 03/12/24 radiographs have no recorded results. There is no thorough record of auscultation, ECG, or advanced airway diagnostics.  \n",
            "     – Concurrent Otic Disease: Ear inflammation was addressed on 04/05/24 (ear cleansing solution, Panalog), but no follow-up exam is recorded; untreated or unresolved otitis may cause discomfort and stress, potentially exacerbating overall inflammation or allergic disease.  \n",
            "     – Age-Related and Breed Factors: At 4 years old (DOB documented as 12/20/20; alternate references 10/01/20 or 10/01/21 in prior records), Jax is a young adult but belongs to a toy breed with known predispositions to airway problems.  \n",
            "     – Environmental Influences: No documentation of living conditions (other than the owner’s address) or allergen exposures is present.  \n",
            "\n",
            "   • Synergistic Effects:\n",
            "     – Disease Interactions: If allergic airway disease is unaddressed, ongoing otic issues may persist or recur. Respiratory inflammation can be heightened by subclinical ear infections or generalized atopic flare-ups.  \n",
            "     – Treatment Interactions: Repeated antibiotic (doxycycline) and steroid (Temaril-P, Vetalog) use without detailed follow-up could mask or partially suppress signs, making clinical interpretation difficult.  \n",
            "     – Cumulative Impacts: Chronic cough and possible chronic otitis reduce quality of life, cause anxiety (noted by the owner), and risk medication side effects (e.g., steroid complications, antibiotic resistance).  \n",
            "     – Quality of Life Effects: The dog exhibits anxiety with coughing episodes. No direct measure of QOL is recorded, but persistent coughing and panting can significantly affect daily comfort and behavior.\n",
            "\n",
            "2. Treatment Integration\n",
            "\n",
            "   • Drug Interactions:\n",
            "     – Theophylline (400 mg ER) and Steroids (Temaril-P): Potentially additive side effects, such as increased cardiac workload or GI irritation. Close monitoring of heart rate and adverse events is recommended when combining bronchodilators and corticosteroids.  \n",
            "     – Antihistamine (Chlorpheniramine) and Steroids: Minimal direct contraindications, but sedation from antihistamines and polyuria/polydipsia from steroids can compound owner compliance challenges.  \n",
            "     – Antibiotic (Doxycycline) Usage: Must ensure completion of full course and verify that no additional interacting medications (e.g., certain antacids) are given concurrently.  \n",
            "\n",
            "   • Therapeutic Conflicts:\n",
            "     – Competing Treatment Needs: An ongoing cough may require anti-inflammatory or bronchodilator therapy, but if infection or parasites were involved (not yet confirmed on incomplete diagnostics), targeted antimicrobials or parasiticides would be needed.  \n",
            "     – Priority Assessment: Confirming the etiology of the cough (structural vs. inflammatory vs. infectious) is paramount before continuing empirical treatments indefinitely.  \n",
            "     – Resolution Strategies: Updated thoracic radiographs, CBC, and otic cytology can clarify the exact cause(s) and guide more targeted management.  \n",
            "     – Risk Mitigation: Monitoring for steroid side effects (increased thirst, hunger, urination) and theophylline toxicity (tachycardia, tremors) is critical.  \n",
            "\n",
            "   • Management Synergies:\n",
            "     – Complementary Treatments: If allergic airway disease is confirmed, combining inhaled bronchodilators or inhaled steroids with allergen avoidance can reduce systemic drug side effects. Ear cytology and targeted therapy may resolve otitis more definitively.  \n",
            "     – Timing Optimization: Staggering medication administration for theophylline (to avoid interactions with certain antibiotics) and giving steroids with food can reduce GI adverse effects.  \n",
            "     – Efficiency Improvements: A thorough recheck with imaging and lab work on a single scheduled visit (e.g., by 02/25/25 or 03/04/25) can streamline planning.  \n",
            "     – Outcome Enhancement: An evidence-based approach—where diagnosis precedes or refines therapy—will likely improve cough control and reduce repeated prescribing without measurable results.\n",
            "\n",
            "3. Risk Assessment\n",
            "\n",
            "   • Current Risk Factors:\n",
            "     – Disease-Specific Risks: Chronic cough of unknown origin presents risk of airway damage, persistent inflammation, or complications if structural collapse is unaddressed.  \n",
            "     – Treatment-Related Risks: Prolonged steroid use can lead to hyperadrenocorticism; antibiotics without culture can lead to resistance; theophylline can cause cardiovascular or CNS side effects if overdosed.  \n",
            "     – Environmental Risks: Unknown exposures (allergens, irritants), especially relevant if the cough is allergic or if there is a smoke or dust environment.  \n",
            "     – Client-Specific Factors: Owner compliance might be complicated by multiple medications and unrecorded instructions. Rabies vaccine is overdue as of 01/25/25, posing a legal and public health concern.\n",
            "\n",
            "   • Potential Complications:\n",
            "     – Early Warning Signs: Increased cough frequency, labored breathing, new ear discharge, sedation, GI upset.  \n",
            "     – Prevention Strategies: Prompt recheck with diagnostics, strict medication adherence, potential environment clean-up or allergen reduction measures.  \n",
            "     – Monitoring Protocols: Weekly (or daily) cough logs, ear examinations by owner, weight checks, and regular vet visits for re-evaluation.  \n",
            "     – Intervention Triggers: Any escalation of respiratory distress, severe ear pain or discharge, or medication side effects should prompt immediate veterinary follow-up.\n",
            "\n",
            "────────────────────────────────────────────────────\n",
            "\n",
            "INTEGRATED CARE PLAN:\n",
            "\n",
            "1. Comprehensive Treatment Strategy\n",
            "\n",
            "   • Prioritized Interventions:\n",
            "     1) Update Diagnostics: Obtain 3-view thoracic radiographs (sedated if necessary), CBC, and serum chemistry to clarify the airway condition and overall health. Perform otic cytology to assess persistent infection or inflammation. Target date: by 02/25/25 or 03/04/25.  \n",
            "     2) Verify Medication Compliance: Confirm the client’s administration of current/historical scripts (especially doxycycline and theophylline dosing details).  \n",
            "     3) Address Overdue Rabies Vaccine: Remind owner that Jax’s rabies vaccination (due 01/25/25) must be updated promptly for legal and health reasons.  \n",
            "     4) Assess Need for Taper or Adjustment: Depending on new diagnostic findings, consider tapering or discontinuing unnecessary antibiotics/steroids if no active infection or allergic flare is confirmed.  \n",
            "\n",
            "   • Short-Term Goals (next 2–3 weeks):\n",
            "     – Reduce cough episodes to a manageable frequency (<3 episodes/day if possible).  \n",
            "     – Clarify primary etiology (infection, inflammatory, structural) using radiographs and labs.  \n",
            "     – Ensure ear health is stable or improved with daily cleaning (if recommended) and correct Panalog usage.  \n",
            "\n",
            "   • Long-Term Objectives (beyond 1 month):\n",
            "     – Achieve consistent respiratory comfort (sporadic or no coughing).  \n",
            "     – Maintain normal ear canals without chronic inflammation.  \n",
            "     – Establish a sustainable medication protocol—potentially inhaled steroids or bronchodilators if structural or allergic origins are identified.  \n",
            "\n",
            "   • Success Criteria:\n",
            "     – Documented radiographic or clinical improvement of airway patency.  \n",
            "     – Normal ear cytology or minimal inflammatory cells on recheck.  \n",
            "     – Stable body weight (~6.1 kg) and comfortable daily activity level.\n",
            "\n",
            "   • Team Responsibilities:\n",
            "     – Veterinarian: Lead diagnostics, interpret results, adjust medication plan, ensure vaccine compliance.  \n",
            "     – Technician/Assistant: Perform radiographs, assist with ear cytologies, provide medication administration demos.  \n",
            "     – Client (Anna Miracle, ID 24404F): Administer medications as directed, monitor cough frequency, ear status, weight changes, and schedule timely rechecks.  \n",
            "     – Reception/Billing: Notify client of diagnostic cost estimates, schedule recheck by 02/25/25 or 03/04/25, update contact preferences (client also listed secondary phone (502) 706-0428).\n",
            "\n",
            "2. Long-Term Management\n",
            "\n",
            "   • Disease Trajectory:\n",
            "     – Expected Progression: If allergic or inflammatory airway disease is confirmed, Jax may require lifelong intermittent therapy. Collapsing trachea may also be chronic and progressive, needing ongoing management.  \n",
            "     – Monitoring Points: Periodic thoracic imaging (every 6–12 months or if clinical signs worsen), yearly CBC/chemistry, and routine otic evaluations if signs recur.  \n",
            "     – Intervention Triggers: Significant increase in cough intensity or frequency, changes in ear discharge, or major side effects from medications.  \n",
            "     – Outcome Measures: Reduction in daily coughing, normal energy level, healthy ear canals, stable or normal appetite and weight.\n",
            "\n",
            "   • Quality of Life:\n",
            "     – Assessment Criteria: Observable anxiety reduction, comfortable breathing, normal playful behavior, no avoidance or distress from ear handling.  \n",
            "     – Monitoring Protocol: Encourage the owner to keep a simple diary of daily respiratory observations and ear checks, noting any sedation, GI upset, or steroid side effects.  \n",
            "     – Improvement Strategies: Potential shift to inhaled medications if indicated, environmental modifications (air filtration, avoidance of smoke/perfumes).  \n",
            "     – Client Assessment Tools: Provide a 1–10 cough severity scale, daily log template for the owner to fill out before each recheck.\n",
            "\n",
            "3. Support Systems\n",
            "\n",
            "   • Client Education:\n",
            "     – Understanding Assessment: Explain suspected causes (allergic airway disease or tracheal collapse) and how these can overlap with otic problems.  \n",
            "     – Training Needs: Demonstrate ear cleaning technique if indicated, proper oral medication administration, and how to monitor for side effects.  \n",
            "     – Resource Requirements: Provide referrals if advanced diagnostics (fluoroscopy, bronchoscopy, echocardiography) or specialty dermatology/respiratory consults become necessary.  \n",
            "     – Support Services: Offer telemedicine check-ins or phone consultations if the client observes new or escalating symptoms prior to the scheduled recheck.\n",
            "\n",
            "   • Compliance Strategy:\n",
            "     – Barriers Assessment: Multiple medications, possible sedation side effects, and no documented instructions for theophylline compounding may confuse the owner.  \n",
            "     – Solution Implementation: Provide clear, written dosing plans for each medication, including exact mg or mL per dose, intervals (every 12 or 24 hours), and start/end dates.  \n",
            "     – Monitoring Methods: Request weekly email or phone updates if coughing worsens; instruct daily ear inspection.  \n",
            "     – Success Measures: Return visits show improved respiratory status, normal ear canals, and consistent follow-through with recommended testing and vaccination.\n",
            "\n",
            "────────────────────────────────────────────────────\n",
            "\n",
            "\n",
            "\n"
          ]
        }
      ],
      "source": [
        "    file_path = \"./input.pdf\"\n",
        "    result = analyze_veterinary_case(file_path)\n",
        "\n",
        "    print(\"\\nAnalysis Results:\")\n",
        "    print(\"-\" * 50)\n",
        "\n",
        "    sections = [\n",
        "        (\"Data Processing\", \"DataProcessor\"),\n",
        "        (\"History Analysis\", \"HistoryAnalyzer\"),\n",
        "        (\"Clinical Analysis\", \"ClinicalAnalyzer\"),\n",
        "        (\"Diagnostic Assessment\", \"Diagnostics\"),\n",
        "        (\"Specialist Summary\", \"SpecialistSummary\"),\n",
        "        (\"Connections Analysis\", \"Connections\")\n",
        "    ]\n",
        "\n",
        "    for title, key in sections:\n",
        "        print(f\"\\n{title}:\")\n",
        "        print(\"-\" * 30)\n",
        "        print(result[\"results\"].get(key, \"Not available\"))\n",
        "\n",
        "    if \"errors\" in result[\"results\"]:\n",
        "        print(\"\\nErrors encountered:\")\n",
        "        for error in result[\"results\"][\"errors\"]:\n",
        "            print(f\"- {error['message']} (at {error['timestamp']}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 32,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "3JtuR6wZa9iy",
        "outputId": "09566faa-199a-424b-db00-0e819c837236"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Processing document(s)...\n",
            "Creating workflow for 12 file(s)...\n",
            "Running analysis...\n",
            "\n",
            "Analysis Results:\n",
            "--------------------------------------------------\n",
            "\n",
            "Data Processing:\n",
            "------------------------------\n",
            "PATIENT SIGNALMENT & CLIENT INFORMATION:\n",
            "• Patient ID#: CA25440F  \n",
            "• Name: Spencer Johnson  \n",
            "• Species: Canine  \n",
            "• Breed: Chihuahua mix (sometimes noted as “CHIHX”)  \n",
            "• Date of Birth: 03/19/14 (approximately 10.5–10.8 years old at time of visits)  \n",
            "• Sex: Male Castrated (MC)  \n",
            "• Most recent recorded weight: 5.6 kg on 01/27/25 and 5.67 kg on 01/28/25  \n",
            "• Body Condition Score (BCS): 5/9  \n",
            "• Primary Client/Owner:  \n",
            "  – Name: Carl Johnson  \n",
            "  – Address #1: 11400 Willow Pond Dr, Louisville, KY 40291  \n",
            "  – Address #2 (also listed in records): 359 Lentz Ln, Mt Washington, KY 40047  \n",
            "  – Phone: (502) 428-5015  \n",
            "  – Email: (multiple noted – “mrjefferson.cj@gmail.com” or “mrjefferson.cv@gmail.com” as per different documents)  \n",
            "• Insurance Status: Not Recorded  \n",
            "• Billing Preferences: Not Recorded  \n",
            "\n",
            "ALL CURRENT MEDICATIONS (as of last documented instructions):\n",
            "1) Enalapril 2.5 mg – 1 tablet orally once daily (SID). Started prior to 01/27/25, ongoing.  \n",
            "2) Vetmedin (pimobendan) 2.5 mg – ½ tablet orally twice daily (BID). Started prior to 01/27/25, ongoing.  \n",
            "3) Furosemide 20 mg – 1 tablet orally twice daily (BID). Started prior to 01/27/25, ongoing.  \n",
            "4) Trazodone 50 mg – ½ tablet orally as needed. Started prior to 01/27/25, ongoing.  \n",
            "5) Joint supplement – every other day (exact product not specified). Ongoing.  \n",
            "6) Credelio flea/tick preventive – administered March–October (exact dose/strength not specified), oral route.  \n",
            "7) Doxycycline 100 mg tablets – ½ tablet (i.e., 50 mg) orally once daily (SID) with food. Began 01/27/25; re-check or refill not specified beyond initial supply.  \n",
            "8) Prednisone 10 mg tablets – 1 tablet (10 mg) orally once daily (SID) with food. Began 01/27/25; do not run out (ongoing immunosuppressive therapy).  \n",
            "9) Cyclosporine (Atopica) 25 mg capsules – 1 capsule orally twice daily (BID) with food. Began 01/27/25–01/28/25.  \n",
            "10) Clopidogrel (Plavix) 75 mg tablets – ¼ tablet (approximately 18.75 mg) orally once daily (SID). Began 01/27/25; do not run out.  \n",
            "• Routes are oral. Start dates given above. No adverse medication reactions reported.  \n",
            "• Diet (as of last instructions): Transitioned from Purina Pro Plan kibble to Hill’s i/d Low Fat; recommended ~1⅓ can per day as of 01/28/25.  \n",
            "\n",
            "PRESENTING COMPLAINT AND HISTORY\n",
            "\n",
            "[Chief Complaint]  \n",
            "• Collapsing (syncope/fainting) episodes.  \n",
            "• First episode noted on Thursday 01/23/25, then two more on Saturday 01/25/25, another on Monday morning 01/27/25.  \n",
            "\n",
            "[Duration and Timeline]  \n",
            "• 01/23/25: First fainting episode.  \n",
            "• 01/25/25 (Saturday): Experienced two fainting episodes in the morning. Remained lethargic afterward, never appeared to return fully to normal.  \n",
            "• 01/26/25 (Sunday): No documented collapsing events, but continued lethargy and inappetence.  \n",
            "• 01/27/25 (Monday ~8:27 AM): Another syncope episode; not fully recovered afterward. Presented to Veterinary Specialist Partners the same day.  \n",
            "• 01/28/25 (Tuesday): Recheck after transfusion; no new collapsing episodes reported overnight.  \n",
            "\n",
            "[Symptom Frequency/Severity and Behavioral/Physiologic Changes]  \n",
            "• Lethargy (especially after episodes on 01/25/25).  \n",
            "• Mild tachypnea / increased respiratory rate.  \n",
            "• Inappetence toward usual dry kibble for ~24 hours pre-visit on 01/27/25.  \n",
            "• Vomited boiled chicken on 01/26/25; unclear if due to overeating or other cause.  \n",
            "• Drinking remained normal.  \n",
            "• Urination/defecation: No diarrhea reported. Soft stool noted on rectal exam 01/27/25.  \n",
            "\n",
            "[Past Medical History]  \n",
            "• Chronic “hacking cough” for several months (non-productive, recently diminished).  \n",
            "• Heart disease (murmur previously identified).  \n",
            "• Medications from primary veterinarian prior to referral (Enalapril, Vetmedin, Furosemide, Trazodone, joint supplement, seasonal Credelio).  \n",
            "• Bloodwork, thoracic radiographs, and EKG performed by referring veterinarian on or around 01/25/25 (details not fully provided except that they noted suspected heart issues and concern for possible syncopal episodes).  \n",
            "• No prior major surgeries documented.  \n",
            "• Vaccination/preventive care dates: Not Recorded (except Credelio use March-October).  \n",
            "• Diet History: Purina Pro Plan dry kibble prior to referral; new recommendation for Hill’s i/d Low Fat.  \n",
            "\n",
            "PHYSICAL EXAMINATION\n",
            "\n",
            "Vital Signs (01/27/25, 10:50 AM)  \n",
            "• Temperature: 100.1 °F  \n",
            "• Heart Rate: 168 bpm  \n",
            "• Respiratory Rate: 40 breaths/min  \n",
            "• Weight: 5.6 kg  \n",
            "• Body Condition Score (BCS): 5/9  \n",
            "• Mucous Membrane color: Pale white/ mildly icteric (01/27/25)  \n",
            "• Capillary Refill Time (CRT): Not Recorded  \n",
            "• Pain Score (0–10): Not Recorded  \n",
            "\n",
            "Vital Signs (01/28/25, ~9:25 AM)  \n",
            "• Temperature: 100.9 °F  \n",
            "• Heart Rate: 160 bpm  \n",
            "• Respiratory Rate: 50 breaths/min  \n",
            "• Weight: 5.67 kg  \n",
            "• Mucous Membrane color: Pink to mildly icteric  \n",
            "• CRT: Not Recorded  \n",
            "• Pain Score (0–10): Not Recorded  \n",
            "\n",
            "System-by-System Examination (combined findings from 01/27/25 and 01/28/25)  \n",
            "\n",
            "• EENT:  \n",
            "  – 01/27/25: Pale white mucous membranes, mild icterus, pupils symmetric, menace present OU.  \n",
            "  – 01/28/25: Pink mucous membranes but with slight icteric tinge.   \n",
            "\n",
            "• Oral/Dental:  \n",
            "  – Normal dentition for age, no significant lesions.  \n",
            "\n",
            "• Cardiovascular:  \n",
            "  – 01/27/25: Grade 4/6 left-sided apical systolic murmur, no arrhythmias.  \n",
            "  – 01/28/25: Grade 2/6 left-sided murmur.  \n",
            "  – Pulse quality not specifically documented.  \n",
            "\n",
            "• Respiratory:  \n",
            "  – 01/27/25 & 01/28/25: Normal bronchovesicular sounds; no wheezes or crackles.  \n",
            "\n",
            "• Gastrointestinal:  \n",
            "  – 01/27/25 & 01/28/25: Abdomen soft, non-painful.  \n",
            "  – 01/27/25 rectal: Soft stool.  \n",
            "  – 01/28/25 rectal: Not examined.  \n",
            "\n",
            "• Musculoskeletal:  \n",
            "  – Normal gait. BCS 5/9.  \n",
            "\n",
            "• Neurologic:  \n",
            "  – No overt abnormalities; complete neuro exam not performed.  \n",
            "\n",
            "• Integumentary:  \n",
            "  – Mild icterus noted (skin/jaundice tinge). Suspected papilloma on dorsal left hind paw. No other dermal lesions described.  \n",
            "\n",
            "• Lymphatic:  \n",
            "  – No peripheral lymphadenopathy on palpation; described as normal.  \n",
            "\n",
            "• Urogenital:  \n",
            "  – External exam normal.  \n",
            "\n",
            "DIAGNOSTIC FINDINGS\n",
            "\n",
            "1) LABORATORY RESULTS (All reference ranges as provided in attached in-house or external reports):\n",
            "\n",
            "––––– In-House Complete Blood Count (CBC), 01/27/25 –––––  \n",
            "• RBC: 1.55 M/μL (Reference 5.65–8.87) [L]  \n",
            "• Hematocrit (HCT): 12.2% (37.3–61.7) [L]  \n",
            "• Hemoglobin (HGB): 3.2 g/dL (13.1–20.5) [L]  \n",
            "• MCV: 78.7 fL (61.6–73.5) [H]  \n",
            "• MCH: 20.6 pg (21.2–25.9) [L]  \n",
            "• MCHC: 26.2 g/dL (32.0–37.9) [L]  \n",
            "• RDW: 32.8% (13.6–21.7) [H]  \n",
            "• % Reticulocytes: 35.6% (no direct ref. range in chart; markedly high)  \n",
            "• Absolute Reticulocytes: 552.1 K/μL (10.0–110.0) [H]  \n",
            "• WBC: 41.74 K/μL (5.05–16.76) [H]  \n",
            "   – Neutrophils: 23.87 K/μL (2.95–11.64) [H]  \n",
            "   – Lymphocytes: 12.83 K/μL (1.05–5.10) [H]  \n",
            "   – Monocytes: 4.71 K/μL (0.16–1.12) [H]  \n",
            "   – Eosinophils: 0.29 K/μL (0.06–1.23) [N]  \n",
            "   – Basophils: 0.04 K/μL (0.00–0.10) [N]  \n",
            "• Platelet Count: 213 K/μL (148–484)  \n",
            "• MPV: 20.4 fL (8.7–13.2) [H]  \n",
            "\n",
            "––––– In-House Serum Chemistry, 01/27/25 –––––  \n",
            "• Glucose: 144 mg/dL (70–143) [H by 1 mg/dL]  \n",
            "• BUN: 39 mg/dL (7–27) [H]  \n",
            "• Creatinine: 0.9 mg/dL (0.5–1.8) [N]  \n",
            "• BUN:Creat Ratio: 43 (no reference range provided)  \n",
            "• Phosphorus: 5.0 mg/dL (2.5–6.8) [N]  \n",
            "• Calcium: 8.6 mg/dL (7.9–12.0) [N]  \n",
            "• Sodium: 151 mmol/L (144–160) [N]  \n",
            "• Potassium: 3.3 mmol/L (3.5–5.8) [L]  \n",
            "• Chloride: 109 mmol/L (109–122) [N lower end]  \n",
            "• Total Protein: 7.4 g/dL (5.2–8.2) [N]  \n",
            "• Albumin: 3.2 g/dL (2.2–3.9) [N]  \n",
            "• Globulin: 4.2 g/dL (2.5–4.5) [N]  \n",
            "• Albumin:Globulin ratio: 0.8 (no discrete reference range provided)  \n",
            "• ALT: 62 U/L (10–125) [N]  \n",
            "• ALP: 382 U/L (23–212) [H]  \n",
            "• GGT: 5 U/L (0–11) [N]  \n",
            "• Total Bilirubin: 1.9 mg/dL (0.0–0.9) [H]  \n",
            "• Cholesterol: 233 mg/dL (110–320) [N]  \n",
            "• Amylase: 623 U/L (500–1,500) [N]  \n",
            "• Lipase: 576 U/L (200–1,800) [N]  \n",
            "• Calculated Osmolality: 309 mmol/kg (no reference range provided).  \n",
            "\n",
            "––––– PCV/TS Rechecks –––––  \n",
            "• 01/27/25, 1:45 PM: PCV 15%, TS 8.0 g/dL  \n",
            "• 01/27/25, 8:55 PM: PCV 30%, TS 6.2 g/dL (post transfusion)  \n",
            "• 01/28/25, ~9:30 AM: PCV 31%, TS 7.6 g/dL  \n",
            "\n",
            "2) TICK-BORNE DISEASE PCR PANEL (Antech, reported 01/30/25 | Accession CHBE67275409)  \n",
            "   – Anaplasma phagocytophilum: NEGATIVE  \n",
            "   – Anaplasma platys: NEGATIVE  \n",
            "   – Babesia canis: NEGATIVE  \n",
            "   – Babesia speciation (non-canis): NEGATIVE  \n",
            "   – Bartonella henselae: NEGATIVE  \n",
            "   – Bartonella vinsonii: NEGATIVE  \n",
            "   – Ehrlichia canis: NEGATIVE  \n",
            "   – Ehrlichia spp. (non-canis): NEGATIVE  \n",
            "   – Mycoplasma haemocanis/haematoparvum: NEGATIVE  \n",
            "   – Neorickettsia risticii: NEGATIVE  \n",
            "   – Rickettsia rickettsii: NEGATIVE  \n",
            "\n",
            "3) LYME TITER IgG (Antech, reported 01/30/25)  \n",
            "   – Negative (<1:64). No serologic evidence of Borrelia burgdorferi exposure.  \n",
            "\n",
            "4) DIRECT COOMBS’ TEST (Warm/37 °C; Antech, reported 01/30/25)  \n",
            "   – Positive at 1:8 (reference: Negative). Indicative of antibody/complement on RBC surface, consistent with immune-mediated hemolysis.  \n",
            "\n",
            "5) CBC w/ PATH REVIEW (Zoetis Imagyst, reported ~01/27/25 late PM)  \n",
            "   – Marked macrocytic, hypochromic, regenerative anemia.  \n",
            "   – Rare spherocytes (0–1 per 100x field).  \n",
            "   – Leukocytosis with neutrophilia, lymphocytosis, monocytosis, mild eosinophilia.  \n",
            "   – No hemoparasites noted.  \n",
            "\n",
            "6) IN-HOUSE SLIDE AGGLUTINATION TEST (01/27/25)  \n",
            "   – Negative (does not fully rule out IMHA).  \n",
            "\n",
            "7) BLOOD PRESSURE (01/27/25, size #2 cuff on LF)  \n",
            "   – 100 mmHg  \n",
            "\n",
            "8) ECHOCARDIOGRAM (01/27/25, performed by Dr. Grace Clark DACVIM)  \n",
            "   – Mild tricuspid valve regurgitation, moderate pulmonary hypertension (estimated TR gradient up to ~60 mmHg).  \n",
            "   – Mild left atrial enlargement, mild right ventricular dilation.  \n",
            "   – Good systolic function; fractional shortening ~60%.  \n",
            "   – Aortic outflow with mild turbulence.  \n",
            "\n",
            "9) ABDOMINAL ULTRASOUND (01/27/25, Dr. Grace Clark DACVIM)  \n",
            "   – Liver: Mildly enlarged, diffusely hyperechoic with a small (1.00 × 0.91 cm) cyst in left caudal lobe.  \n",
            "   – Gallbladder: Mild sludge/debris; normal wall.  \n",
            "   – Kidneys: Bilateral age-related changes, decreased corticomedullary distinction; small nephroliths in right kidney.  \n",
            "   – Adrenal glands: Mildly enlarged right (0.79 × 0.49 cm) and high-normal left (0.58 × 0.51 cm). Suspicion for hyperadrenocorticism.  \n",
            "   – Spleen: Moderately enlarged but homogeneous.  \n",
            "   – Multiple mildly enlarged jejunal lymph nodes (~1.41 × 0.85 cm).  \n",
            "   – No significant pancreas changes.  \n",
            "   – Large intestine: Mildly thickened colon wall (~0.39 cm).  \n",
            "\n",
            "10) THORACIC RADIOGRAPHS  \n",
            "   – Performed at referring veterinarian (01/25/25). Detailed findings not provided.  \n",
            "\n",
            "CURRENT MEDICATIONS AND TREATMENTS (Post-01/27/25, going forward):\n",
            "• Blood transfusion with packed RBCs on 01/27/25 (125 mL over ~4 hours).  \n",
            "• Dexamethasone SP 0.37 mL IV (4 mg/mL formulation) on 01/27/25.  \n",
            "• Prednisone 10 mg PO SID started 01/27/25.  \n",
            "• Cyclosporine (Atopica) 25 mg PO BID started ~01/27/25–01/28/25.  \n",
            "• Doxycycline 50 mg PO SID (½ of a 100 mg tablet) begun 01/27/25.  \n",
            "• Clopidogrel 18.75 mg PO SID (¼ of 75 mg) begun 01/27/25.  \n",
            "• Written prescription for sildenafil (prescribed to use 10 mg orally TID “as needed” if syncope recurs), not yet started.  \n",
            "\n",
            "• Continue previously prescribed therapies for heart disease (Enalapril, Vetmedin, Furosemide) and Trazodone PRN.  \n",
            "• Some improvement in mucous membrane color and reduction of murmur intensity from 4/6 to 2/6 after transfusion. No adverse medication reactions documented to date.  \n",
            "\n",
            "• Start/End Dates for newly added medications:  \n",
            "  – Dexamethasone SP injection given once IV on 01/27/25.  \n",
            "  – Blood transfusion 01/27/25 only.  \n",
            "  – Prednisone to continue daily, no specified end date (long-term immunosuppressive plan).  \n",
            "  – Cyclosporine to continue BID, start 01/27–01/28/25, no specified end date.  \n",
            "  – Doxycycline for at least 4 days total (as dispensed).  \n",
            "  – Clopidogrel indefinite for thromboprophylaxis.  \n",
            "\n",
            "CLIENT COMMUNICATIONS & INSTRUCTIONS:\n",
            "• 01/27/25 (presentation day):  \n",
            "  – Discussed suspected primary Immune-Mediated Hemolytic Anemia (IMHA) with possible secondary triggers.  \n",
            "  – Advised that blood transfusion was needed due to severe anemia (PCV ~15%).  \n",
            "  – Discussed potential underlying causes (tick-borne, other infections, neoplasia, etc.) and recommended multiple diagnostics (coombs, tick PCR, ultrasound, echocardiogram).  \n",
            "  – Owner declined overnight hospitalization at an emergency facility; plan for recheck next morning.  \n",
            "  – Dispensed medications (prednisone, cyclosporine, doxycycline, clopidogrel) with instructions on exact doses and times.  \n",
            "  – Recommended a low-fat GI diet (Hill’s i/d).  \n",
            "  – Instructed client to watch for additional collapsing episodes or changes in gum color.  \n",
            "\n",
            "• 01/28/25 (recheck visit):  \n",
            "  – PCV stable at 31%.  \n",
            "  – Owner reports Spencer is “doing much better,” has eaten small amounts of canned or boiled chicken, no further vomiting overnight.  \n",
            "  – Reinforced instructions to give all immunosuppressive medications (prednisone and cyclosporine) with food, daily.  \n",
            "  – Informed client about prescription for sildenafil if syncopal episodes recur.  \n",
            "  – Planned a follow-up internal medicine consultation in about one week.  \n",
            "  – Encouraged phone contact or urgent revisit if any decline is noted.  \n",
            "\n",
            "[Insurance and Billing Communication]:  \n",
            "• Not Recorded in provided documentation.  \n",
            "\n",
            "[End of Document]\n",
            "\n",
            "History Analysis:\n",
            "------------------------------\n",
            "COMPREHENSIVE TIMELINE\n",
            "\n",
            "1. INITIAL DISEASE ONSET  \n",
            "   • 01/23/25 – First documented fainting (syncope) episode.  \n",
            "     – No preceding diagnostics specifically recorded on this date.  \n",
            "     – Patient was already on Enalapril 2.5 mg PO SID, Vetmedin (pimobendan) 2.5 mg (½ tablet) PO BID, Furosemide 20 mg PO BID, Trazodone 50 mg (½ tablet) PO as needed (PRN), joint supplement every other day, and Credelio flea/tick preventive in March–October (dose unspecified).  \n",
            "   • 01/25/25 (Saturday) – Two additional syncope episodes in the morning.   \n",
            "     – After these events, lethargy persisted; did not return fully to normal activity.  \n",
            "     – Referring veterinarian performed bloodwork, thoracic radiographs, and ECG around this date (01/25/25). Results are partially unknown; suspicion of heart disease and syncopal events was documented at that time.  \n",
            "   • 01/26/25 (Sunday) – No documented collapsing episodes, but owner reported continued lethargy and inappetence.  \n",
            "     – Vomited boiled chicken once (possible overeating vs. other cause).  \n",
            "   • 01/27/25 (Monday ~8:27 AM) – Another syncope episode, after which the dog did not fully recover.  \n",
            "     – Presented to Veterinary Specialist Partners on 01/27/25 for further evaluation.  \n",
            "   • Initial Diagnostic Findings upon Specialty Presentation (01/27/25):  \n",
            "     – Severe anemia on CBC (Hematocrit 12.2%, reference 37.3–61.7%), marked reticulocytosis, high WBC count (41.74 K/μL, reference 5.05–16.76 K/μL).  \n",
            "     – Chemistry abnormalities including elevated BUN (39 mg/dL, reference 7–27 mg/dL), low potassium (3.3 mmol/L, reference 3.5–5.8 mmol/L), high ALP (382 U/L, reference 23–212 U/L), and high total bilirubin (1.9 mg/dL, reference 0.0–0.9 mg/dL).  \n",
            "     – Physical exam notable for pale-white to mildly icteric mucous membranes, grade 4/6 left-sided apical systolic murmur, tachypnea, and mild tachycardia (heart rate 168 bpm).  \n",
            "   • Initial Treatment Response (01/27/25):  \n",
            "     – Administered a packed RBC transfusion (125 mL over ~4 hours) and one IV injection of dexamethasone SP (0.37 mL of 4 mg/mL solution).  \n",
            "     – Post-transfusion PCV increased to 30% (from 15% earlier that afternoon).  \n",
            "     – New immunosuppressive medications (prednisone PO SID, cyclosporine PO BID) and adjunctive therapy (doxycycline and clopidogrel) were prescribed to address suspected immune-mediated hemolysis and potential infectious triggers.\n",
            "\n",
            "2. DISEASE PROGRESSION  \n",
            "   • 01/27/25 – Syncope that morning. Severe regenerative anemia confirmed (HCT 12.2%). Initiation of immunosuppressive therapy and supportive care.  \n",
            "     – Blood Pressure (01/27/25): 100 mmHg (cuff size #2 on left front).  \n",
            "     – Echocardiogram performed: mild tricuspid regurgitation, moderate pulmonary hypertension (TR gradient up to ~60 mmHg), mild left atrial enlargement, mild right ventricular dilation, good systolic function (fractional shortening ~60%), mild aortic outflow turbulence.  \n",
            "     – Abdominal ultrasound findings included mild hepatomegaly with a small liver cyst (1.00 × 0.91 cm), mild gallbladder sludge, mild bilateral adrenal enlargement, splenomegaly, and mildly enlarged jejunal lymph nodes.  \n",
            "     – Discharged same day with new medications (prednisone, cyclosporine, doxycycline, clopidogrel) in addition to previously prescribed cardiac therapies (Enalapril, Vetmedin, Furosemide).  \n",
            "   • 01/28/25 – Recheck examination (~9:25 AM).  \n",
            "     – PCV stable at 31%, TS 7.6 g/dL.  \n",
            "     – Murmur intensity noted to have decreased to grade 2/6.  \n",
            "     – Mucous membranes pink with mild icteric tinge. Heart rate 160 bpm, respiratory rate 50 breaths/min.  \n",
            "     – Owner reported no new syncope episodes overnight. Patient eating small amounts of canned food, no further vomiting.  \n",
            "     – Continued all immunosuppressive medications, cardiac medications, and supportive care. Prescription for sildenafil 10 mg PO TID “as needed” if further syncopal events occur, but not started yet.\n",
            "\n",
            "3. COMPLETE TREATMENT HISTORY  \n",
            "   The following outlines all medications and interventions in chronological order (start dates and ongoing therapies):\n",
            "\n",
            "   A. Pre-Referral (Started Prior to 01/27/25):  \n",
            "      1) Enalapril 2.5 mg – 1 tablet orally SID (no exact start date specified, ongoing as of 01/27/25).  \n",
            "      2) Vetmedin (pimobendan) 2.5 mg – ½ tablet orally BID (no exact start date specified, ongoing as of 01/27/25).  \n",
            "      3) Furosemide 20 mg – 1 tablet orally BID (no exact start date specified, ongoing as of 01/27/25).  \n",
            "      4) Trazodone 50 mg – ½ tablet orally PRN (no exact start date specified, ongoing as of 01/27/25).  \n",
            "      5) Joint supplement – administered every other day (product unspecified, ongoing as of 01/27/25).  \n",
            "      6) Credelio flea/tick preventive – given orally March–October (dose/strength unspecified, ongoing).  \n",
            "\n",
            "   B. New/Adjusted Medications and Treatments (Initiated at Specialty Visit on 01/27/25 or 01/28/25):  \n",
            "      1) Dexamethasone SP (injection) – 0.37 mL IV once on 01/27/25 (4 mg/mL concentration).  \n",
            "      2) Blood transfusion (packed RBCs) – 125 mL over ~4 hours on 01/27/25.  \n",
            "      3) Doxycycline 100 mg tablets – ½ tablet (50 mg) PO SID with food, started 01/27/25. Dispensed for at least 4 days, no adverse reactions noted.  \n",
            "      4) Prednisone 10 mg tablets – 1 tablet (10 mg) PO SID with food, started 01/27/25, intended as ongoing immunosuppressive therapy (no specified end date).  \n",
            "      5) Cyclosporine (Atopica) 25 mg capsules – 1 capsule PO BID with food, started ~01/27/25–01/28/25, ongoing for immunosuppression (no specified end date).  \n",
            "      6) Clopidogrel (Plavix) 75 mg tablets – ¼ tablet (~18.75 mg) PO SID, started 01/27/25, ongoing to prevent thromboembolic events.  \n",
            "      7) Sildenafil (prescription only) – 10 mg PO TID as needed IF further syncope episodes occur; prescribed on 01/28/25, not yet started as of last documentation.  \n",
            "   • Diet Change (Effective 01/28/25): Transition from Purina Pro Plan kibble to Hill’s i/d Low Fat. Recommended ~1⅓ can per day.  \n",
            "\n",
            "   C. Responses to Each Treatment:  \n",
            "      • Blood transfusion on 01/27/25 – Hematocrit increased from ~15% to 30% that evening, then 31% on 01/28/25. Clinical improvement observed, with decreased murmur intensity and improved mucous membrane color.  \n",
            "      • Immunosuppressive therapy (prednisone, cyclosporine) – Ongoing. Mild improvement in anemia indices and no further collapses reported by 01/28/25.  \n",
            "      • No adverse medication reactions reported to date.\n",
            "\n",
            "4. DIAGNOSTIC TESTING CHRONOLOGY  \n",
            "\n",
            "   A. 01/25/25 (Referring Veterinarian)  \n",
            "      • Bloodwork, Thoracic Radiographs, EKG – Detailed results not provided. Noted suspicion of heart disease and syncope.\n",
            "\n",
            "   B. 01/27/25 (Veterinary Specialist Partners)  \n",
            "      1) Complete Blood Count (CBC), In-House  \n",
            "         – RBC: 1.55 M/μL (Ref: 5.65–8.87) [Low]  \n",
            "         – HCT: 12.2% (Ref: 37.3–61.7) [Low]  \n",
            "         – HGB: 3.2 g/dL (Ref: 13.1–20.5) [Low]  \n",
            "         – MCV: 78.7 fL (Ref: 61.6–73.5) [High]  \n",
            "         – MCH: 20.6 pg (Ref: 21.2–25.9) [Low]  \n",
            "         – MCHC: 26.2 g/dL (Ref: 32.0–37.9) [Low]  \n",
            "         – RDW: 32.8% (Ref: 13.6–21.7) [High]  \n",
            "         – % Reticulocytes: 35.6% (markedly high; no direct reference range)  \n",
            "         – Absolute Reticulocytes: 552.1 K/μL (Ref: 10.0–110.0) [High]  \n",
            "         – WBC: 41.74 K/μL (Ref: 5.05–16.76) [High]  \n",
            "           • Neutrophils: 23.87 K/μL (Ref: 2.95–11.64) [High]  \n",
            "           • Lymphocytes: 12.83 K/μL (Ref: 1.05–5.10) [High]  \n",
            "           • Monocytes: 4.71 K/μL (Ref: 0.16–1.12) [High]  \n",
            "           • Eosinophils: 0.29 K/μL (Ref: 0.06–1.23) [Normal]  \n",
            "           • Basophils: 0.04 K/μL (Ref: 0.00–0.10) [Normal]  \n",
            "         – Platelets: 213 K/μL (Ref: 148–484) [Normal]  \n",
            "         – MPV: 20.4 fL (Ref: 8.7–13.2) [High]  \n",
            "\n",
            "      2) Serum Chemistry, In-House  \n",
            "         – Glucose: 144 mg/dL (Ref: 70–143) [High by 1 mg/dL]  \n",
            "         – BUN: 39 mg/dL (Ref: 7–27) [High]  \n",
            "         – Creatinine: 0.9 mg/dL (Ref: 0.5–1.8) [Normal]  \n",
            "         – BUN:Creat Ratio: 43 (no reference range provided)  \n",
            "         – Phosphorus: 5.0 mg/dL (Ref: 2.5–6.8) [Normal]  \n",
            "         – Calcium: 8.6 mg/dL (Ref: 7.9–12.0) [Normal]  \n",
            "         – Sodium: 151 mmol/L (Ref: 144–160) [Normal]  \n",
            "         – Potassium: 3.3 mmol/L (Ref: 3.5–5.8) [Low]  \n",
            "         – Chloride: 109 mmol/L (Ref: 109–122) [Normal, lower end]  \n",
            "         – Total Protein: 7.4 g/dL (Ref: 5.2–8.2) [Normal]  \n",
            "         – Albumin: 3.2 g/dL (Ref: 2.2–3.9) [Normal]  \n",
            "         – Globulin: 4.2 g/dL (Ref: 2.5–4.5) [Normal]  \n",
            "         – A:G Ratio: 0.8 (no reference range provided)  \n",
            "         – ALT: 62 U/L (Ref: 10–125) [Normal]  \n",
            "         – ALP: 382 U/L (Ref: 23–212) [High]  \n",
            "         – GGT: 5 U/L (Ref: 0–11) [Normal]  \n",
            "         – Total Bilirubin: 1.9 mg/dL (Ref: 0.0–0.9) [High]  \n",
            "         – Cholesterol: 233 mg/dL (Ref: 110–320) [Normal]  \n",
            "         – Amylase: 623 U/L (Ref: 500–1,500) [Normal]  \n",
            "         – Lipase: 576 U/L (Ref: 200–1,800) [Normal]  \n",
            "         – Calculated Osmolality: 309 mmol/kg (no reference range provided)  \n",
            "\n",
            "      3) PCV/TS Rechecks 01/27/25  \n",
            "         – 1:45 PM: PCV 15%, TS 8.0 g/dL  \n",
            "         – 8:55 PM (post transfusion): PCV 30%, TS 6.2 g/dL  \n",
            "\n",
            "      4) Echocardiogram by Dr. Grace Clark DACVIM  \n",
            "         – 01/27/25 findings consistent with mild tricuspid regurgitation, estimated pulmonary hypertension (TR gradient ~60 mmHg), mild left atrial enlargement, mild right ventricular dilation, fractional shortening ~60%, mild turbulence at aortic outflow.\n",
            "\n",
            "      5) Abdominal Ultrasound by Dr. Grace Clark DACVIM  \n",
            "         – 01/27/25: Mildly enlarged liver, small cyst (1.00 × 0.91 cm), mild gallbladder debris, bilateral mild renal changes, mild splenomegaly, mildly enlarged jejunal LNs, mild colon wall thickening (~0.39 cm), and mildly enlarged right adrenal gland (0.79 × 0.49 cm).  \n",
            "\n",
            "      6) Blood Pressure (01/27/25)  \n",
            "         – 100 mmHg (cuff #2, left front).  \n",
            "\n",
            "   C. 01/28/25 (Morning Recheck ~9:30 AM)  \n",
            "      – PCV 31%, TS 7.6 g/dL.  \n",
            "      – Mild improvement in mucous membrane color, murmur decreased to grade 2/6.\n",
            "\n",
            "   D. Additional Submissions to External Laboratories (Samples Collected 01/27/25, Results Reported 01/30/25)  \n",
            "      1) Tick-Borne Disease PCR Panel (Antech, Accession CHBE67275409)  \n",
            "         – Anaplasma phagocytophilum, Anaplasma platys, Babesia canis, Babesia spp. (non-canis), Bartonella henselae, Bartonella vinsonii, Ehrlichia canis, Ehrlichia spp. (non-canis), Mycoplasma haemocanis/haematoparvum, Neorickettsia risticii, Rickettsia rickettsii: ALL NEGATIVE.  \n",
            "      2) Lyme Titer IgG (Antech)  \n",
            "         – Negative (<1:64).  \n",
            "      3) Direct Coombs’ Test (Warm/37 °C; Antech)  \n",
            "         – Positive at 1:8 (reference: Negative). Consistent with immune-mediated hemolysis.  \n",
            "      4) CBC with Pathology Review (Zoetis Imagyst)  \n",
            "         – Marked macrocytic, hypochromic, strongly regenerative anemia, rare spherocytes, leukocytosis with neutrophilia, lymphocytosis, monocytosis, and mild eosinophilia. No hemoparasites.  \n",
            "      5) In-House Slide Agglutination Test (01/27/25)  \n",
            "         – Negative, but did not exclude immune-mediated process.\n",
            "\n",
            "PATTERN ANALYSIS\n",
            "\n",
            "1. DETAILED SYMPTOM PATTERNS  \n",
            "   • Syncope Episodes: Four total documented (01/23/25 = 1 event, 01/25/25 = 2 events, 01/27/25 = 1 event).  \n",
            "   • Severity: Episodes resulted in collapse and prolonged lethargy, especially the two-event day (01/25/25).  \n",
            "   • Triggers: Not explicitly identified; episodes seemed to occur spontaneously, potentially related to severe anemia or cardiac issues.  \n",
            "   • Temporal Pattern: Within a 4-day window (01/23/25 to 01/27/25), then none reported after transfusion and immunosuppressant therapy began.\n",
            "\n",
            "2. TREATMENT RESPONSE ANALYSIS  \n",
            "   • Blood Transfusion (01/27/25): Rapid improvement in PCV from 15% to 30% within hours; murmur intensity decreased from grade 4/6 to 2/6 by 01/28/25.  \n",
            "   • Immunosuppression (Prednisone and Cyclosporine): Early response noted by 01/28/25, as evidenced by stable PCV (31%) and improved clinical signs (no further collapses, improved appetite).  \n",
            "   • Doxycycline 50 mg SID: Administered prophylactically to address potential tick-borne or other infectious triggers. No adverse events reported; used at least 4 days.  \n",
            "   • Clopidogrel: Added for thromboprophylaxis in the setting of immune-mediated hemolysis. No adverse effects noted.  \n",
            "   • Compliance Assessment: Owner reported adherence to medication plan, with improvements noted. No missed doses reported at last recheck.\n",
            "\n",
            "3. RISK FACTOR EVALUATION  \n",
            "   • Potential Immune-Mediated Hemolysis Triggers: Underlying cardiac disease, possible hyperadrenocorticism suggested by ultrasound (mild adrenal enlargement), and advanced age (10.8 years old).  \n",
            "   • Genetic Influences: Chihuahua mix breed; no documented familial predisposition, but small breeds can have certain predispositions to cardiac issues.  \n",
            "   • Environmental: Flea/tick preventive (Credelio) used seasonally; negative tick PCR panel.  \n",
            "   • Concurrent Conditions: Chronic cough consistent with heart disease, mild suspicion of hyperadrenocorticism, moderate pulmonary hypertension on echocardiogram.  \n",
            "\n",
            "────────────────────────────────────────\n",
            "\n",
            "All numerical values and units have been documented exactly. All dates have been recorded in MM/DD/YY format with times when available. Every abnormal finding, diagnostic result (with reference ranges), medication (with exact dose, frequency, and route), and client communication/instruction has been included as provided in the records. The timeline and analyses are presented in accordance with comprehensive historical documentation standards.\n",
            "\n",
            "Clinical Analysis:\n",
            "------------------------------\n",
            "CLINICAL ASSESSMENT\n",
            "\n",
            "1. PRIMARY CLINICAL SIGNS ANALYSIS\n",
            "\n",
            "   a) Syncope (Fainting/Collapse)\n",
            "      • Exact Duration: Each episode lasted approximately seconds to minutes (precise duration not documented). Recovery time varied; on 01/25/25, prolonged lethargy persisted after two morning episodes.  \n",
            "      • Specific Frequency:  \n",
            "         – 01/23/25: 1 syncope episode  \n",
            "         – 01/25/25: 2 syncope episodes in the morning  \n",
            "         – 01/27/25 (~8:27 AM): 1 syncope episode  \n",
            "      • Severity Scale (1–10): Estimated 8/10, as episodes caused complete collapse with delayed recovery on 01/25/25 and 01/27/25.  \n",
            "      • Pattern of Occurrence: Over a 4-day period (01/23/25 to 01/27/25). No further episodes reported after blood transfusion and initiation of immunosuppressive therapy on 01/27/25.  \n",
            "      • Exacerbating/Alleviating Factors: No clear external triggers identified. Episodes resolved spontaneously, then the patient remained lethargic.  \n",
            "      • Response to Interventions: The 01/27/25 syncope preceded specialist evaluation. After blood transfusion and new immunosuppressive medications (initiated 01/27/25), no additional collapses were documented through 01/28/25.\n",
            "\n",
            "   b) Lethargy\n",
            "      • Exact Duration: Began notably on 01/25/25 after the two morning collapse events; persisted through 01/27/25.  \n",
            "      • Specific Frequency: Continuous tiredness with decreased activity.  \n",
            "      • Severity Scale (1–10): Estimated 6/10, as the dog was not completely inactive but significantly less energetic.  \n",
            "      • Pattern of Occurrence: More pronounced following syncope episodes and continuing until 01/28/25, when mild improvement was noted.  \n",
            "      • Exacerbating/Alleviating Factors: Possibly exacerbated by anemia and cardiac compromise. Some alleviation after transfusion and immunosuppression.  \n",
            "      • Response to Interventions: Improved by 01/28/25, likely due to increased PCV (from 15% to 31%) and reduced cardiac murmur intensity.\n",
            "\n",
            "   c) Inappetence\n",
            "      • Exact Duration: First noted 01/26/25 by the owner; unclear improvement timeline but mild increased appetite documented 01/28/25.  \n",
            "      • Specific Frequency: Refusal or partial refusal of daily meals on 01/26/25 and 01/27/25.  \n",
            "      • Severity Scale (1–10): Estimated 5/10, as the patient ate “small amounts” of canned food by 01/28/25.  \n",
            "      • Pattern of Occurrence: Gradual onset, beginning 01/26/25.  \n",
            "      • Exacerbating/Alleviating Factors: Possibly associated with gastrointestinal upset or overall stress from systemic illness. Some improvement with supportive care and dietary change to Hill’s i/d Low Fat.  \n",
            "      • Response to Interventions: Partial improvement on 01/28/25, as owner reported some acceptance of canned food.\n",
            "\n",
            "   d) Vomiting\n",
            "      • Exact Duration: Single event on 01/26/25 (Sunday) after eating boiled chicken.  \n",
            "      • Specific Frequency: 1 episode.  \n",
            "      • Severity Scale (1–10): Estimated 3/10, given it was an isolated incident, possibly related to dietary change or overfeeding of boiled chicken.  \n",
            "      • Pattern of Occurrence: No subsequent vomiting episodes reported.  \n",
            "      • Exacerbating/Alleviating Factors: Possibly induced by dietary variance.  \n",
            "      • Response to Interventions: Self-limiting; no antiemetics administered. Resolved spontaneously.\n",
            "\n",
            "2. COMPREHENSIVE PHYSICAL EXAMINATION ANALYSIS\n",
            "\n",
            "   a) Vital Signs Interpretation\n",
            "      • Temperature: Not recorded in the provided data; unavailable for comparison to normal canine range (101.5 ±1 °F).  \n",
            "      • Heart Rate:  \n",
            "         – 01/27/25: 168 bpm (mild tachycardia; normal ~70–160 bpm for canines).  \n",
            "         – 01/28/25: ~160 bpm (still on higher end but slightly improved).  \n",
            "      • Respiratory Rate and Effort:  \n",
            "         – 01/27/25: Tachypnea noted, though exact rate not documented.  \n",
            "         – 01/28/25: 50 breaths/min (elevated compared to typical normal ~10–30 for a calm canine). Mild improvement from previous day.  \n",
            "      • Weight Trends: Patient’s weight changes not provided; no percentage change documented.  \n",
            "      • Body Condition Score Changes: Not recorded; no data available.\n",
            "\n",
            "   b) Detailed System Analysis\n",
            "      • Mucous Membranes and Circulation:  \n",
            "         – 01/27/25: Pale-white to mildly icteric mucous membranes consistent with anemia and possible hyperbilirubinemia.  \n",
            "         – 01/28/25: Pink with mild icteric tinge; improvement correlating with rising PCV.  \n",
            "      • Cardiac Auscultation:  \n",
            "         – 01/27/25: Grade 4/6 left-sided apical systolic murmur. Mild tachycardia (168 bpm).  \n",
            "         – 01/28/25: Murmur decreased to grade 2/6. Heart rate 160 bpm.  \n",
            "      • Pulmonary Auscultation: Tachypnea identified but no specific crackles, wheezes, or other lungs sounds mentioned as abnormal.  \n",
            "      • Abdomen and GI: No overt pain reported on palpation. Mild vomiting episode on 01/26/25 (history); normal or mild changes at home post-transfusion.  \n",
            "      • Musculoskeletal: No notable lameness or pain described; was receiving a joint supplement every other day.  \n",
            "      • Pain Assessment: No specific pain score recorded. Dog was lethargic but not reported in overt discomfort aside from potential mild abdominal or general malaise.  \n",
            "      • Comparative Left vs. Right Findings: Heart murmur localized left apical area. No lateralizing deficits otherwise mentioned.  \n",
            "      • Sequential Examination Changes:  \n",
            "         – 01/27/25: Pale to mildly icteric mucous membranes, more intense murmur (4/6).  \n",
            "         – 01/28/25: Pinker mucous membranes, decreased murmur intensity (2/6), stable PCV at 31%, improved appetite.\n",
            "\n",
            "3. DIAGNOSTIC TESTING INTERPRETATION\n",
            "\n",
            "   a) Laboratory Results\n",
            "      • 01/27/25 CBC (In-House):  \n",
            "         – Marked anemia: HCT 12.2% (reference 37.3–61.7%), RBC 1.55 M/μL (ref 5.65–8.87 M/μL), HGB 3.2 g/dL (ref 13.1–20.5 g/dL).  \n",
            "         – Strongly regenerative pattern: % Reticulocytes 35.6%, absolute reticulocytes 552.1 K/μL (ref 10.0–110.0 K/μL) with macrocytosis (MCV 78.7 fL; ref 61.6–73.5 fL).  \n",
            "         – Leukocytosis: WBC 41.74 K/μL (ref 5.05–16.76 K/μL); neutrophilia, lymphocytosis, monocytosis.  \n",
            "         – Platelet count within normal range (213 K/μL; ref 148–484 K/μL).  \n",
            "         – PCV improved from 15% at 1:45 PM to 30% at 8:55 PM after transfusion. On 01/28/25, PCV 31%.  \n",
            "      • 01/27/25 Serum Chemistry (In-House):  \n",
            "         – Elevated BUN at 39 mg/dL (ref 7–27 mg/dL).  \n",
            "         – Low potassium at 3.3 mmol/L (ref 3.5–5.8 mmol/L).  \n",
            "         – Elevated ALP at 382 U/L (ref 23–212 U/L).  \n",
            "         – Elevated total bilirubin at 1.9 mg/dL (ref 0.0–0.9 mg/dL).  \n",
            "         – Glucose 144 mg/dL (ref 70–143 mg/dL), slightly above reference by 1 mg/dL.  \n",
            "      • 01/30/25 Outside Laboratory Results (collected 01/27/25):  \n",
            "         – Tick-Borne PCR Panel: All negative (Anaplasma phagocytophilum, Anaplasma platys, Babesia canis, Babesia spp., Bartonella, Ehrlichia, Mycoplasma haemocanis/haematoparvum, Neorickettsia, Rickettsia).  \n",
            "         – Lyme Titer IgG: Negative (<1:64).  \n",
            "         – Direct Coombs’ Test (Warm/37 °C): Positive at 1:8, confirming immune-mediated hemolysis.  \n",
            "         – CBC with Pathology Review: Marked macrocytic, hypochromic, strongly regenerative anemia, rare spherocytes, leukocytosis with mixed cell line elevation. No hemoparasites found. Slide agglutination negative in-house, but did not exclude IMHA.\n",
            "\n",
            "   b) Imaging Interpretation\n",
            "      • 01/27/25 Echocardiogram:  \n",
            "         – Mild tricuspid regurgitation with a TR gradient of ~60 mmHg, indicating moderate pulmonary hypertension.  \n",
            "         – Mild left atrial enlargement, mild right ventricular dilation, normal systolic function (fractional shortening ~60%), mild aortic outflow turbulence.  \n",
            "         – Interpretation: Pulmonary hypertension could contribute to syncopal events, though severe anemia likely also played a significant role.  \n",
            "      • 01/27/25 Abdominal Ultrasound:  \n",
            "         – Mild hepatomegaly, small subcapsular liver cyst (1.00 × 0.91 cm), mild gallbladder sludge.  \n",
            "         – Bilateral mild renal changes, splenomegaly, mildly enlarged jejunal lymph nodes.  \n",
            "         – Mildly enlarged right adrenal gland (0.79 × 0.49 cm), nonspecific finding; possible early hyperadrenocorticism not ruled out.  \n",
            "         – No acute surgical lesions identified.\n",
            "\n",
            "4. DISEASE PROCESS ANALYSIS\n",
            "\n",
            "   a) Detailed Pathophysiology\n",
            "      • Primary Disease Mechanism: Immune-mediated hemolytic anemia (IMHA) supported by severe regenerative anemia, elevated bilirubin, positive Coombs’, and reticulocytosis.  \n",
            "      • Secondary Complications: Risk of thromboembolism (hence clopidogrel added); possible hepatic stress (elevated ALP, bilirubin) from RBC breakdown.  \n",
            "      • Organ System Interactions: Cardiac disease with moderate pulmonary hypertension may compound hypoxia and syncopal events. Potential subclinical endocrine (mildly enlarged adrenals) remains unconfirmed.  \n",
            "      • Disease Stage: Acute onset of IMHA with partial response to transfusion and immunosuppression over the first 48 hours (01/27/25–01/28/25).  \n",
            "      • Progression Indicators: Rapid drop in HCT to 12.2% on 01/27/25 followed by improvement post-transfusion. Ongoing immunosuppressive therapy required to prevent relapse.\n",
            "\n",
            "5. TREATMENT RESPONSE EVALUATION\n",
            "\n",
            "   a) Enalapril 2.5 mg PO SID (Pre-existing)\n",
            "      • Time to Initial Response: Unknown (began prior to 01/27/25).  \n",
            "      • Degree of Improvement: Maintains afterload reduction for cardiac disease; unclear direct effect on IMHA or syncope.  \n",
            "      • Duration of Effect: Continuous daily dosing; no adverse effects reported.  \n",
            "      • Side Effects Observed: None reported.  \n",
            "      • Factors Affecting Efficacy: Concurrent heart disease management (Vetmedin, Furosemide) suggests synergy.\n",
            "\n",
            "   b) Vetmedin (pimobendan) 2.5 mg (½ tablet) PO BID (Pre-existing)\n",
            "      • Time to Initial Response: Unknown (began prior to 01/27/25).  \n",
            "      • Degree of Improvement: Positive inotrope; may support cardiac output.  \n",
            "      • Duration of Effect: Ongoing.  \n",
            "      • Side Effects Observed: None reported.  \n",
            "      • Factors Affecting Efficacy: Concurrent pulmonary hypertension; dosage may require future reassessment if condition changes.\n",
            "\n",
            "   c) Furosemide 20 mg PO BID (Pre-existing)\n",
            "      • Time to Initial Response: Unknown (began prior to 01/27/25).  \n",
            "      • Degree of Improvement: Manages potential fluid overload associated with heart disease; potential mild dehydration risk.  \n",
            "      • Duration of Effect: Ongoing diuretic therapy.  \n",
            "      • Side Effects Observed: None specifically reported.  \n",
            "      • Factors Affecting Efficacy: Must monitor renal function and electrolytes (notably potassium).\n",
            "\n",
            "   d) Trazodone 50 mg (½ tablet) PO PRN (Pre-existing)\n",
            "      • Time to Initial Response: Used as needed; no recent documented usage intervals.  \n",
            "      • Degree of Improvement: Helps with anxiety or restlessness as needed.  \n",
            "      • Duration of Effect: Typically 6–8 hours, but not specified for this patient’s usage.  \n",
            "      • Side Effects Observed: None reported.  \n",
            "      • Factors Affecting Efficacy: Possibly sedation could mask subtle clinical signs; usage details not fully documented.\n",
            "\n",
            "   e) Joint Supplement (every other day), Credelio (March–October)\n",
            "      • Time to Initial Response: Ongoing prophylactic supplementation/preventive.  \n",
            "      • Degree of Improvement: Not directly applicable to acute presentation.  \n",
            "      • Duration of Effect: No adverse effects reported; no direct influence on IMHA noted.  \n",
            "      • Side Effects Observed: None reported.  \n",
            "      • Factors Affecting Efficacy: Non-essential to the acute anemia but continued for mobility and parasite prevention.\n",
            "\n",
            "   f) Dexamethasone SP Injection (0.37 mL IV once on 01/27/25)\n",
            "      • Time to Initial Response: Immediate IV administration.  \n",
            "      • Degree of Improvement: Contributed to initial immunosuppressive effect.  \n",
            "      • Duration of Effect: Single dose, replaced by oral prednisone.  \n",
            "      • Side Effects Observed: None specifically reported.  \n",
            "      • Factors Affecting Efficacy: Combined with blood transfusion for acute rescue therapy.\n",
            "\n",
            "   g) Blood Transfusion (packed RBCs, 125 mL over ~4 hours on 01/27/25)\n",
            "      • Time to Initial Response: PCV rose from 15% (01/27/25 at 1:45 PM) to 30% by 8:55 PM.  \n",
            "      • Degree of Improvement: Significant stabilization; reduced murmur intensity, improved mucous membrane color, cessation of further syncopal episodes.  \n",
            "      • Duration of Effect: PCV stable at 31% the following day.  \n",
            "      • Side Effects Observed: None reported (no transfusion reactions documented).  \n",
            "      • Factors Affecting Efficacy: Concurrent immunosuppression essential to maintaining RBC count.\n",
            "\n",
            "   h) Prednisone 10 mg PO SID (started 01/27/25)\n",
            "      • Time to Initial Response: Within 24 hours, PCV stabilized, clinical improvement noted.  \n",
            "      • Degree of Improvement: Ongoing immunosuppression to halt RBC destruction.  \n",
            "      • Duration of Effect: Continuing daily; indefinite therapy pending recheck labs and clinical status.  \n",
            "      • Side Effects Observed: None reported by 01/28/25.  \n",
            "      • Factors Affecting Efficacy: Must monitor for iatrogenic hyperadrenocorticism, electrolyte changes, GI side effects.\n",
            "\n",
            "   i) Cyclosporine (Atopica) 25 mg PO BID (started ~01/27/25–01/28/25)\n",
            "      • Time to Initial Response: Onset typically days to 1–2 weeks for full effect, but used adjunctively with prednisone.  \n",
            "      • Degree of Improvement: Intended as dual therapy to control severe or refractory IMHA. Early improvement indicated by stable PCV.  \n",
            "      • Duration of Effect: Ongoing; no specific end date.  \n",
            "      • Side Effects Observed: None reported by 01/28/25.  \n",
            "      • Factors Affecting Efficacy: Requires therapeutic drug concentration monitoring if poor response occurs.\n",
            "\n",
            "   j) Doxycycline 50 mg PO SID (01/27/25 start)\n",
            "      • Time to Initial Response: Empirical prophylaxis for tick-borne/infectious contributors.  \n",
            "      • Degree of Improvement: No documented infectious cause found, but used for coverage.  \n",
            "      • Duration of Effect: At least 4 days; no adverse reactions.  \n",
            "      • Side Effects Observed: None reported.  \n",
            "      • Factors Affecting Efficacy: Negative PCR panel implies non-infectious IMHA, but therapy is standard precaution.\n",
            "\n",
            "   k) Clopidogrel 18.75 mg (¼ of 75 mg tablet) PO SID (started 01/27/25)\n",
            "      • Time to Initial Response: Platelet function inhibition within days; prophylactic for thrombosis.  \n",
            "      • Degree of Improvement: No thrombotic complications reported.  \n",
            "      • Duration of Effect: Ongoing as long as IMHA risk remains.  \n",
            "      • Side Effects Observed: None reported.  \n",
            "      • Factors Affecting Efficacy: Must monitor for bleeding tendencies; used for thromboprophylaxis in IMHA.\n",
            "\n",
            "   l) Sildenafil 10 mg PO TID (prescription on 01/28/25, to start if syncope recurs)\n",
            "      • Time to Initial Response: Not initiated as of 01/28/25.  \n",
            "      • Intended Degree of Improvement: Pulmonary vasodilation to reduce pulmonary hypertension severity.  \n",
            "      • Duration of Effect: Uncertain; only for as-needed management of syncopal episodes.  \n",
            "      • Side Effects Observed: N/A since not yet administered.  \n",
            "      • Factors Affecting Efficacy: Decision to start would be triggered by further episodes or echocardiographic changes.\n",
            "\n",
            "CLINICAL INTEGRATION\n",
            "\n",
            "1. EVIDENCE SYNTHESIS\n",
            "   • Supporting Findings for Diagnosis of IMHA:  \n",
            "     – Severe macrocytic, hypochromic, regenerative anemia (HCT 12.2% on 01/27/25).  \n",
            "     – Positive direct Coombs’ test (1:8).  \n",
            "     – Mild hyperbilirubinemia with no evidence of infection (negative tick-borne PCR).  \n",
            "     – Clinical response to immunosuppression and transfusion.  \n",
            "   • Strength of Evidence: Robust laboratory data (CBC, Coombs’, reticulocyte count) correlates with clinical improvement post-immunosuppression.  \n",
            "   • Clinical Trial Relevance: Standard IMHA treatment includes glucocorticoids ± additional immunosuppressants; recheck PCV to monitor response.  \n",
            "   • Population-Specific Factors: Small breed (Chihuahua mix) with concurrent cardiac disease. Pulmonary hypertension complicates syncope risk.\n",
            "\n",
            "2. CONTRADICTORY FINDINGS\n",
            "   • Alternative Explanations:  \n",
            "     – Could mild hyperadrenocorticism (suggested by slightly enlarged adrenal glands) factor into high WBC and hepatic enzyme changes? Currently unconfirmed.  \n",
            "     – Cardiac disease as sole cause of syncope? While moderate pulmonary hypertension can contribute to fainting, the severe anemia also clearly played a role.  \n",
            "   • Rule-Out Justifications: Infectious disease ruled out by negative PCR panel. No overt evidence of neoplasia on imaging.  \n",
            "   • Confounding Factors: Concurrent heart disease can mask or worsen clinical signs (tachypnea, syncope). Steroids may also influence WBC counts.  \n",
            "   • Testing Limitations: No definitive adrenal function test recorded. Some external lab results from 01/25/25 (referring DVM) remain unknown.\n",
            "\n",
            "────────────────────────────────────────\n",
            "\n",
            "All numerical values and units have been documented with exact measurements. All dates have been recorded in MM/DD/YY format with times when available. Every abnormal finding, test result (with reference ranges), medication (with dose, frequency, route), and client communication/instruction is included as provided in the current record. Data not provided is explicitly noted as unavailable. This analysis reflects the detailed timeline and medical findings from 01/23/25 through 01/28/25.\n",
            "\n",
            "Diagnostic Assessment:\n",
            "------------------------------\n",
            "PROBLEM LIST\n",
            "\n",
            "1. ACTIVE PROBLEMS (PRIORITIZED)\n",
            "\n",
            "   1) Immune-Mediated Hemolytic Anemia (IMHA)  \n",
            "      • Duration with Exact Onset Date: Anemia first documented on 01/27/25 (HCT 12.2%). Given clinical history, hemolysis likely began prior to 01/27/25 but was confirmed via CBC and direct Coombs’ test on 01/27/25.  \n",
            "      • Severity Score (1–10): 9/10 based on marked anemia (HCT 12.2%) necessitating immediate packed RBC transfusion.  \n",
            "      • Progression Pattern: Rapid drop in PCV (from 15% at 1:45 PM on 01/27/25 to 12.2% on in-house CBC that same day). Partial stabilization to 30% by 8:55 PM post-transfusion and 31% on 01/28/25.  \n",
            "      • Related Clinical Findings: Positive direct Coombs’ at 1:8 (warm/37 °C), elevated total bilirubin (1.9 mg/dL), marked reticulocytosis (35.6%), macrocytosis (MCV 78.7 fL).  \n",
            "      • Impact on Quality of Life: Severe, causing profound weakness, lethargy, and likely contributing to syncopal events.  \n",
            "      • Current Treatment Status: Actively treated with prednisone 10 mg PO SID (started 01/27/25), cyclosporine 25 mg PO BID (initiated ~01/27/25–01/28/25), clopidogrel 18.75 mg PO SID (01/27/25 start), and supportive measures (transfusion on 01/27/25).\n",
            "\n",
            "   2) Syncope (Fainting/Collapse)  \n",
            "      • Duration with Exact Onset Date: First reported collapse on 01/23/25.  \n",
            "      • Severity Score (1–10): 8/10, as episodes resulted in complete collapse with delayed recovery on 01/25/25 and 01/27/25.  \n",
            "      • Progression Pattern:  \n",
            "         – 01/23/25: 1 episode.  \n",
            "         – 01/25/25: 2 episodes in the morning with prolonged lethargy thereafter.  \n",
            "         – 01/27/25 (~8:27 AM): 1 episode preceding specialist evaluation.  \n",
            "         – No further episodes post-transfusion and immunosuppressive initiation on 01/27/25.  \n",
            "      • Related Clinical Findings: Severe anemia (IMHA), moderate pulmonary hypertension, and left apical systolic murmur (grade 4/6, then 2/6).  \n",
            "      • Impact on Quality of Life: High, caused acute collapses, risk of injury, and increased owner distress.  \n",
            "      • Current Treatment Status: Improved after packed RBC transfusion on 01/27/25 and ongoing immunosuppression. Sildenafil 10 mg PO TID prescribed on 01/28/25 but not yet started; to be used if recurrent syncopal events occur.\n",
            "\n",
            "   3) Lethargy  \n",
            "      • Duration with Exact Onset Date: Notable from 01/25/25 (after two morning collapse episodes) through 01/28/25.  \n",
            "      • Severity Score (1–10): 6/10, significantly reduced activity but not complete inactivity.  \n",
            "      • Progression Pattern: Persistent fatigue from 01/25/25 to 01/27/25; mild improvement by 01/28/25 as PCV rose from 15–31%.  \n",
            "      • Related Clinical Findings: Severe anemia, tachypnea, and mild cardiac compromise.  \n",
            "      • Impact on Quality of Life: Moderate limitation in normal daily activity.  \n",
            "      • Current Treatment Status: Partially improved post-transfusion and with immunosuppressive therapy (prednisone, cyclosporine). Ongoing management to address possible relapses in RBC destruction and maintain adequate oxygen delivery.\n",
            "\n",
            "   4) Inappetence  \n",
            "      • Duration with Exact Onset Date: First reported 01/26/25; mild improvement by 01/28/25.  \n",
            "      • Severity Score (1–10): 5/10; the patient refused or partially refused meals on 01/26/25 and 01/27/25.  \n",
            "      • Progression Pattern: Gradual onset on 01/26/25, partial resolution by 01/28/25 with acceptance of small amounts of canned food.  \n",
            "      • Related Clinical Findings: Likely secondary to systemic illness (IMHA), mild GI upset, and general debilitation.  \n",
            "      • Impact on Quality of Life: Moderate. Reduced nutritional intake can compromise recovery.  \n",
            "      • Current Treatment Status: Improving appetite with dietary modification (Hill’s i/d Low Fat) and supportive care. Still monitored for full return to normal feeding.\n",
            "\n",
            "   5) Pulmonary Hypertension  \n",
            "      • Duration with Exact Onset Date: Identified on 01/27/25 echocardiogram (tricuspid regurgitation gradient ~60 mmHg).  \n",
            "      • Severity Score (1–10): 5/10, classified as moderate pulmonary hypertension.  \n",
            "      • Progression Pattern: Chronic or progressive nature unclear; discovered during acute IMHA workup.  \n",
            "      • Related Clinical Findings: Mild right ventricular dilation, mild left atrial enlargement. May contribute to syncope and tachypnea.  \n",
            "      • Impact on Quality of Life: Moderate risk of recurrent syncopal events and potential for further cardiac compromise if uncontrolled.  \n",
            "      • Current Treatment Status: Potential therapy (sildenafil 10 mg PO TID) on standby if syncope recurs or if echocardiographic parameters worsen.\n",
            "\n",
            "   6) Cardiac Murmur (Left Apical Systolic)  \n",
            "      • Duration with Exact Onset Date: Present before 01/27/25 (pre-existing heart disease). Exact onset date not recorded.  \n",
            "      • Severity Score (1–10): Fluctuated from 4/6 (01/27/25) to 2/6 (01/28/25). Subjectively 5/10 at its peak.  \n",
            "      • Progression Pattern: Murmur intensity improved as anemia corrected (PCV rose), suggesting partial flow-related murmur.  \n",
            "      • Related Clinical Findings: Heart rate 168 bpm on 01/27/25, 160 bpm on 01/28/25. Possibly degenerative valvular disease.  \n",
            "      • Impact on Quality of Life: Low to moderate. Chronic condition managed medically.  \n",
            "      • Current Treatment Status: Ongoing therapy with enalapril 2.5 mg PO SID, Vetmedin (pimobendan) 2.5 mg PO BID, and furosemide 20 mg PO BID.\n",
            "\n",
            "2. INACTIVE/RESOLVED PROBLEMS\n",
            "\n",
            "   1) Vomiting  \n",
            "      • Original Diagnosis Date: 01/26/25 (single vomiting episode after boiled chicken).  \n",
            "      • Resolution Date: Self-limiting, no further vomiting after 01/26/25.  \n",
            "      • Treatment Provided: None specific; dietary modification to Hill’s i/d Low Fat was advised.  \n",
            "      • Risk of Recurrence: Mild to moderate, especially if dietary indiscretion or GI upset recurs.  \n",
            "      • Monitoring Requirements: Observe for any future vomiting episodes; adjust diet accordingly and alert veterinary team if multiple episodes recur.\n",
            "\n",
            "────────────────────────────────────────\n",
            "\n",
            "DIFFERENTIAL DIAGNOSES\n",
            "\n",
            "1. PRIMARY DIFFERENTIAL LIST\n",
            "\n",
            "   A) Immune-Mediated Hemolytic Anemia (IMHA)  \n",
            "      • Supporting Evidence:  \n",
            "         – Marked regenerative anemia (HCT 12.2% on 01/27/25), positive direct Coombs’ test (1:8), reticulocytosis (35.6%).  \n",
            "         – Elevated bilirubin (1.9 mg/dL) suggestive of hemolysis, agglutination-like picture (rare spherocytes).  \n",
            "         – Rapid clinical improvement with transfusion and immunosuppression (prednisone, cyclosporine).  \n",
            "      • Contradicting Evidence: None strongly identified; slide agglutination negative, but that does not exclude IMHA.  \n",
            "      • Diagnostic Criteria Met/Unmet: Meets classic laboratory criteria (regenerative anemia + positive Coombs’ test).  \n",
            "      • Population Prevalence: Common autoimmune disorder in canines, especially middle-aged to older dogs; can occur in small-breed dogs including Chihuahua mixes.  \n",
            "      • Age/Breed Predisposition: Middle-aged, small-breed dogs. The patient is a Chihuahua mix.  \n",
            "      • Required Diagnostics: Ongoing CBC/chemistry monitoring, serum bilirubin, and reticulocyte counts to confirm continued response to immunosuppression.\n",
            "\n",
            "   B) Cardiac Syncope Secondary to Pulmonary Hypertension  \n",
            "      • Supporting Evidence:  \n",
            "         – Echocardiographic findings (tricuspid regurgitation gradient ~60 mmHg).  \n",
            "         – Tachycardia, syncope episodes.  \n",
            "      • Contradicting Evidence: Syncope resolved quickly once severe anemia was corrected, suggesting hemolysis/anemia was a major factor.  \n",
            "      • Diagnostic Criteria Met/Unmet: Mild right ventricular dilation and documented elevated TR gradient. No direct invasive measurement of pulmonary artery pressure performed.  \n",
            "      • Population Prevalence: Pulmonary hypertension is not rare in older dogs with cardiac disease.  \n",
            "      • Age/Breed Predisposition: Small-breed dogs with chronic valvular changes are predisposed.  \n",
            "      • Required Diagnostics: Repeat echocardiogram if symptoms recur, possible measurement of BNP or troponin if indicated.\n",
            "\n",
            "2. SECONDARY DIFFERENTIAL LIST\n",
            "\n",
            "   A) Hyperadrenocorticism (Cushing’s Disease)  \n",
            "      • Reason for Lower Priority: Only mild adrenal enlargement on ultrasound (0.79 × 0.49 cm right adrenal). Mild liver enzyme elevations could be from other causes (e.g., steroid-induced or hemolysis). Leukocytosis can be multifactorial (IMHA, steroids).  \n",
            "      • Required Rule-Out Criteria: ACTH stimulation test or low-dose dexamethasone suppression test.  \n",
            "      • Testing Recommendations: If persistent clinical signs (PU/PD, elevated ALP, elevated WBCs) or inadequate IMHA control, consider endocrine testing.\n",
            "\n",
            "   B) Neoplastic Process (e.g., Hematopoietic Tumor)  \n",
            "      • Reason for Lower Priority: Imaging (abdominal ultrasound) showed no discrete masses; strongly regenerative anemia and positive Coombs’ suggest immune-mediated pathology rather than primary neoplasia.  \n",
            "      • Required Rule-Out Criteria: Bone marrow aspirate/biopsy if nonresponsive to immunosuppression or if unexplained cytopenias develop.  \n",
            "      • Testing Recommendations: Only if refractory anemia or suspicion arises on follow-up labs/imaging.\n",
            "\n",
            "   C) Infectious Hemolytic Anemia (Babesia, Ehrlichia, Mycoplasma, etc.)  \n",
            "      • Reason for Lower Priority: Tick-borne PCR panel negative for Anaplasma, Ehrlichia, Babesia, Mycoplasma, Bartonella, and others.  \n",
            "      • Required Rule-Out Criteria: Confirmed negative PCR, negative Lyme titer.  \n",
            "      • Testing Recommendations: Already completed (01/27/25); no further testing unless new regional threats manifest.\n",
            "\n",
            "────────────────────────────────────────\n",
            "\n",
            "DIAGNOSTIC PLAN\n",
            "\n",
            "1. IMMEDIATE DIAGNOSTICS\n",
            "\n",
            "   (Currently Performed or Completed)\n",
            "\n",
            "   • CBC with Reticulocyte Count (01/27/25):  \n",
            "     – Specific Justification: Evaluate red blood cell indices, confirm severity of anemia, assess regeneration.  \n",
            "     – Expected Findings: Low HCT, high reticulocyte percentage if regenerative.  \n",
            "     – Result Interpretation Criteria: Persistently low PCV <20% indicates need for acute intervention; strong reticulocyte response indicates robust marrow activity.  \n",
            "     – Cost-Benefit Assessment: Essential for acute stabilization decisions; standard baseline test.  \n",
            "     – Sample Handling Requirements: EDTA tube, processed in-house and at reference lab.  \n",
            "     – Timing Considerations: Performed emergently on 01/27/25, repeated daily (01/28/25) to confirm response.\n",
            "\n",
            "   • Serum Chemistry (01/27/25):  \n",
            "     – Specific Justification: Assess organ function, bilirubin elevation, potential causes for anemia.  \n",
            "     – Expected Findings: Potential elevated bilirubin, ALP changes, electrolyte shifts.  \n",
            "     – Result Interpretation Criteria: High bilirubin supports hemolysis; watch for kidney/liver impact.  \n",
            "     – Cost-Benefit Assessment: Medium cost with high clinical utility.  \n",
            "     – Sample Handling Requirements: Serum separator tube, immediate centrifugation.  \n",
            "     – Timing Considerations: Completed on 01/27/25; repeat if new concerns arise.\n",
            "\n",
            "   • Coombs’ Test (direct antiglobulin test), Tick-Borne PCR, Lyme Titer IgG (01/27/25–01/30/25 results):  \n",
            "     – Specific Justification: Confirm immune-mediated origin, rule out infectious causes.  \n",
            "     – Expected Findings: Direct Coombs’ positive in IMHA, negative PCR for tick-borne pathogens.  \n",
            "     – Result Interpretation Criteria: Positive Coombs’ at 1:8 meets diagnostic threshold for IMHA.  \n",
            "     – Cost-Benefit Assessment: Key confirmatory tests; moderately costly but essential to guide therapy.  \n",
            "     – Sample Handling Requirements: Fresh whole blood for PCR; specialized Coombs’ test at reference lab.  \n",
            "     – Timing Considerations: Samples collected on 01/27/25, final results on 01/30/25.\n",
            "\n",
            "   • Echocardiogram (01/27/25)  \n",
            "     – Specific Justification: Determine if structural heart disease or pulmonary hypertension explained syncope.  \n",
            "     – Expected Findings: Mild left atrial enlargement, moderate pulmonary hypertension (TR gradient ~60 mmHg).  \n",
            "     – Result Interpretation Criteria: Tricuspid regurgitation gradient >50 mmHg consistent with moderate to severe pulmonary hypertension.  \n",
            "     – Cost-Benefit Assessment: Higher cost, but crucial for syncope workup and anesthetic risk evaluation.  \n",
            "     – Sample Handling Requirements: Noninvasive ultrasound study.  \n",
            "     – Timing Considerations: Performed 01/27/25; repeat if clinical signs worsen.\n",
            "\n",
            "2. MONITORING DIAGNOSTICS\n",
            "\n",
            "   • Serial PCV/Total Solids  \n",
            "     – Frequency of Measurement: Daily until stable (currently measured 01/27/25 and 01/28/25), then every 2–3 days based on clinical improvement.  \n",
            "     – Alert Thresholds: PCV <20% or significant drop (>10% points) from previous indicates possible ongoing hemolysis or transfusion need.  \n",
            "     – Trend Analysis Criteria: Upward or stable PCV indicates therapy success; downward trend prompts immediate re-evaluation.  \n",
            "     – Action Triggers: Significant drops → possible second transfusion, intensify immunosuppression.\n",
            "\n",
            "   • Complete Blood Count and Serum Biochemistry  \n",
            "     – Frequency of Measurement: Every 1–2 weeks after discharge, then monthly as immunosuppression tapers.  \n",
            "     – Alert Thresholds: Rising liver enzymes, abnormal WBC trends, or falling RBC parameters.  \n",
            "     – Trend Analysis Criteria: Gradual normalization or stable improvement is ideal; spikes in WBC or persistent abnormal RBC indices require therapy adjustment.  \n",
            "     – Action Triggers: Any sign of relapse or adverse medication effects.\n",
            "\n",
            "   • Blood Pressure and Heart Rate  \n",
            "     – Frequency of Measurement: At each recheck (initially weekly).  \n",
            "     – Alert Thresholds: Persistent tachycardia (>160 bpm at rest) or hypotension (<100 mmHg systolic) triggers therapy reassessment.  \n",
            "     – Trend Analysis Criteria: Improvement in heart rate correlates with resolution of anemia.  \n",
            "     – Action Triggers: Ongoing tachycardia or syncopal episodes → consider sildenafil.\n",
            "\n",
            "   • Echocardiography  \n",
            "     – Frequency of Measurement: Re-evaluate in ~2–4 weeks if syncope recurs or at 2–3 months to assess pulmonary pressures.  \n",
            "     – Alert Thresholds: Worsening TR gradient (>70 mmHg), progression of chamber dilation.  \n",
            "     – Trend Analysis Criteria: Stable or improved TR gradient suggests effective management.  \n",
            "     – Action Triggers: Significant elevation → initiate or adjust sildenafil therapy.\n",
            "\n",
            "────────────────────────────────────────\n",
            "\n",
            "THERAPEUTIC PLAN\n",
            "\n",
            "1. IMMEDIATE INTERVENTIONS\n",
            "\n",
            "   • Packed RBC Transfusion (125 mL over ~4 hours on 01/27/25)  \n",
            "     – Drug/Intervention Name: Canine packed red blood cells.  \n",
            "     – Exact Dose Calculation: 125 mL administered based on target PCV increment from 15% to 30%.  \n",
            "     – Administration Details: IV infusion over ~4 hours with close monitoring for transfusion reactions.  \n",
            "     – Monitoring Requirements: Vital signs every 15–30 minutes during transfusion, post-transfusion PCV.  \n",
            "     – Expected Response Timeline: Immediate increase in PCV within hours.  \n",
            "     – Adverse Effect Monitoring: Watch for fever, urticaria, hemolytic reaction.\n",
            "\n",
            "   • Dexamethasone SP Injection (0.37 mL IV once on 01/27/25)  \n",
            "     – Drug Name (Generic/Brand): Dexamethasone sodium phosphate (generic injectable corticosteroid).  \n",
            "     – Exact Dose Calculation: 0.37 mL IV once (concentration details not provided, assumed standard dexamethasone SP 4 mg/mL).  \n",
            "     – Administration Details: Single IV bolus for acute immunosuppressive effect.  \n",
            "     – Monitoring Requirements: Observe for acute steroid side effects (PU/PD, GI upset).  \n",
            "     – Expected Response Timeline: Onset within hours.  \n",
            "     – Adverse Effect Monitoring: Blood glucose elevation, GI bleeding, changes in behavior.\n",
            "\n",
            "   • Prednisone 10 mg PO SID (started 01/27/25)  \n",
            "     – Drug Name (Generic/Brand): Prednisone (generic).  \n",
            "     – Exact Dose Calculation: 10 mg once daily by mouth; dose based on patient’s weight (not specified).  \n",
            "     – Administration Details: With food if possible to reduce GI upset.  \n",
            "     – Monitoring Requirements: CBC/chemistry to assess response and side effects (liver enzymes, GI signs).  \n",
            "     – Expected Response Timeline: Clinical stabilization within 24–72 hours; full immunosuppressive effect in 1–2 weeks.  \n",
            "     – Adverse Effect Monitoring: PU/PD, polyphagia, potential GI ulceration, elevated liver enzymes.\n",
            "\n",
            "   • Cyclosporine (Atopica) 25 mg PO BID (initiated ~01/27/25–01/28/25)  \n",
            "     – Drug Name (Generic/Brand): Cyclosporine (Atopica).  \n",
            "     – Exact Dose Calculation: 25 mg every 12 hours orally; dose typically ~5 mg/kg or as prescribed.  \n",
            "     – Administration Details: Give on an empty stomach when possible, 2 hours before or after a meal.  \n",
            "     – Monitoring Requirements: Assess serum chemistry (especially liver/kidneys), watch for GI upset.  \n",
            "     – Expected Response Timeline: May take 7–14 days for maximal immunosuppressive effect.  \n",
            "     – Adverse Effect Monitoring: GI upset, gingival hyperplasia, hirsutism, potential drug interactions.\n",
            "\n",
            "   • Doxycycline 50 mg PO SID (01/27/25 to present)  \n",
            "     – Drug Name (Generic/Brand): Doxycycline (generic).  \n",
            "     – Exact Dose Calculation: 50 mg once daily by mouth; prophylactic dose for potential tick-borne infections.  \n",
            "     – Administration Details: Provide with food to reduce esophageal irritation.  \n",
            "     – Monitoring Requirements: GI tolerance, resolution of any subclinical infection.  \n",
            "     – Expected Response Timeline: Typically 7–14 days for completing an empirical course, though negative PCR suggests low infectious risk.  \n",
            "     – Adverse Effect Monitoring: Vomiting, diarrhea, esophagitis if administered without water/food.\n",
            "\n",
            "   • Clopidogrel 18.75 mg PO SID (started 01/27/25)  \n",
            "     – Drug Name (Generic/Brand): Clopidogrel (Plavix).  \n",
            "     – Exact Dose Calculation: ¼ of a 75 mg tablet once daily (18.75 mg).  \n",
            "     – Administration Details: PO with or without food.  \n",
            "     – Monitoring Requirements: Platelet function oversuppression (risk of bleeding); watch for bruising or hematuria.  \n",
            "     – Expected Response Timeline: Platelet inhibition begins within hours–days.  \n",
            "     – Adverse Effect Monitoring: GI bleeding, lethargy, platelet count changes.\n",
            "\n",
            "2. LONG-TERM MANAGEMENT\n",
            "\n",
            "   • Specific Outcome Goals:  \n",
            "     – Maintain stable hematocrit (>30%) without ongoing hemolysis.  \n",
            "     – Achieve clinical remission of IMHA (no relapse for ≥4 months).  \n",
            "     – Control or reduce pulmonary hypertension to prevent future syncope.  \n",
            "\n",
            "   • Timeline for Reassessment:  \n",
            "     – Recheck PCV/TS daily until discharge, then every 2–3 days for two weeks. Subsequent rechecks every 1–2 weeks as therapy tapers.  \n",
            "     – Repeat echocardiogram in ~2–3 months or sooner if syncope recurs.  \n",
            "\n",
            "   • Quality of Life Parameters:  \n",
            "     – Return to normal energy levels, appetite, and activity without collapse.  \n",
            "     – Stable respiratory rate (<40 breaths/min at rest), no additional fainting episodes.  \n",
            "\n",
            "   • Client Education Points:  \n",
            "     – Monitor for signs of relapse (pale gums, increased lethargy, dark urine, collapse).  \n",
            "     – Watch for side effects of steroids and cyclosporine (PU/PD, GI upset, hair coat changes).  \n",
            "     – Follow medication schedule precisely; do not discontinue steroids abruptly.  \n",
            "\n",
            "   • Environmental Modifications:  \n",
            "     – Provide calm, low-stress surroundings to reduce triggers for syncope.  \n",
            "     – Avoid strenuous activity until anemia and pulmonary pressures are well-controlled.  \n",
            "\n",
            "   • Dietary Recommendations:  \n",
            "     – Continue Hill’s i/d Low Fat or other easily digestible diet to support appetite and reduce GI upset.  \n",
            "     – Observe for any GI intolerance (vomiting, diarrhea).  \n",
            "     – Encourage hydration but monitor for overconsumption if on steroids (PU/PD).  \n",
            "\n",
            "   • Criteria for Success/Failure:  \n",
            "     – Success: Increasing/stable PCV ≥30% for ≥2 weeks, resolution of syncope, improvement in appetite and activity.  \n",
            "     – Failure: Drop in PCV >10% points, recurrence of collapse, or medication side effects requiring regimen change.\n",
            "\n",
            "────────────────────────────────────────\n",
            "\n",
            "ALL CLIENT COMMUNICATIONS AND INSTRUCTIONS\n",
            "\n",
            "• Owner was informed on 01/27/25 about the severity of the anemia and immediate need for blood transfusion and immunosuppressive therapy.  \n",
            "• Detailed discussion on 01/27/25 regarding the risk of thromboembolism in IMHA patients; clopidogrel prescribed.  \n",
            "• Education given on 01/28/25 about potential addition of sildenafil (10 mg PO TID) if future syncopal events recur or if pulmonary hypertension worsens on recheck echo.  \n",
            "• Advised to feed Hill’s i/d Low Fat for improved appetite and GI support. Owner noted mild improvement in oral intake on 01/28/25.  \n",
            "• Proper administration of prednisone, cyclosporine, and doxycycline emphasized; reminded to monitor for GI side effects (vomiting, diarrhea) and report any changes promptly.  \n",
            "• Client instructed to monitor mucous membrane color, overall energy level, and watch for any additional episodes of collapse or vomiting.  \n",
            "• Recheck appointment scheduled to measure PCV on next available date (within 2–3 days of discharge); additional phone updates requested if any signs worsen.\n",
            "\n",
            "────────────────────────────────────────\n",
            "\n",
            "All numerical values and units have been documented exactly. All dates appear in MM/DD/YY format with times where provided (e.g., 8:27 AM on 01/27/25). Every abnormal finding, diagnostic result (with reference ranges), medication (with names, doses, frequencies, routes), and client instruction is recorded here. Data not provided is explicitly noted as unavailable. This concludes the specialist-level comprehensive diagnostic assessment for the patient’s presentation from 01/23/25 through 01/28/25.\n",
            "\n",
            "Specialist Summary:\n",
            "------------------------------\n",
            "SPECIALIST CONSULTATION:\n",
            "\n",
            "1. CASE SUMMARY  \n",
            "   • Chronological History  \n",
            "     – 01/23/25: First reported syncopal (collapse) episode.  \n",
            "     – 01/25/25: Two morning collapse episodes with prolonged lethargy afterward.  \n",
            "     – 01/26/25: Inappetence noted; one episode of vomiting (resolved).  \n",
            "     – 01/27/25: Severe anemia confirmed (HCT 12.2%; reference range ~37–55%), positive direct Coombs’ test at 1:8 (normal: negative or <1:2), elevated total bilirubin 1.9 mg/dL (reference range ~0.1–0.6 mg/dL), marked reticulocytosis at 35.6% (reference range ~0.5–1.5%), and macrocytosis (MCV 78.7 fL; reference range ~60–77 fL). Rapid drop in PCV from 15% at 1:45 PM to 12.2% later that day; immediately treated with packed RBC transfusion (125 mL over ~4 hours) and immunosuppressive therapy. Echocardiogram revealed moderate pulmonary hypertension (tricuspid regurgitation gradient ~60 mmHg; normal typically <25 mmHg). Heart murmur graded 4/6.  \n",
            "     – 01/28/25: Post-transfusion, PCV stabilized at 30% by 8:55 PM on 01/27/25 and rose to 31% on 01/28/25. Syncope did not recur after transfusion. Mild improvement in appetite and lethargy. Murmur grade decreased to 2/6.  \n",
            "\n",
            "   • All Prior Treatments With Responses  \n",
            "     – Prednisone 10 mg PO SID starting 01/27/25: Partial resolution of hemolysis, improved energy.  \n",
            "     – Cyclosporine 25 mg PO BID initiated between 01/27/25–01/28/25: Additional immunosuppressive support.  \n",
            "     – Clopidogrel 18.75 mg PO SID (initiated 01/27/25): Thromboprophylaxis for IMHA.  \n",
            "     – Packed RBC transfusion (01/27/25): Increased PCV from 12.2% to 30%, resolved immediate crisis.  \n",
            "     – Doxycycline 50 mg PO SID (started 01/27/25): Empiric coverage for possible tick-borne disease despite negative PCR.  \n",
            "     – Furosemide 20 mg PO BID, Enalapril 2.5 mg PO SID, Pimobendan 2.5 mg PO BID (pre-existing regimen for cardiac disease): Continued for suspected chronic valvular disease and heart failure support.  \n",
            "     – Vomiting on 01/26/25 resolved without antiemetic therapy; diet changed to Hill’s i/d Low Fat.  \n",
            "\n",
            "   • Every Diagnostic Result (With Reference Ranges)  \n",
            "     – CBC (01/27/25):  \n",
            "       ◦ HCT: 12.2% (reference range ~37–55%) – severely decreased.  \n",
            "       ◦ Reticulocyte %: 35.6% (reference range ~0.5–1.5%) – markedly elevated.  \n",
            "       ◦ Macrocytosis: MCV 78.7 fL (reference range ~60–77 fL).  \n",
            "     – Serum Chemistry (01/27/25):  \n",
            "       ◦ Total bilirubin: 1.9 mg/dL (reference range ~0.1–0.6 mg/dL) – elevated indicative of hemolysis.  \n",
            "       ◦ Mildly elevated ALP (exact value not provided) – possible steroid or cholestatic effect.  \n",
            "     – Direct Coombs’ test (01/27/25): Positive at 1:8 titer (normal: negative/<1:2).  \n",
            "     – Tick-Borne PCR & Lyme Titer (01/27/25): Negative for Anaplasma, Ehrlichia, Babesia, Mycoplasma, Bartonella, and Lyme disease.  \n",
            "     – Echocardiogram (01/27/25):  \n",
            "       ◦ Tricuspid regurgitation gradient ~60 mmHg (normal <25 mmHg) consistent with moderate pulmonary hypertension.  \n",
            "       ◦ Mild right ventricular dilation and mild left atrial enlargement.  \n",
            "       ◦ Murmur initially grade 4/6 on 01/27/25, decreased to 2/6 on 01/28/25.  \n",
            "\n",
            "   • Specific Clinical Progression  \n",
            "     – Rapid onset of profound anemia and repeated syncopal episodes from 01/23/25 to 01/27/25.  \n",
            "     – Stabilization after transfusion and initiation of immunosuppressants, with PCV increasing from 12.2% to 31% and resolution of syncopal events by 01/28/25.  \n",
            "     – Gradual improvement in appetite, reduced lethargy.  \n",
            "   \n",
            "   • Current Status Assessment  \n",
            "     – Active IMHA with partial hematologic stabilization (PCV 31% on 01/28/25).  \n",
            "     – Improved syncopal episodes post-transfusion (no recurrences after 01/27/25).  \n",
            "     – Moderate pulmonary hypertension remains a risk factor for future events.  \n",
            "     – Mild to moderate improvement in lethargy and appetite.\n",
            "\n",
            "2. DISEASE PROCESS ANALYSIS  \n",
            "   • Detailed Pathophysiology (IMHA)  \n",
            "     – Autoimmune destruction of red blood cells, evidenced by a positive direct Coombs’ test at 1:8, macrocytosis, elevated reticulocyte count, and elevated bilirubin consistent with hemolysis.  \n",
            "     – Likely primary (idiopathic) or possible secondary trigger not definitively identified.  \n",
            "\n",
            "   • Current Disease Stage  \n",
            "     – Acute to subacute IMHA with partial remission following transfusion and immunosuppression.  \n",
            "     – Pulmonary hypertension categorized as moderate based on TR gradient ~60 mmHg.  \n",
            "\n",
            "   • Progression Factors  \n",
            "     – Ongoing RBC destruction if immune response is not adequately suppressed.  \n",
            "     – Potential thromboembolic complications from hypercoagulable state in IMHA.  \n",
            "     – Cardiac compromise from pulmonary hypertension and valvular disease.  \n",
            "\n",
            "   • Complicating Conditions  \n",
            "     – Underlying cardiac disease with left apical systolic murmur (likely degenerative valvular disease).  \n",
            "     – Potential side effects from high-dose steroids and cyclosporine (GI upset, liver enzyme elevation).  \n",
            "\n",
            "   • Prognosis Assessment  \n",
            "     – Prognosis guarded to fair for IMHA due to severity of initial anemia (HCT 12.2%); partial stabilization is a favorable sign.  \n",
            "     – Prognosis for syncope depends on controlling anemia and managing pulmonary hypertension.  \n",
            "     – Prognosis improves with consistent monitoring, timely therapeutic adjustments, and owner vigilance.\n",
            "\n",
            "3. TREATMENT ANALYSIS  \n",
            "   • Response to Previous Treatments  \n",
            "     – Prompt improvement in PCV to 30–31% following RBC transfusion and immunosuppression.  \n",
            "     – Syncope resolved after anemia correction.  \n",
            "     – Appetite and lethargy partially improved with supportive care.  \n",
            "\n",
            "   • Current Treatment Efficacy  \n",
            "     – Prednisone and cyclosporine appear effective, given the stabilizing hematocrit.  \n",
            "     – Clopidogrel used preemptively to reduce thrombotic risk.  \n",
            "     – Cardiac drugs (furosemide, enalapril, pimobendan) helping manage underlying cardiac issues, though further evaluation is required.  \n",
            "\n",
            "   • Treatment Complications  \n",
            "     – Potential risk of GI side effects, PU/PD, steroid-induced hepatopathy, or immunosuppression-related infections.  \n",
            "     – Pulmonary hypertension remains untreated pharmaceutically at present; sildenafil on standby.  \n",
            "\n",
            "   • Compliance Assessment  \n",
            "     – Owner has been diligent in administering medications as prescribed since 01/27/25.  \n",
            "     – Dietary compliance with Hill’s i/d Low Fat. Continued monitoring needed.  \n",
            "\n",
            "   • Risk-Benefit Analysis  \n",
            "     – High-dose immunosuppression is necessary to halt hemolysis; benefits outweigh risks given severity of anemia.  \n",
            "     – Clopidogrel’s antithrombotic effect is critical, though bleeding must be monitored.  \n",
            "     – Sildenafil’s benefit would outweigh risk if syncope recurs or if pulmonary pressures worsen.\n",
            "\n",
            "4. SPECIALIST RECOMMENDATIONS  \n",
            "   A. Continue Immunosuppressive Protocol (Prednisone + Cyclosporine)  \n",
            "      – Scientific Rationale: Combined immunosuppression is standard for severe IMHA to halt RBC destruction.  \n",
            "      – Expected Outcome: Gradual normalization of PCV with decreased hemolysis over 1–4 weeks.  \n",
            "      – Monitoring Parameters: Weekly CBC initially, watching for decreasing bilirubin and stable RBC indices.  \n",
            "      – Alternatives: Azathioprine or mycophenolate if cyclosporine intolerance occurs or if response is inadequate.  \n",
            "\n",
            "   B. Maintain Thromboprophylaxis (Clopidogrel)  \n",
            "      – Scientific Rationale: IMHA predisposes to thromboembolism; prevention reduces morbidity and mortality.  \n",
            "      – Expected Outcome: Diminished risk of clot formation, reduced chance of stroke or pulmonary embolism.  \n",
            "      – Monitoring Parameters: Watch for signs of abnormal bleeding, bruising, or hematuria.  \n",
            "      – Alternatives: Low-dose aspirin or combination therapies if clopidogrel not tolerated.  \n",
            "\n",
            "   C. Pulmonary Hypertension Management (Consider Sildenafil If Syncope Recurs)  \n",
            "      – Scientific Rationale: Phosphodiesterase-5 inhibitor lowers pulmonary arterial pressure, reducing collapse risk.  \n",
            "      – Expected Outcome: Fewer syncopal episodes and improved exercise tolerance if pulmonary pressures are reduced.  \n",
            "      – Monitoring Parameters: Clinical signs and repeat echocardiogram. Initiate if TR gradient remains high (>60 mmHg) or if fainting episodes return.  \n",
            "      – Alternatives: Additional vasodilators (e.g., bosentan) in refractory cases.  \n",
            "\n",
            "   D. Maintain Cardiac Support (Furosemide, Enalapril, Pimobendan)  \n",
            "      – Scientific Rationale: Address possible congestive heart failure or valvular insufficiency.  \n",
            "      – Expected Outcome: Stabilized cardiac function, controlled heart rate, reduced fluid overload.  \n",
            "      – Monitoring Parameters: Respiratory rate at rest (<40 breaths/min), repeat thoracic auscultation, potential chest X-rays if indicated.  \n",
            "      – Alternatives: Adjust dosing frequencies or switch diuretics if clinical signs worsen.  \n",
            "\n",
            "   E. Dietary Management (Hill’s i/d Low Fat)  \n",
            "      – Scientific Rationale: Easily digestible formula supports GI function during immunosuppression.  \n",
            "      – Expected Outcome: Improved appetite, stable weight, reduced GI upset.  \n",
            "      – Monitoring Parameters: Appetite, body weight, stool quality.  \n",
            "      – Alternatives: Other prescription GI support diets (e.g., Purina EN).\n",
            "\n",
            "COMPREHENSIVE PLAN:\n",
            "\n",
            "1. MEDICAL MANAGEMENT  \n",
            "   • Prednisone 10 mg PO SID (started 01/27/25)  \n",
            "     – Dose Calculation: 10 mg total daily; exact weight-based dosing not provided but clinically appropriate for moderate-size small-breed dog.  \n",
            "     – Administration Protocol: Give with food in the morning to minimize GI upset.  \n",
            "     – Monitoring Requirements: Check liver enzymes (ALT, ALP) and CBC every 1–2 weeks.  \n",
            "     – Duration of Therapy: Induction phase ~2–4 weeks, then gradual taper if HCT remains stable.  \n",
            "     – Success Criteria: Hematocrit ≥30% persistently, no signs of ongoing hemolysis.  \n",
            "     – Modification Triggers: Adverse effects (severe PU/PD, GI hemorrhage), inadequate response (dropping PCV).  \n",
            "\n",
            "   • Cyclosporine 25 mg PO BID (initiated ~01/27/25–01/28/25)  \n",
            "     – Dose Calculation: ~5 mg/kg every 12 hours for immunosuppression (patient weight data not provided).  \n",
            "     – Administration Protocol: Preferably on an empty stomach, 2 hours before or after a meal.  \n",
            "     – Monitoring Requirements: Periodic trough drug levels if indicated, monthly CBC/chemistry.  \n",
            "     – Duration of Therapy: Often continued ≥3–4 months; taper based on clinical status and PCV trends.  \n",
            "     – Success Criteria: Lack of hemolysis with stable RBC parameters.  \n",
            "     – Modification Triggers: Severe GI upset, drug interactions, or inadequate immunosuppression.  \n",
            "\n",
            "   • Clopidogrel 18.75 mg PO SID (began 01/27/25)  \n",
            "     – Dose Calculation: ¼ of a 75 mg tablet to reduce thrombotic risk.  \n",
            "     – Administration Protocol: Once daily, with or without food.  \n",
            "     – Monitoring Requirements: Observe for signs of bleeding (petechiae, melena, hematuria).  \n",
            "     – Duration of Therapy: Indefinite during active IMHA or until hematocrit is stable for several months.  \n",
            "     – Success Criteria: No evidence of thrombosis or clinical complications.  \n",
            "     – Modification Triggers: Excessive bleeding, thrombosis despite therapy.  \n",
            "\n",
            "   • Doxycycline 50 mg PO SID (prophylactic, begun 01/27/25)  \n",
            "     – Dose Calculation: 50 mg once daily for a small-breed dog as empirical tick-borne coverage.  \n",
            "     – Administration Protocol: Administer with food or a small amount of water to reduce esophageal irritation.  \n",
            "     – Monitoring Requirements: GI tolerance, lack of further systemic signs.  \n",
            "     – Duration of Therapy: Typically 7–14 days, given negative tick panel; reevaluate necessity upon next exam.  \n",
            "     – Success Criteria: No development of infectious hemolysis.  \n",
            "     – Modification Triggers: GI upset, confirmed negative need if no further infectious concern.  \n",
            "\n",
            "   • Cardiac Medications (Long-Standing)  \n",
            "     – Furosemide 20 mg PO BID, Enalapril 2.5 mg PO SID, Pimobendan 2.5 mg PO BID.  \n",
            "     – Administration Protocols: Continue as directed for suspected chronic valvular disease.  \n",
            "     – Monitoring Requirements: Monitor respiratory rate at rest, follow-up echocardiograms, renal values.  \n",
            "     – Duration of Therapy: Ongoing.  \n",
            "     – Success Criteria: Controlled CHF signs, stable murmur intensity, no pulmonary edema.  \n",
            "     – Modification Triggers: Worsening cough, dyspnea, or changes in renal function.  \n",
            "\n",
            "2. MONITORING PROTOCOL  \n",
            "   • PCV/Total Solids  \n",
            "     – Measurement Frequency: Daily until discharge stability, then every 2–3 days for two weeks, then weekly.  \n",
            "     – Specific Target Values: PCV ≥30%.  \n",
            "     – Acceptable Ranges: 30–45%.  \n",
            "     – Action Thresholds: PCV <20% or a drop >10% points from prior level.  \n",
            "     – Response Protocols: If PCV falls below threshold, consider repeat transfusion, intensify immunosuppression.  \n",
            "\n",
            "   • Complete Blood Count (CBC) and Serum Biochemistry  \n",
            "     – Frequency: Biweekly for first month, then monthly as therapy is tapered.  \n",
            "     – Target Values: Improving RBC indices, stable WBC/platelets, normal bilirubin.  \n",
            "     – Acceptable Ranges: HCT 37–55% (goal), normal liver enzymes, BUN, creatinine.  \n",
            "     – Action Thresholds: Rising liver enzymes (suspect steroid hepatopathy) or decreasing RBC parameters.  \n",
            "     – Response Protocols: Adjust drugs if elevated liver enzymes or relapsing anemia.  \n",
            "\n",
            "   • Blood Pressure and Heart Rate  \n",
            "     – Frequency: Weekly initially, then every 2 weeks as stable.  \n",
            "     – Specific Target Values: Heart rate <160 bpm at rest, systolic BP 110–150 mmHg.  \n",
            "     – Acceptable Ranges: Heart rate up to 160 bpm if clinically normal, BP up to 160 mmHg systolic.  \n",
            "     – Action Thresholds: Persistent tachycardia >160 bpm at rest, BP <100 or >180 mmHg.  \n",
            "     – Response Protocols: Evaluate for pain, hypovolemia, or over-/under-treatment of heart disease.  \n",
            "\n",
            "   • Echocardiograms  \n",
            "     – Frequency: Reassess in 2–3 months or sooner if syncope recurs.  \n",
            "     – Specific Target Values: TR gradient <50 mmHg indicates improvement; stable cardiac chambers.  \n",
            "     – Acceptable Ranges: TR gradient 25–50 mmHg (mild–moderate PH).  \n",
            "     – Action Thresholds: TR gradient >70 mmHg or clinical deterioration.  \n",
            "     – Response Protocols: Initiate or adjust sildenafil if pressures worsen or syncopal events return.\n",
            "\n",
            "3. CLIENT EDUCATION  \n",
            "   • Disease Process Explanation  \n",
            "     – IMHA arises from an autoimmune reaction causing RBC destruction; requires long-term immunosuppression.  \n",
            "     – Pulmonary hypertension and cardiac disease may contribute to collapse episodes.  \n",
            "\n",
            "   • Treatment Rationale  \n",
            "     – Prednisone with cyclosporine to halt immune-mediated RBC destruction.  \n",
            "     – Clopidogrel to reduce clot formation risk.  \n",
            "     – Optional sildenafil if pulmonary hypertension or syncope worsens.  \n",
            "\n",
            "   • Administration Instructions  \n",
            "     – Give oral prednisone with food once daily; cyclosporine on an empty stomach twice daily.  \n",
            "     – Ensure clopidogrel is given once daily at 18.75 mg; watch for bleeding.  \n",
            "     – Continue furosemide, enalapril, and pimobendan as previously instructed.  \n",
            "\n",
            "   • Monitoring Requirements  \n",
            "     – Check gum color daily. Pale or white gums may signal relapse.  \n",
            "     – Note any return of collapse or intensification of lethargy/weakness.  \n",
            "     – Record appetite and water intake, call if persistent vomiting or diarrhea occurs.  \n",
            "\n",
            "   • Warning Signs  \n",
            "     – Sudden lethargy, collapse, labored breathing, or significant mucosal bleeding.  \n",
            "     – Rapid heart rate (>180 bpm) or respiratory rate at rest (>40 breaths/min).  \n",
            "\n",
            "   • Emergency Protocols  \n",
            "     – Contact the clinic immediately if PCV is suspected to drop (weakness, pale gums) or if fainting recurs.  \n",
            "     – For after-hours emergencies, use the nearest 24-hour facility with transfusion capabilities.  \n",
            "\n",
            "4. FOLLOW-UP SCHEDULE  \n",
            "   • Specific Recheck Dates  \n",
            "     – PCV recheck recommended within 2–3 days of discharge (target ~01/30/25–01/31/25).  \n",
            "     – Subsequent weekly visits for 2 weeks, then biweekly if stable.  \n",
            "\n",
            "   • Testing Schedule  \n",
            "     – CBC and serum chemistry every 1–2 weeks initially to monitor immunosuppressive side effects.  \n",
            "     – Repeat echocardiogram in ~2–3 months (or earlier if collapse returns).  \n",
            "\n",
            "   • Progress Assessment Criteria  \n",
            "     – Maintenance of PCV ≥30% without transfusion.  \n",
            "     – Absence of syncopal episodes and stable respiratory rate.  \n",
            "\n",
            "   • Long-Term Monitoring Plan  \n",
            "     – Gradual steroid taper once PCV is stable for ≥4 weeks and reticulocyte count normalizes.  \n",
            "     – Re-evaluate cyclosporine dosing based on clinical response and side effects.  \n",
            "\n",
            "   • Quality of Life Assessment  \n",
            "     – Return to normal energy, appetite, and household activities.  \n",
            "     – Ongoing monitoring for medication-induced side effects, bleeding, or arrhythmias.\n",
            "\n",
            "────────────────────────────────────────\n",
            "ALL CLIENT COMMUNICATIONS AND INSTRUCTIONS (DOCUMENTED)\n",
            "\n",
            "• 01/27/25: Advised owner of severe anemia (HCT 12.2%), urgent transfusion need, and immunosuppression. Risks of hypercoagulability and rationale for clopidogrel discussed.  \n",
            "• 01/28/25: Educated on standby use of sildenafil (10 mg PO TID) if syncope or echocardiographic parameters worsen.  \n",
            "• Diet change to Hill’s i/d Low Fat explained to address mild GI upset and inappetence.  \n",
            "• Emphasized proper administration of prednisone, cyclosporine, doxycycline, and clopidogrel, including potential side effects (vomiting, diarrhea, PU/PD).  \n",
            "• Instructed to observe mucous membranes, activity level, and to report any further collapse or reappearance of vomiting.  \n",
            "• Follow-up visit arranged in 2–3 days for PCV check; phone updates requested for any deterioration.\n",
            "\n",
            "All numerical values, dates (MM/DD/YY format), abnormal findings, and medications (with names, doses, frequencies, routes) have been recorded precisely. Reference ranges are provided or approximated where possible. This document is intended to allow any veterinary professional to continue care seamlessly.\n",
            "\n",
            "Connections Analysis:\n",
            "------------------------------\n",
            "CASE SYNTHESIS:\n",
            "\n",
            "1. DISEASE INTERACTIONS\n",
            "\n",
            "   • Primary–Secondary Disease Relationships:\n",
            "     – Causal Connections:  \n",
            "       Immune-mediated hemolytic anemia (IMHA), confirmed by a positive direct Coombs’ test at 1:8 on 01/30/25 (blood drawn 01/27/25), represents the primary disorder causing severe anemia (HCT 12.2% on 01/27/25). Syncope (four episodes between 01/23/25 and 01/27/25) was likely exacerbated by the low hematocrit. Concurrent heart disease (documented murmur and moderate pulmonary hypertension with tricuspid regurgitation gradient ~60 mmHg on 01/27/25) contributed an additional stressor on cardiovascular stability.  \n",
            "     – Exacerbating Factors:  \n",
            "       The patient’s anemia (PCV dropping to 15% by 01/27/25 at 1:45 PM) intensified hypoxia and risk of fainting. Pre-existing cardiac disease (left-sided apical systolic murmur, moderate pulmonary hypertension) further compromised cardiovascular response.  \n",
            "     – Systemic Effects:  \n",
            "       Hemolysis led to elevated total bilirubin (1.9 mg/dL on 01/27/25), pale-to-icteric mucous membranes, and heightened risk of thromboembolic events. Pulmonary hypertension increased risk of syncope due to inadequate oxygen delivery.  \n",
            "     – Progressive Impacts:  \n",
            "       Without transfusion or immunosuppression, ongoing RBC destruction could have worsened anemia, clinical collapse, and possibly organ failure. Early intervention (transfusion on 01/27/25) stabilized PCV from 15% to 30% on the same day (8:55 PM).\n",
            "\n",
            "   • Complicating Factors:\n",
            "     – Concurrent Conditions:  \n",
            "       Chronic valvular heart disease, moderate pulmonary hypertension, and possible mild adrenal enlargement (suggesting subclinical hyperadrenocorticism) each added complexity to managing IMHA.  \n",
            "     – Age-Related Factors:  \n",
            "       At ~10.8 years old (DOB 03/19/14), the patient is geriatric for a Chihuahua mix, heightening susceptibility to both cardiac disease and immunologic dysregulation.  \n",
            "     – Breed Predispositions:  \n",
            "       Small breeds may exhibit increased risk for degenerative valvular disease, contributing to the identified systolic murmur.  \n",
            "     – Environmental Influences:  \n",
            "       Tick exposure was considered, but all tick-borne PCR tests reported negative (01/30/25). Seasonal flea/tick preventive was noted (Credelio March–October).\n",
            "\n",
            "   • Synergistic Effects:\n",
            "     – Disease Interactions:  \n",
            "       Severe IMHA reduced oxygen-carrying capacity, making the dog more prone to decompensation from existing cardiac issues. Pulmonary hypertension further magnified syncopal risks.  \n",
            "     – Treatment Interactions:  \n",
            "       Immunosuppressants (prednisone begun 01/27/25, cyclosporine beginning 01/27–01/28/25) combined with ongoing cardiac medications (furosemide 20 mg BID, enalapril 2.5 mg SID, pimobendan 2.5 mg BID) require monitoring of renal function, electrolytes, and blood pressure.  \n",
            "     – Cumulative Impacts:  \n",
            "       High-dose steroids can elevate ALP (already 382 U/L on 01/27/25). Diuretics (furosemide) can exacerbate hypokalemia (3.3 mmol/L on 01/27/25).  \n",
            "     – Quality of Life Effects:  \n",
            "       Prior to transfusion, frequent collapse (four episodes) and lethargy compromised well-being. Post-transfusion (01/27/25) and immunosuppression, the dog’s appetite improved, and no new syncopal events were reported through 01/28/25.\n",
            "\n",
            "2. TREATMENT INTEGRATION\n",
            "\n",
            "   • Drug Interactions:\n",
            "     – Known Interactions:  \n",
            "       Long-term steroid use (prednisone 10 mg SID) plus NSAIDs are typically avoided together, but no NSAIDs are documented here. Combining steroids with cyclosporine increases immunosuppressive potency but also GI and hepatic side-effect risks. Clopidogrel improves thromboprophylaxis in IMHA but increases risk of GI bleeding when combined with steroids—clinical vigilance is necessary.  \n",
            "     – Potential Interactions:  \n",
            "       Furosemide and prednisone could potentiate electrolyte abnormalities (low potassium). Silent hepatic or renal compromise may be exacerbated by immunosuppressants.  \n",
            "     – Monitoring Requirements:  \n",
            "       Repeat CBC (weekly–biweekly), liver enzymes (ALP, ALT), electrolytes (especially potassium), and echocardiography if new syncope arises or murmur worsens.  \n",
            "     – Adjustment Protocols:  \n",
            "       If PCV drops below 20% or falls >10 percentage points from a prior value, consider increasing immunosuppressants or transfusion. If significant GI bleeding occurs, re-evaluate clopidogrel.\n",
            "\n",
            "   • Therapeutic Conflicts:\n",
            "     – Competing Treatment Needs:  \n",
            "       Addressing IMHA requires immunosuppression, but steroids may exacerbate subclinical hyperadrenocorticism and can mask infection. Heart disease demands diuretics, which can aggravate hypovolemia or electrolyte imbalances in an anemic patient.  \n",
            "     – Priority Assessment:  \n",
            "       Stabilizing the life-threatening anemia (PCV <20%) took precedence on 01/27/25; transfusion was administered promptly to raise PCV to 30%.  \n",
            "     – Resolution Strategies:  \n",
            "       Concurrently manage fluid status and weekly labs to track creatinine/BUN. Instruct the client to watch for signs of dehydration or excessive urination.  \n",
            "     – Risk Mitigation:  \n",
            "       Clopidogrel was started (18.75 mg SID on 01/27/25) to address thromboembolism risk. A prescription for sildenafil (10 mg TID “as needed”) was provided for potential recurrent syncopal events secondary to pulmonary hypertension.\n",
            "\n",
            "   • Management Synergies:\n",
            "     – Complementary Treatments:  \n",
            "       Immunosuppression (prednisone + cyclosporine) halts RBC destruction, while transfusion acutely corrects anemia. Cardiac medications help manage underlying murmur and fluid balance.  \n",
            "     – Timing Optimization:  \n",
            "       RBC transfusion was given on 01/27/25 over ~4 hours. Steroids were initiated the same day for immediate immunomodulation.  \n",
            "     – Efficiency Improvements:  \n",
            "       Early combination therapy (steroids + cyclosporine) can hasten IMHA control and potentially reduce total steroid duration.  \n",
            "     – Outcome Enhancement:  \n",
            "       Quick correction of PCV improved oxygen delivery, lessening syncope and improving appetite by 01/28/25 (~9:25 AM recheck).\n",
            "\n",
            "3. RISK ASSESSMENT\n",
            "\n",
            "   • Current Risk Factors:\n",
            "     – Disease-Specific Risks:  \n",
            "       Ongoing hemolysis, high risk of thromboembolism in IMHA. Potential relapse if immunosuppressive therapy is insufficient.  \n",
            "     – Treatment-Related Risks:  \n",
            "       Gastrointestinal bleeding (from steroids + clopidogrel), steroid-induced polyuria/polydipsia, potential cyclosporine GI upset, furosemide-induced hypokalemia.  \n",
            "     – Environmental Risks:  \n",
            "       Possible future tick exposure despite negative PCR; Credelio use must remain consistent. Stress or excitement could precipitate syncopal events in presence of pulmonary hypertension.  \n",
            "     – Client-Specific Factors:  \n",
            "       Owner’s willingness to monitor gum color, keep scheduled rechecks, and administer multiple medications accurately is crucial to success.\n",
            "\n",
            "   • Potential Complications:\n",
            "     – Early Warning Signs:  \n",
            "       Dropping PCV (<20% again), returned pallor or icterus, renewed fainting episodes, or dark tarry stools indicating GI bleed.  \n",
            "     – Prevention Strategies:  \n",
            "       Ensure strict adherence to daily medication schedule, dietary consistency (Hill’s i/d Low Fat ~1⅓ can/day).  \n",
            "     – Monitoring Protocols:  \n",
            "       Frequent PCV/TS checks initially (every 2–3 days), weekly CBC/chemistry, monthly evaluation of dose taper feasibility.  \n",
            "     – Intervention Triggers:  \n",
            "       PCV drop >10 points, uncontrolled vomiting/diarrhea, or persistent tachycardia (HR >160 bpm) may prompt adjusting therapy or hospital admission.\n",
            "\n",
            "INTEGRATED CARE PLAN:\n",
            "\n",
            "1. COMPREHENSIVE TREATMENT STRATEGY\n",
            "\n",
            "   • Prioritized Interventions:\n",
            "     – Immediate Actions (01/27/25):  \n",
            "       Administer packed RBC transfusion (125 mL IV over ~4 hours), give dexamethasone SP 0.37 mL IV once.  \n",
            "     – Short-Term Goals (Days 1–7):  \n",
            "       Maintain PCV ≥30%; assess daily PCV if needed. Begin prednisone 10 mg PO SID, cyclosporine 25 mg PO BID, clopidogrel 18.75 mg PO SID, and doxycycline 50 mg PO SID. Evaluate response on 01/30/25–01/31/25 recheck.  \n",
            "     – Long-Term Objectives (Weeks 2–8):  \n",
            "       Stabilize RBC indices (PCV 35–45%), prevent further hemolysis, avoid thromboembolic events. Continue cardiac medications to control pulmonary hypertension risk.  \n",
            "     – Success Criteria:  \n",
            "       Absence of syncope, stable or rising PCV ≥30%, normal to mildly elevated bilirubin, minimal side effects (no GI bleed, no severe PU/PD).\n",
            "\n",
            "   • Coordinated Care:\n",
            "     – Team Responsibilities:  \n",
            "       • Internal Medicine Specialist: Oversee IMHA immunosuppressive regimen, interpret serial CBC/chemistries.  \n",
            "       • Cardiology/Ultrasound Specialist: Recheck echocardiogram if new syncope or in 2–3 months.  \n",
            "       • Primary Veterinarian: Periodic monitoring (CBC, chemistries, PCV checks), communicate findings to specialist.  \n",
            "     – Communication Protocols:  \n",
            "       Phone updates if any collapse, pale gums, or adverse medication effects. Document all abnormal events.  \n",
            "     – Documentation Requirements:  \n",
            "       Record exact PCV/TS recheck dates, times, and results. Each medication must have dose/frequency/route/time.  \n",
            "     – Quality Assurance:  \n",
            "       Confirm proper dosing intervals, monitor for medication compliance, and track laboratory trends consistently.\n",
            "\n",
            "2. LONG-TERM MANAGEMENT\n",
            "\n",
            "   • Disease Trajectory:\n",
            "     – Expected Progression:  \n",
            "       Most dogs with IMHA can achieve remission with consistent immunosuppression over months. Pulmonary hypertension may persist; requires targeted therapy if recurrent syncopal episodes emerge.  \n",
            "     – Monitoring Points:  \n",
            "       Weekly–biweekly CBC/chemistry for 4–6 weeks, then monthly as conditions stabilize.  \n",
            "     – Intervention Triggers:  \n",
            "       PCV fall below 20%, elevated bilirubin, or ongoing clinical signs (ollapse, severe lethargy).  \n",
            "     – Outcome Measures:  \n",
            "       Maintenance of PCV ≥30% for ≥1 month, normal or stable liver/kidney values, absence of collapses.\n",
            "\n",
            "   • Quality of Life:\n",
            "     – Assessment Criteria:  \n",
            "       Appetite, energy level, normal respiratory rate (<40 breaths/min), no collapse events.  \n",
            "     – Monitoring Protocol:  \n",
            "       Owner logs daily gum color checks, appetite, respiratory rate.  \n",
            "     – Improvement Strategies:  \n",
            "       Taper steroids slowly once stable to minimize side effects (PU/PD, muscle weakness). Maintain gentle, low-stress routine to reduce cardiac workload.  \n",
            "     – Client Assessment Tools:  \n",
            "       Provide a home log for syncope episodes, appetite amounts, stool quality, and medication times.\n",
            "\n",
            "3. SUPPORT SYSTEMS\n",
            "\n",
            "   • Client Education:\n",
            "     – Understanding Assessment:  \n",
            "       Emphasize that IMHA requires vigilant monitoring. Blood transfusion corrected the immediate crisis but long-term immunosuppression is essential to prevent relapse.  \n",
            "     – Training Needs:  \n",
            "       Instruct on correct splitting of clopidogrel tablets (¼ of 75 mg), timing of prednisone vs. cyclosporine administration, and checking mucous membranes daily.  \n",
            "     – Resource Requirements:  \n",
            "       Access to 24-hour emergency care if PCV acutely drops or if severe collapse recurs.  \n",
            "     – Support Services:  \n",
            "       Offer routine phone follow-ups. Encourage client to schedule weekly or biweekly checks (PCV/TS, CBC).\n",
            "\n",
            "   • Compliance Strategy:\n",
            "     – Barriers Assessment:  \n",
            "       Multiple daily medications, potential financial constraints, and living between two addresses.  \n",
            "     – Solution Implementation:  \n",
            "       Provide calendar for medication schedule. Explain cost-effective recheck intervals to ensure essential monitoring.  \n",
            "     – Monitoring Methods:  \n",
            "       Document each administered dose. Observe for missed appointments or incomplete therapy.  \n",
            "     – Success Measures:  \n",
            "       Stable or rising hematocrit, no further syncope, normal appetite, consistent follow-up attendance.\n",
            "\n",
            "-------------------------------------------------------------------------------\n",
            "\n",
            "ALL NUMERICAL VALUES AND UNITS (EXACT) AND ALL DATES/TIMES (MM/DD/YY FORMAT) HAVE BEEN RECORDED.  \n",
            "ABNORMAL FINDINGS (E.G., HCT 12.2%, HCT 15%, TOTAL BILIRUBIN 1.9 MG/DL, HIGH ALP 382 U/L) ARE NOTED WITH REFERENCE RANGES WHERE PROVIDED.  \n",
            "MEDICATIONS (ENALAPRIL 2.5 MG SID, PIMOBENDAN 2.5 MG BID, FUROSEMIDE 20 MG BID, TRAZODONE 50 MG PRN, JOINT SUPPLEMENT QOD, CREDELIO SEASONALLY, DOXYCYCLINE 50 MG SID, PREDNISONE 10 MG SID, CYCLOSPORINE 25 MG BID, CLOPIDOGREL 18.75 MG SID, SILDENAFIL 10 MG TID PRN) INCLUDE DOSES, FREQUENCIES, AND ROUTES (ALL ORAL).  \n",
            "CLIENT INSTRUCTIONS INCLUDE THE 01/27/25 EXPLANATION OF IMHA AND TRANSFUSION NEED, 01/28/25 RECHECK DISCUSSIONS, AND FOLLOW-UP PLANS.  \n",
            "\n",
            "THIS INTEGRATION ENSURES COMPREHENSIVE ACTIONABLE CARE FOR SPENCER JOHNSON (PATIENT ID# CA25440F). ALL TEAM MEMBERS AND THE CLIENT SHOULD ADHERE TO THE ABOVE RECOMMENDED MONITORING AND TREATMENT PLAN TO OPTIMIZE OUTCOMES.\n"
          ]
        }
      ],
      "source": [
        "result = analyze_veterinary_case([\n",
        "    \"./IMG_5188.jpeg\",\n",
        "    \"./IMG_5604.jpeg\",\n",
        "    \"./J-VSMR.pdf\",\n",
        "    \"./LabReport.pdf\",\n",
        "    \"./SP-Doc-1.pdf\",\n",
        "    \"./SP-Doc-2.pdf\",\n",
        "    \"./SP-Doc-3.pdf\",\n",
        "    \"SP-Imagyst.pdf\",\n",
        "    \"SP-Report-1.pdf\",\n",
        "    \"SP-Report-2.pdf\",\n",
        "    \"Signed-Auth-Form.pdf\",\n",
        "    \"THX - Right Lat.jpeg\"\n",
        "])\n",
        "\n",
        "print(\"\\nAnalysis Results:\")\n",
        "print(\"-\" * 50)\n",
        "\n",
        "sections = [\n",
        "    (\"Data Processing\", \"DataProcessor\"),\n",
        "    (\"History Analysis\", \"HistoryAnalyzer\"),\n",
        "    (\"Clinical Analysis\", \"ClinicalAnalyzer\"),\n",
        "    (\"Diagnostic Assessment\", \"Diagnostics\"),\n",
        "    (\"Specialist Summary\", \"SpecialistSummary\"),\n",
        "    (\"Connections Analysis\", \"Connections\")\n",
        "]\n",
        "\n",
        "for title, key in sections:\n",
        "    print(f\"\\n{title}:\")\n",
        "    print(\"-\" * 30)\n",
        "    print(result[\"results\"].get(key, \"Not available\"))\n",
        "\n",
        "if \"errors\" in result[\"results\"]:\n",
        "    print(\"\\nErrors encountered:\")\n",
        "    for error in result[\"results\"][\"errors\"]:\n",
        "        print(f\"- {error['message']} (at {error['timestamp']}\")"
      ]
    }
  ],
  "metadata": {
    "colab": {
      "provenance": [],
      "authorship_tag": "ABX9TyPzxTC9JN9FRTq7T7kcII58",
      "include_colab_link": true
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}